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Summary
Short-chain fatty acids (SCFA) are a sub-group of fatty acids including formic
acid, acetic acid, propionic acid, isobutyric acid, butyric acid, isovaleric acid
and valeric acid. Acetate, propionate and butyrate are three major short-
chain fatty acids, which are mainly formed in the gastrointestinal tract via
colonic bacteria fermentation of carbohydrates, especially resistant starches
and dietary fibre. There has been increasing interest in the idea that the
short-chain fatty acids play crucial roles in a range of physiological functions.
Recently, increasing evidence suggested there is a strong link between
short-chain fatty acids and energy homeostasis. Several studies highlighted
the protective effects of the short-chain fatty acids on high-fat diet induced
obesity and other harmful metabolic disorders in mice. However, the
coherent understanding of the multi-level network in which short-chain fatty
acids exert their effects still needs to be elucidated. Up to date, it has been
demonstrated that short-chain fatty acids can mediate energy balance via
affecting appetite control in brain, increasing adipogenesis in white adipocyte,
and regulating insulin sensitivities in white adipose tissue and muscle, etc..
However, the effects of short-chain fatty acids on brown adipocytes have not
been fully investigated.
In this study, we examined the roles of short-chain fatty acid acetate and its
receptor(s) in the regulation of brown adipocyte differentiation and
metabolism. Firstly, we identified the expression of short-chain fatty acids
sensing GPR43 in brown adipose tissue and immortalized brown adipocytes
15
by real-time PCR, Western blots and immunohistochemistry. Moreover,
GPR43 expression was found to increase during the adipogenesis of
cultured brown adipocytes. Pro-adipogenic reagent PPARγ agonist 
stimulation led to a further augment of GPR43 expression while anti-
adipogenic reagents such as PPARγ antagonist, RXR antagonist and STAT5 
inhibitor played the opposite role on GPR43 expression. Transcription factors
such as XBP1 and STAT5 were identified to be involved in GPR43
expression regulation in brown adipocytes.
Furthermore, we also examined the role of acetate in the regulation of brown
adipogenesis. Our results showed that acetate treatment during
adipogenesis up-regulated AP2, PGC-1α and UCP1 expression and affected 
the morphological changes of brown adipocytes. Moreover, an increase in
mitochondrial biogenesis was observed after acetate treatment. Acetate also
elicited the activation of ERK and CREB, and these responses were
sensitive to G(i/o)-type G-protein inactivator, Gβγ-subunit inhibitor, PLC 
inhibitor and MEK inhibitor, indicating a role for the G(i/o)βγ/PLC/PKC/MEK 
signalling pathway in these responses. These effects of acetate were
mimicked by treatment with 4-CMTB, a synthetic GPR43 agonist, and were
impaired in GPR43 knock-down cells, further supported the hypothesis that
GPR43 mediates the pro-adipogenic effects of acetate in brown adipocytes.
Furthermore, the effects of acetate treatment on brown adipose tissue were
also measured in vivo. Mice fed with acetate demonstrated increased PGC-
1α in brown adipose tissue, which was in agreement with the results 
obtained from immortalized brown adipocytes.
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In addition, we also measured the effects of acetate on lipid metabolism in
differentiated brown adipocytes. The results showed effects of acetate
treatment on lipolysis were different in white adipocytes and brown
adipocytes. Acetate treatment significantly decreased the lipolysis in white
adipocytes while had little effects on lipolysis in brown adipocytes. Besides,
acetate treatment was also found to decrease TF2-C12 fatty acid uptake in
differentiated IM-BAT cells, suggesting acetate may affect many aspects of
lipid metabolism in brown adipocytes.
Collectively, our results indicated that acetate might have important
physiological roles in brown adipocytes. Short-chain fatty acids may serve to
regulate brown adipose tissue functions and therefore improve metabolic
health.
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MAPKK: mitogen-activated protein kinase kinase
MAPK: mitogen-activated protein kinase
MEM: minimal essential medium
mA: milliampere
min: minutes
mg: milligram
mL: millilitre
mM: millimolar
mRNA: messenger ribonucleic acid
mtDNA: mitochondrial deoxyribonucleic acid
MTT: 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide
MTS: 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-
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sulfophenyl)-2H-tetrazolium
NAD: Nicotinamide adenine dinucleotide
NADH: Nicotinamide adenine dinucleotide, reduced
PBS: phosphate buffer saline
PCR: polymerase chain reaction
Pen/Strep: penicillin/streptomycin
PYY: peptide YY
real-time PCR: real-time quantitative reverse transcription PCR
RNase: ribonuclease
RT-PCR: reverse transcription polymerase chain reaction
shRNA: small hairpin ribonucleic acid
siRNA: small interfering ribonucleic acid
TAE: tris-acetate-EDTA
TBS: tris-buffered saline
TEMED: tetramethylethylenediamine
UV: ultraviolet
V: volts
WAT: white adipose tissue
WB: Western blot
XBP1: X-box binding protein 1
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Chapter 1: Introduction
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1.1 Free fatty acids
Free fatty acids (FFAs) are a group of carboxylic acids with a long aliphatic
chain, which can be categorized according to their chemical properties or
metabolism profiles (Calder, 2015)
For example, according to the absence or existence of the carbon-carbon
double bond within fatty acid chain, fatty acids can be divided into saturated
and unsaturated fatty acids (figure 1-1) (Lobb and Chow, 2007); while
according to the aliphatic chain length, the fatty acids can be categorized into
short-chain fatty acids (with aliphatic chain shorter than 6 carbons), medium-
chain fatty acids (with aliphatic chain of 6-12 carbons), and long-chain fatty
acids (with aliphatic chain longer than 13 carbons) (Gunstone, 1996)
Figure 1-1 Difference in structures of saturated and unsaturated fatty acids.
Red circle represents the cis double bonds in aliphatic chain of linoleic acid, while
blue circles shows the trans double bond in aliphatic chain of trans-linoleic acid.
(Watson, 2008).
Besides, fatty acids also can be classified into essential fatty acids and non-
essential fatty acids according to their dietary necessity (Elkins, 1999). The
essential fatty acids are fatty acids required for biological processes but can
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not be synthesized in the body and must be obtained from diet (Kaur et al.,
2014). Until now, two fatty acids: alpha-linolenic acid and linoleic acid are
recognized as essential fatty acids for human beings (Kaur et al., 2014).
Besides, several other fatty acids such as docosahexaenoic acid (DHA) and
eicosapentaenoic acid (EPA) are needed under certain developmental or
disease conditions, therefore sometimes are defined as conditionally
essential fatty acids (Cunnane, 2003).
The major role of fatty acids is producing energy, especially in the negative
energy balance status (Calder, 2015). Due to the advantage that the same
amount of fats (esterified fatty acids) can release more stored chemical
energy in the form of ATP compared to carbohydrates and proteins, fatty
acids are the most effective way to store excess energy in the form of
triglycerides (Numa, 1984). However, fatty acids not only function as energy
sources but also act to influence cell and tissue metabolism. Increasing
evidence supports the hypothesis that free fatty acids and their receptors
function as nutrient sensors to regulate a variety of physiological
homeostasis, including energy homeostasis (Ichimura et al., 2009). It is now
clear that fatty acids are linked with a range of diseases such as obesity,
type 2 diabetes, hypertension, atherogenic dyslipidaemia, and non-alcoholic
fatty liver disease (Boden, 2011). For example, plasma free fatty acids levels
are up-regulated in obesity patient (Opie and Walfish, 1963). Increased free
fatty acids level leads to the insulin resistance in skeletal muscle and liver
(DeFronzo et al., 1981, Boden et al., 2002). Besides, free fatty acids have
also been proved to level up NF-γB activation and pro-inflammatory 
cytokines expression in human skeletal muscle (Itani et al., 2002) and
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adipocyte (Chung et al., 2005). Furthermore, free fatty acids were also found
to induce ER stress in adipocyte (Guo et al., 2007), liver cells, and pancreatic
β-cells (Urano et al., 2000). Indeed, a better understanding of fatty acids
functions may provide potential therapeutic avenues to tackle many diseases.
1.1.1 Long-chain fatty acids and medium-chain fatty acids
Long-chain fatty acids contain more than 13 carbon atoms on their aliphatic
chains. Both saturated and unsaturated long-chain fatty acids have been
found to be vital for normal physical functions. Palmitic acid (16:0) and
stearic acid (18:0) are two most abundant saturated fatty acids in nature.
They widely exist in animal products of diets. Several studies have shown
that intake of these two fatty acids leads to the rise of cholesterol in blood,
which was thought to be the risk factor for cardiovascular disease. However,
recent evidence showed that there is no significant direct association
between saturated long-chain fatty acids consumption and heart disease
(Felton et al., 1994, Siri-Tarino et al., 2010). In contrast, saturated fat and
dietary cholesterol display protective functions in the heart and reduce
endothelial inflammation. It is now believed that combination of high-sugar
diet, trans fat and long-chain saturated fat contributes to the development of
cardiovascular disease more than long-chain saturated fat itself.
Besides, circulating concentrations of saturated long-chain fatty acids can
also reflect the risk of type 2 diabetes. A study including 12,403 people with
incident type 2 diabetes and 16,154 comparator individuals demonstrated an
interesting finding that plasma palmitic, and stearic acids were positively
associated with incident type 2 diabetes while pentadecanoic acid (15:0),
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heptadecanoic acid (17:0), arachidic acid (20:0), behenic acid (22:0),
tricosanoic acid (23:0), and lignoceric acid (24:0) were inversely associated
with incident type 2 diabetes, suggesting the saturated long-chain fatty acids
might be not homogeneous in their metabolic effects (Forouhi et al., 2014).
Polyunsaturated long-chain fatty acids, especially the long-chain omega-3
polyunsaturated fatty acids such as eicosapentaenoic acid (EPA, 20:5, n-3)
and docosahexaenoic acid (DHA, 22:6, n-3), have demonstrated a range of
beneficial effects including lowering blood pressure, treating depression and
decreasing the risk of heart attacks (Miyajima et al., 2001, Grosso et al.,
2014, Marik and Varon, 2009). In addition, EPA and DHA play crucial roles in
central nervous system and visual function development in infants (Innis,
2007). Studies have demonstrated that exposure to higher levels of DHA
promoted cognitive development in human infants such as increased scores
on the Fagan test of novelty preference at 6 months of age (O'Connor et al.,
2001); better problem solving abilities at 9 (Willatts et al., 1998b) and 10
(Willatts et al., 1998a) months of age; more rapid information processing at
6.5, 9 and 12 months of age (Werkman and Carlson, 1996); and more
development of attention at 12 and 18 months of age (Colombo et al., 2004).
Because of its crucial role in the growth and development of infants, DHA is
also regarded as a conditionally essential fatty acid and added as
supplement to most infant formula (Cunnane, 2003).
Medium-chain fatty acids have between 6 and 12 carbon atoms. The major
medium-chain fatty acids in edible oils and diet include caproic acid (6:0),
caprylic acid (8:0), capric acid (10:0) and lauric acid (12:0). In a double-blind,
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controlled human trial, the results demonstrated that medium-chain fatty
acids decreased body weight and suppressed fat deposition, suggesting
medium-chain fatty acids might own health beneficial properties on metabolic
disorders (Tsuji et al., 2001). Meanwhile, as ketogenic diet, medium-chain
saturated fatty acids and their esterified form (medium-chain triglycerides)
were found to alleviate neurodegenerative disorders such as Alzheimer’s
disease (Maalouf et al., 2009). A randomized, double-blind, placebo-
controlled, multicenter trial showed that ketogenic agent AC-1202 (a
commercial form of medium-chain triglycerides) improved ADAS-Cog scores
in mild to moderate Alzheimer's disease (Henderson et al., 2009). Medium-
chain saturated fatty acids are also linked to the control of immune
responses. Lauric acid (12:0) and its monoglyceride (monolaurin) are
considered to offer wide-spectrum anti-viral, anti-bacterial and anti-fungal
properties (Lieberman et al., 2006). Indeed, monolaurin exists in breast milk
and plays important roles for infant immunity.
In addition to these discovered functions of long-chain fatty acids and
medium-chain fatty acids, future studies can provide more information about
the functions of these fatty acids and may provide nutrient and therapeutic
benefits for humans.
1.1.2 Short-chain fatty acids
Short-chain fatty acids (SCFAs) are a sub-group of fatty acids containing less
than 6 carbon atoms, including formic acid, acetic acid, propionic acid,
isobutyric acid, butyric acid, isovaleric acid and valeric acid.
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Short-chain fatty acids are the major by-products formed in the
gastrointestinal tract via colonic bacteria fermentation of carbohydrates,
especially resistant starch and dietary fibre (Andoh et al., 2003). It has been
recognised for a long history that dietary fibre would benefit the digestive
system healthy and contribute to other health issues, such as lowering
cholesterol level and controlling blood glucose level (Brown et al., 1999,
Causey et al., 2000). Recently, studies have revealed that these beneficial
effects of high-fibre diets are, at least partly, attributed to its end-products by
digestion as short-chain fatty acids (Canfora et al., 2015). It has been
suggested that dietary intake of resistant starch in excess of 30 g per day
leads to high-peripheral circulating acetate in blood (Robertson et al., 2005).
In human, acetate, propionate and butyrate are three major short-chain fatty
acids, which account for 83% of short-chain fatty acids produced in gut
(Velazquez et al., 1997). Because substrate for colonic fermentation is at
highest level in proximal colon (including ascending colon and transverse
colon), the colonic fermentation mainly occurs in proximal colon. Therefore,
the total amount of short-chain fatty acids in the proximal colon is higher (at
around 70 to 140 mM) than that in the distal colon (ranged from 20 to 70 mM)
(Topping and Clifton, 2001).
After produced in gastrointestinal tract, short-chain fatty acids are absorbed
by colon rapidly and efficiently. It is estimated that only less than 10% of
short-chain fatty acids produced in colon would be excreted in human feces.
Butyrate is largely absorbed in colon and plays as the major energy source
for colonocytes (Wong et al., 2006). Butyrate oxidation has been shown to
27
make up around 70% and 60% of the oxygen consumed in human
descending colon and ascending colon when physiological levels of glucose
and butyrate was present (Roediger, 1980). Liver is another organ which can
absorb the short-chain fatty acids. Propionate is mainly absorbed in the liver
(Wong et al., 2006). Recently, a research to measure short-chain fatty acids
exchange across the gut and liver in humans at surgery showed little
intestinal produced butyrate and propionate escaped the splanchnic area
because of highly efficient hepatic uptake of propionate (Bloemen et al.,
2009).
Followed by colonic fermentation, most of acetate enters the peripheral
circulation to be metabolized by peripheral tissues (Wong et al., 2006). Usual
short-chain fatty acids concentration in the bloodstream are 100-150 µM for
acetate, 4-5 µM for propionate and 1-3 µM for butyrate (Wolever et al., 1997),
indicating the majority of short-chain fatty acids functions in peripheral
tissues are attribute to the acetate. Indeed, recent research shows this blood
concentration of acetate is in the range for activating its receptors such as
GPR43 and GPR41 (Brown et al., 2003).
Clinical studies have found that short-chain fatty acids administration
positively influenced the treatment of ulcerative colitis, Crohn’s disease, and
antibiotic-associated diarrhea (Harig et al., 1989, Vernia et al., 1995, Di
Sabatino et al., 2005, Binder, 2010), which highlighted the involvment of
short-chain fatty acids in a wide range of biological functions. Besides, short-
chain fatty acids also showed significant anti-proliferative activity on colon
cancer both in in vitro and in vivo studies, among which butyrate displayed
28
most potential (Goncalves and Martel, 2013). Indeed, it has been indicated
that incidence rates of bowel cancer, diabetes and coronary heart disease
are much lower in countries with traditionally high-fibre diets (Slavin, 2013).
Recent studies also showed that short-chain fatty acids are important
regulators in metabolism and energy homeostasis. For example, acetate
may cross the blood-brain barrier and lead to appetite suppression via
mediating neuropeptides in appetite regulation, indicating short-chain fatty
acids can affect energy intake via central appetite regulation (Frost et al.,
2014). Also, dietary supplementation of butyrate improved insulin sensitivity
and increased energy expenditure in adipose tissue, muscle and liver of
dietary-obese C57BL/6J mice, suggesting short-chain fatty acids may have
potential application in the treatment of metabolic syndrome via peripheral
organs (Gao et al., 2009). Indeed, a better understanding towards the roles
of short-chain fatty acids in metabolism may provide useful information for
keeping energy homeostasis.
1.2 Free fatty acids-sensing G protein-coupled receptors
1.2.1 G-Protein coupled receptor
G-Protein coupled receptors, also known as GPCRs, constitute the largest
family of cell membrane receptors in eukaryotes and play significant roles in
a diversity of cellular physiology (Salon et al., 2011). Although GPCRs
function diversely and sense various ligands with different structures, they
share a common structure called seven-transmembrane domain (Lu et al.,
2002). GPCRs are thus also described as seven-transmembrane domain
29
receptors or 7-TM receptors (figure 1-2) (Pierce et al., 2002). Besides, most
GPCRs (Class 1 GPCRs) also have a common palmitoylated cysteine at C-
terminus or intracellular loops (Goddard and Watts, 2012). In contrast,
GPCRs show great multiplicity in the regions of extracellular N-terminus,
intracellular C-terminus, intra- and extra-cellular loops, which could be the
structure basis for its diversity functions.
According sequence homology, GPCRs are classically divided into three
main classes: Class 1 (aka Class A, Rhodopsin-like), Class 2 (aka Class B,
Secretin-like), Class 3 (aka Class C, Glutamate Receptor-like). Three distinct
GPCR families display their own characteristic sequence and evolutionary
relationship.
Majority (approximately 90%) of GPCRs belongs to Class 1 (Class A)
GPCRs (Davenport et al., 2013), which can be further classified into 19 sub-
families (Subfamily A1 – A19) according to a phylogenetic analysis (Joost
and Methner, 2002).
The Class 2 (Class B) GPCRs feature a globular N-terminal extracellular
domain (ECD) with conserved disulfide bonds and a characteristic seven-
transmembrane signature (Hollenstein et al., 2014).
The Class 3 (Class C) GPCRs normally contain a unique large hydrophilic
extracellular agonist-binding regions and several conserved cysteine
residues (Brauner-Osborne et al., 2007).
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Figure 1-2 The structures of G-protein coupled receptors families. Family 1
(family A) GPCRs: red circles show highly conserved amino acids; black line
represents a disulfide bridge connecting the first and second extracellular loops;
orange zigzag show the palmitoylation of carboxyl-terminal tail, which serves as an
anchor to the membrane. Family 2 (family B) GPCRs: red circles show cysteines
located in the N-terminal extracellular domain, which normally form conserved
disulfide bridges. Family 3 (family C) GPCRs: yellow shows an example of
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hydrophilic extracellular agonist-binding regions of family 3 GPCRs. (EllisClare,
2004) .
Due to their involvement in multiple physiological functions, GPCRs have
been the centre of drug discovery (Salon et al., 2011). It is estimated that
currently nearly 40% of the drugs on the market function through GPCRs
(Overington et al., 2006).
Despite no detectable shared sequence homology between classes, all
GPCRs have a common mechanism of signal transduction. GPCRs transmit
signals into cell through its coupled guanine nucleotide-binding proteins (G
proteins). G proteins, also known as heterotrimeric G proteins complexes,
are composed of Gα, Gβ and Gγ subunits (Cabrera-Vera et al., 2003). The 
standard model of G protein signalling is shown in figure 1-3 (EllisClare,
2004). In the inactive state of GPCRs, the Gα subunit binds to a molecular of 
GDP and forms a tight association with Gβγ heterodimer at the inside 
surface of cell membrane (Conklin and Bourne, 1993). Once GPCRs are
activated by ligands, the Gα subunit undergoes a conformational change 
leading to an exchange of GTP for GDP, allowing it dissociating from Gβγ 
heterodimer (McCudden et al., 2005). Both dissociated Gα subunit and Gβγ 
heterodimer can transduce the downstream signals, respectively (Clapham
and Neer, 1993). The signals will be terminated by intrinsic GTPase activity
of Gα subunit, which catalyses the hydrolysis of bound GTP into GDT and 
leads to the re-association of Gα subunit and Gβγ heterodimer (Kleuss et al., 
1994).
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Figure 1-3 Standard model of GDP/GTP cycle in GPCR signalling pathways. In
the resting state, Gα subunit is GDP bound and closely associated with the Gβγ 
heterodimer to form heterotrimeric G proteins, which interacts with the cytosolic
loops of GPCRs located on cell membrane. Gβγ stabilizes Gα coupling to GPCR 
and also functions as a guanine nucleotide dissociation inhibitor (GDI) to inhibiting
the spontaneous exchange of GDP for GTP on Gα subunit. When ligand binds to 
GPCR, the receptor act as guanine nucleotide exchange factors (GEFs) and
induces a GDP to GTP exchange in the Gα subunit and the dissociation from Gβγ 
heterodimer. Both Gα subunit and Gβγ heterodimer trigger downstream effects. The 
cycle returns to the resting state when Gα hydrolyses GTP back to GDP. GTPase-
accelerating proteins (GAPs), such as the Regulator of G-protein Signalling (RGS)
proteins, could accelerate this process (McCudden et al., 2005).
According to their sequence homology and functional similarity, the Gα 
subunits can be divided into four major catalogues including Gαs family
(Gα(s/olf)), Gα(i/o) family (Gα(i1/i2/i3/o/t-rod/t-cone/gust/z)), Gαq family (Gα(q/11/14/16)), and
Gα(12/13) family (Simon et al., 1991). Gαs subunits mainly stimulate adenylyl
cyclase (AC) and increase cellular levels of cAMP, which is an important
second messenger in cells (Hanoune and Defer, 2001). In contrast, Gαi
subunits play an opposite role to Gαs subunits, which inhibit adenylyl cyclase
(AC) and decrease cellular levels of cAMP (Simonds, 1999, Hanoune and
Defer, 2001). Gαq subunits activate phospholipase C (PLC), which then
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cleave phosphatidylinositol 4,5-bisphosphate (PIP2) into diacyl glycerol
(DAG) and inositol 1,4,5-triphosphate (IP3), followed by Ca2+ release from
endoplasmic reticulum (ER) and protein kinase C (PKC) activation (Ross,
2011). Compared to widely studied Gαs, Gαi and Gαq signals, Gα(12/13) signal
was less understood. Up to date, it has been found that Gα(12/13) subunits
mainly regulate small G-protein Rho activity (Riobo and Manning, 2005).
Besides, dissociated Gβγ heterodimer also regulates large number of 
downstream effectors including PI3Kγ, MAPKs, and Ion channels, etc.. 
(Tilley, 2011).
A range of selective inhibitors have been discovered to differentiate the
signalling pathways elicited by different G protein subunits. For example,
pertussis toxin (PTX) catalyses the ADP-ribosylation of the Gα(i/o) subunits
and prevents the G proteins interacting with GPCRs on the cell membrane,
thus interfering the downstream signalling (Mangmool and Kurose, 2011).
Therefore, PTX has become a widely used biochemical tool to study the
signal transduction of Gα(i/o)-coupled receptor signalling. Meanwhile, NF 449
and NF 503 were found to be selective Gαs antagonists, with little effects on
Gα(i/o) and Gα(q/11)-coupled receptors (Hohenegger et al., 1998). Recently,
Gα(q/11)-selective inhibitors such as YM-254890 and WU-07047 have also
been reported, which blocks the exchange of GDP for GTP in Gα(q/11)
activation (Rensing et al., 2015). Besides, Gallein, a cell-permeable
xanthene compound, binds to Gβγ with high affinity and effectively blocks 
Gβγ-dependent cellular activities (Lehmann et al., 2008). Taken together, 
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these specific inhibitors and loss-of-function G-proteins mutants can be used
to determine the downstream signalling after GPCRs activation.
Figure 1-4 Diversity of G-protein-coupled receptor signalling. GPCRs interact
with heterotrimeric G proteins composed of Gα subunit and Gβγ heterodimer that 
are GDP bound in the absence of ligands. Following activation by ligands, GPCRs
catalyses the exchange of GDP to GTP in the Gα subunit and the dissociation of Gα 
subunit from Gβγ heterodimer. Dissociated Gα subunits trigger distinct downstream 
effectors (such as adenylyl cyclase (AC), phospholipase C (PLC)) and cause the
changes of secondary messengers (such as cAMP, IP3 or Ca2+). In addition to the
regulation of these classical secondary messenger generating systems, Gβγ 
heterodimer also activate signalling molecules, including phospholipases, ion
channels and lipid kinases. Ultimately, the integrated G-protein-regulated signalling
mediates target genes expression and generate diverse biological responses
(Dorsam and Gutkind, 2007).
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GPCRs are widely and essentially involved in the regulation of energy
homeostasis. For example, olfactory, visual and taste GPCRs play crucial
roles in sensing the palatability of the food and regulating the appetite
(Gaillard et al., 2004, Loper et al., 2015). A range of energy regulating
hormones, such as gastric inhibitory polypeptide / glucose-dependent
insulinotropic peptide (GIP), glucagon-like peptide-1 (GLP-1), pancreatic
polypeptide (PYY) and cholecystokinin (CCK) also target GPCRs (e.g. GIP
receptor; GLP-1 receptor; Y1 receptor, Y2 receptor, Y5 receptor; CCK
receptors) respectively and regulate energy balance via appetite control,
insulin and glucagon release, and gastrointestinal motility (Meier and Nauck,
2005, Kjems et al., 2003, Batterham et al., 2003, Fink et al., 1998).
Furthermore, several GPCRs such as CRHR1 (corticotropin-releasing
hormone receptor 1), CRHR2, GPR24 have been identified as genes
causing monogenic obesity. Loss or mutation any of these genes leads to
severe obesity in humans (Farooqi and O'Rahilly, 2005), highlighting the
importance of these GPCRs in energy homeostasis.
1.2.2 Free fatty acids-sensing GPCRs
There has been more than one decade since the discovery of free fatty acids
as the ligands of several G-protein coupled receptors, including GPR40,
GPR41, GPR43, GPR84, GPR119 and GPR120 (Ichimura et al., 2009). The
deorphanization of these free fatty acids sensing GPCRs has revealed that
extracellular free fatty acids not only function as energy source for cells, but
also serve as signalling molecules to mediate wide range of biological
processes.
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1) GPR40
Human GPR40 gene was firstly identified as putative GPCR gene during the
search for novel galanin receptor (GALR) subtypes (Sawzdargo et al., 1997).
Human GPR40 gene, also known as free fatty acid receptor 1 gene or
FFAR1 gene, together with GPR41, GPR42 and GPR43 are localized on
chromosome 19q13.1 (figure 1-5) (Sawzdargo et al., 1997). Interestingly,
only homologous genes of GPR40, GPR41 and GPR43 are found in rodent
species. Furthermore, no free fatty acid has been found to activate human
GPR42 receptor, indicating human GPR42 might be a pseudo gene formed
by a duplication of human GPR41 gene during the evolution (Liaw and
Connolly, 2009).
Figure 1-5 The relative localizations of GPR40, GPR41, GPR42, and GPR43
genes in human genome. The relative localizations of GPR40, GPR41, GPR42,
and GPR43 genes in relation to the human CD22 gene on the sequences of two
overlapping clones under the GenBank accession numbers U62631 and AC002511
(Sawzdargo et al., 1997).
The predominant expression sites of GPR40 are pancreatic β-cells and 
enteroendocrine cells, where GPR40 regulates glucose-stimulated insulin
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and GLP-1, GIP release, respectively (Itoh et al., 2003, Tomita et al., 2006,
Edfalk et al., 2008). Besides, GPR40 was also found in pancreatic α-cells, 
type I cells of taste bud, and breast cancer cell line MCF-7 (Yonezawa et al.,
2004, Flodgren et al., 2007, Cartoni et al., 2010).
GPR40 can be activated by medium- and long-chain fatty acids.
Approximately 42 different saturated and unsaturated free fatty acids with
more than six carbons have been proved with the potency of activating
human GPR40 in HEK293 cells, with 5,8.11-eicosatriynoic acid being the
most potent (Briscoe et al., 2003).
GPR40 is coupled to pertussis toxin (PTX) insensitive Gα(q/11) G-protein,
leading to the activation of phospholipase C and elevation of intracellular
Ca2+ concentration; meanwhile, the ERK1/2 phosphorylation was also
observed after GPR40 agonist stimulation (Briscoe et al., 2003). Besides, it
was also found that activation of human GPR40 slightly decreased cAMP
production in forskolin-stimulated CHO cells expressing human GPR40,
suggesting that human GPR40 might also couple to Gα(i/o) G-protein partially,
however, this finding was not observed in the cells expressing mouse
GPR40 (Briscoe et al., 2003).
Due to the potential of stimulating both insulin secretion in β-cells and GLP-1 
secretion in L-cells simultaneously (Briscoe et al., 2006, Edfalk et al., 2008),
a number of synthetic agonists and antagonist of GPR40 have been
discovered (Garrido et al., 2006). Thiazolidinedione (TZDs), a kind of drugs
developed in the late 1990s as PPARγ ligand, was also identified as GPR40 
agonist using high-throughput reporter assay with clone election
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(HighTRACE) system (Kotarsky et al., 2003a, Kotarsky et al., 2003b).
Another anti-diabetogenic drug MEDICA16 also selectively activates GPR40
and elevates intracellular Ca2+ concentration in cells expressing GPR40
(Hara et al., 2009, Takeuchi et al., 2013). Meanwhile, pharmacy companies
also showed great interest in finding novel GPR40 agonists due to the
potential of GPR40 as the target of diabetes treatment. A number of GPR40
agonists or antagonists have been discovered. For example, GW9508
(agonist of GPR40) and GW1100 (antagonist of GPR40) were firstly reported
by GSK (Briscoe et al., 2006). Merck also reported 5-aryloxy-2,4-
thiazolidinediones (Compound C) (Zhou et al., 2010) and 3-substituted 3-(4-
aryloxyaryl)-propanoic acids (Walsh et al., 2011) as GPR40 agonist based
on their systematic structure-activity relationship (SAR) studies. Moreover,
the key sites of GPR40 for the agonist GW9508 and linoleate binding were
successfully illustrated (figure 1-6). These findings laid a solid foundation for
the development of novel GPR40 agonists with higher potential and
selectivity (Sum et al., 2007).
Figure 1-6 Binding pocket of GPR40 in complex with GW9508 and linoleic acid.
The ligands are labelled in green. The hydrogen bond between ligands and Arg183,
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Asn244, and Arg258 are marked as dash line. Transmembrane helices of receptor
are shown as blue wires. Key residues in binding pocket are shown with their
position and the Ballesteros Weinstein GPCR numbering. (Sum et al., 2007)
Recently, potent GPR40 agonists (AMG837 and TAK-875) with oral
bioavailability were reported by independent groups (Lin et al., 2011, Houze
et al., 2012). The evidence from in vitro assay, animal model assay and
phase III clinical trials on Japanese type 2 diabetes patients indicated TAK-
875 is a promising drug to improve the insulin and glucagon secretion to treat
type 2 diabetes (Kaku et al., 2013).
Taken together, GPR40 is a very promising therapeutic target for the
treatment of type 2 diabetes.
2) GPR41
Human GPR41 gene also locates at GPR40-43 genes cluster. Strikingly,
GPR41 mRNA transcription shares the same promoter of GPR40 gene, and
its protein translation is mediated by internal ribosome entry site (IRSE)
(Bahar Halpern et al., 2012). GPR41 have been deorphanizated by paired
with short-chain fatty acids, with propionate, butyrate, and pentanonate as
the preference (Brown et al., 2003).
Since GPR41 shares the promoter of GPR40 gene, GPR41 is also highly
expressed in pancreatic β-cells and enteroendocrine L-cells (Bahar Halpern 
et al., 2012). Although it has been reported that short-chain fatty acids
stimulated glucagon-like peptide-1 secretion was decreased in GPR41
knock-out mice, however, there is no conclusive evidence showing GPR41
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directly regulates GLP-1 secretion since loss of GPR41 caused a decrease
in GPR43 expression, which also controls short-chain fatty acids induced
GLP-1 secretion (Tolhurst et al., 2012).
Interestingly, the expression and functions of GPR41 in adipocytes are also
controversial. It was firstly reported that GPR41 is highly expressed in
adipose tissue and stimulates leptin secretion after short-chain fatty acids
simulation (Xiong et al., 2004). Over expression of GPR41 led to an increase
in leptin production, which was abolished by knockdown of GPR41 (Xiong et
al., 2004). In contrast, recent studies claimed GPR41 is not detectable in
adipocytes, while the effects of short-chain fatty acids on leptin secretion
might go through GPR43 instead of GPR41 (Zaibi et al., 2010). Further
investigation is needed to resolve this discrepancy.
Recent studies also showed GPR41 might associate with inflammatory and
metabolic diseases. Stimulation with butyrate attenuated inflammation and
lipolysis in macrophages and white adipocytes, which is abolished by
blocking GPR41 (Ohira et al., 2013). Interestingly, GPR41 knock-out mice
showed attenuated inflammatory responses in intestinal epithelial cells
following ethanol or 2, 4, 6-trinitrobenzene sulfonic-acid (TNBS) treatment
(Kim et al., 2013). Therefore, further investigation is still needed to illustrate
the link between GPR41 and inflammation. Besides, male mice with GPR41
knock-out also showed low energy expenditure and increased body fat
content (Bellahcene et al., 2013).
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GPR41 is exclusively coupled to pertussis toxin (PTX) sensitive Gα(i/o) G-
protein (Brown et al., 2003). Upon activation, GPR41 inhibits intracellular
cAMP accumulation.
Up to date, there is only β-hydroxybutyrate reported as antagonist for GPR41, 
a ketone body produced during starvation or diabetes (Kimura et al., 2011).
Interestingly, short-chain fatty acids increased sympathetic nervous system
(SNS) activities via GPR41 while β-hydroxybutyrate suppressed SNS activity 
by antagonizing GPR41, suggesting a mechanism by which dietary status
can directly mediate energy expenditure by regulating the activity of the
sympathetic nervous system (Kimura et al., 2011).
3) GPR43
Similar to GPR41 gene, human GPR43 gene also locates at GPR40-43 gene
cluster on chromosome 19q13.1 (Sawzdargo et al., 1997). However, unlike
GPR41, it has its own promoter; therefore, GPR43 has a distinct expression
pattern wider than GPR40 and GPR41 (Bahar Halpern et al., 2012). GPR43
has been reported to be present in adipocytes, immune cells,
enteroendocrine L-cells and islets cells (Cornall et al., 2011, Karaki et al.,
2006, Karaki et al., 2008). Besides, GPR43 was also identified in cancer
cells including MCF7 cells (Yonezawa et al., 2007), BaF3 cells (Bindels et al.,
2012), and colon cancer cells (Tang et al., 2011). However, the roles of
GPR43 in the proliferation of cancer cells are still controversial.
Although GPR43 possesses affinities for short-chain fatty acids overlapping
with GPR41, acetate is 100-fold less potent on GPR41 as compared with
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propionate and butyrate, whereas acetate activates GPR43 with a strongest
potency (Le Poul et al., 2003). Considering the fact that concentration of
acetate reaches 100-150 µM in blood while concentration of propionate and
butyrate are only 1-3 µM and 4-5 µM, respectively (Wolever et al., 1997), the
GPR43 in peripheral tissues could be activated by acetate in blood. However,
the average concentration of propionate and butyrate in blood are
considered too low to activate GPR41 or GPR43 (Le Poul et al., 2003).
Interestingly, increasing evidence showed the expression of GPR43 is
regulated by a range of factors. For example, co-culture bovine muscle
satellite cells dramatically increased GPR43 expression in white adipocytes
(Choi et al., 2013). Besides, high-fat diet also increased GPR43 expression
in adipose tissue, liver and soleus and EDL skeletal muscles (Cornall et al.,
2011, Dewulf et al., 2011). These findings suggested GPR43 might link with
adipose tissue metabolism. Recent studies also supported this hypothesis. It
has been demonstrated that stimulation with short-chain fatty acids
significantly decreased lipolysis in white adipose tissue (Ge et al., 2008) and
promoted leptin secretion in white adipocytes (Zaibi et al., 2010). However,
the overall effects of GPR43 on metabolism in vivo is still unclear. The
knock-out of GPR43 was found to improve glucose homeostasis and reduce
body fat mass under a high-fat diet feeding in mice (Bjursell et al., 2011).
However, another study showed GPR43 knock-out mice exhibited obesity on
a normal diet while over-expressing GPR43 in adipose tissue kept mice lean
when fed a high-fat diet (Kimura et al., 2013).
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Similar to GPR40 and GPR41, GPR43 has been proved to affect GLP-1
secretion both in vitro and in vivo (Tolhurst et al., 2012). Therefore, it also
draws attention to identify selective GPR43 agonists as a therapeutic
strategy for obesity and diabetes treatment.
GPR43 also profoundly affects inflammatory response. GPR43 has been
proved to mediate neutrophil chemotaxis (Vinolo et al., 2011) and
recruitment (Sina et al., 2009). GPR43 is also involved in polymorphonuclear
cell activation, recruitment of polymorphonuclear cell populations toward
sites of bacterial infection (Le Poul et al., 2003). Furthermore, GPR43
deficient mice also demonstrated significant alteration of inflammatory
responses in vivo (Maslowski et al., 2009).
GPR43 is mainly coupled to Gαq and Gα(i/o) G-proteins (Brown et al., 2003).
Upon stimulation, GPR43 activates intracellular signalling such as
cytoplasmic Ca2+ increase, p38 and ERK activation and inhibition of cAMP
production (Seljeset and Siehler, 2012).
Both GPR43 agonists and antagonists have been reported. For example,
orthosteric agonist (2-methylacrylic acid), allosteric agonists (Compound 58,
Compound 34), inverse agonists (Compound 4) have been discovered
(figure 1-7) (Bindels et al., 2013). Meanwhile, GLPG0974, a potent and
selective antagonist of GPR43, which inhibits GPR43 mediated activation
and migration of neutrophils, has demonstrated favourable safety profile and
good pharmacokinetic and pharmacodynamic properties in Phase I clinical
trial to treat patients with mild-to-moderate ulcerative colitis (Pizzonero et al.,
2014, Vermeire et al., 2015).
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Figure 1-7 Chemical structures of physiological and synthetic ligands of
GPR43. pEC50 and pIC50 represent the negative log of the half maximal effective
concentration, and half maximal inhibitory concentration, respectively (Bindels et al.,
2013).
4) GPR84
Human GPR84 gene was identified nearly simultaneously by two
independent groups in 2001 using different approaches (Wittenberger et al.,
2001, Yousefi et al., 2001). Wittenberger et al., firstly reported five putative
G-protein coupled receptors including GPR84 by expressed sequence tag
(EST) database mining strategy. Using northern blots, the expression of
human GPR84 and murine GPR84 were confirmed in brain, heart, muscle,
colon, thymus, spleen, kidney, liver, intestine, placenta, lung, and leukocytes
(Wittenberger et al., 2001). Subsequently, Yousefi et al., also reported a
novel G-protein-coupled receptor identified as GPR84 expressed on
granulocytes (Yousefi et al., 2001).
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Human GPR84 gene localized on chromosome 12q13.13, while murine
GPR84 gene is identified on chromosome 15, the encoded proteins of which
share 85% amino acid identity, suggesting they are ortholog of each other
(Wittenberger et al., 2001). Notably, the coding sequence of human GPR84
gene contains no introns (Wittenberger et al., 2001).
To identify the endogenous ligands of GPR84, saturated and unsaturated
free fatty acids from C1 to C22 in length have been tested. The results
demonstrated that only medium-chain saturated free fatty acids (C9-C14)
selectively activated GPR84 in CHO cells expressing human GPR84, with
capric acid (C10:0), undecanoic acid (C11:0) and lauric acid (C12:0) being
the most potent (Wang et al., 2006). Interestingly, no unsaturated free fatty
acids showed the potency to activate GPR84. (Wang et al., 2006).
Besides, two synthetic small molecules (diinodrylmethane and indol-3-
calbinol) were identified as GPR84 agonists with EC50 at 11μM and 100 μM, 
respectively, by [35S]GTPαS binding assay (figure 1-8) (Takeda et al., 2003). 
Galapagos also presented pre-clinical evidence for GPR84 inhibitor
GLPG1205 as novel treatment for inflammatory bowel diseases, however, no
further details were disclosed.
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Figure 1-8 Chemical structures of GPR84 surrogate agonists. Diindorylmethane
and indol-3-calbinol were identified as GPR84 agonist with EC50 at 11 μM and 100 
μM, respectively (Takeda et al., 2003).
GPR84 predominantly expresses in immune cells, including various
leukocytes, macrophages, microglia, T lymphocytes, and B lymphocytes
(Wang et al., 2006, Lattin et al., 2008). Besides, northern blots analysis also
revealed GPR84 mRNA in brain, heart, muscle, colon, thymus, spleen,
kidney, liver, intestine, placenta, lung and leucocytes (Wittenberger et al.,
2001). Recently, GPR84 was also found in murine white adipose tissue and
white adipocyte 3T3-L1 (Nagasaki et al., 2012). Evidence about GPR84
expression suggested the involvement of GPR84 in inflammatory response
in immune system. For example, lipopolysaccharides or pro-inflammatory
cytokines stimulation could increase GPR84 expression in neutrophils,
macrophage and neutrophil granulocytes (Wang et al., 2006, Bouchard et al.,
2007, Nagasaki et al., 2012).
Using CHO cells expressing human GPR84, GPR84 was demonstrated
almost exclusively binding to pertussis toxin (PTX)-sensitive Gα(i/o) G-protein.
Stimulating GPR84 with its agonist diindolylmethane also dramatically lower
intracellular cyclic AMP (cAMP) production after forskolin stimulation (Wang
et al., 2006).
Besides, GPR84 was also considered as a necessary receptor for eye
development in Xenopus laevis. Knock-down of GPR84 could significantly
modulate the proliferation and apoptosis of eye tissues and cause deficient
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of retina and lens development (Perry et al., 2010). Due to the fact that X.
laevis GPR84 distantly resembles human, mouse and rat GPR84, the
relationship between GPR84 and eye development in human and rodent
species still need more investigation.
5) GPR119
Human GPR119 gene was firstly identified by Fredriksson et al., by
searching human genome database and analysing expressed sequence tag
database (Fredriksson et al., 2003). The orthologues of GPR119 have been
identified in a number of species, including mouse, rat, hamsters,
chimpanzees, rhesus monkey, cattle, dog, and fugu (pufferfish) (Zhu et al.,
2013). Human GPR119 gene localizes on chromosome Xp26.1, while mouse
GPR119 gene localizes on chromosome chrX: 34322403-34323407 (Zhu et
al., 2013).
GPR119 was firstly deorphanized to be the receptor of oleoylethanolamide
(OEA, C18:1) with EC50 at 3.2 µM for human GPR119 and 2.9 µM for mouse
GPR119 (Overton et al., 2006). Additionally, previous studies also reported
that N-oleoyldopamine (OLDA) and lysophosphatidylcholine (LPC) could
stimulate GPR119 in the cells over-expressing GPR119 (Chu et al., 2010).
Similar to the expression profiles of GPR40, human GPR119 gene
expresses abundantly only in a limited range of cells, including pancreatic β-
cells and enteroendocrine cells in the small intestine (Chu et al., 2010).
Recently, the evidence of GPR119 expression in cultured skeletal muscle
myotubes was reported (Cornall et al., 2013).
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Stimulation of GPR119 leads to an enhancement of both glucose-induced
insulin secretion and GLP-1 secretion as GPR40 (Fyfe et al., 2008). However,
the detailed mechanism seems to be different. GPR119 is coupled to Gαs G-
protein. Upon activation, GPR119 increases intracellular cAMP levels,
followed by increased glucose-dependent insulin release in β-cells, GLP-1 
release in L-cells and GIP release in K-cells (figure 1-9) (Overton et al.,
2008).
Figure 1-9 Proposed mechanisms of GPR119-mediated glucose metabolism.
GPR119 is coupled to Gαs G-protein and increases cAMP levels via activation of
adenylate cyclase in L and K cells in guts and β cells in islets, which leads to the 
increase in the release of glucagon-like peptide 1 (GLP-1), glucose-dependent
insulinotropic peptide (GIP) or insulin in L, K cells and β cells, respectively. Besides, 
GLP-1 and GIP secreted from L, and K cells can also further trigger insulin secretion
in β cells via their receptors, respectively, to mediate glucose metabolism. (Ohishi
and Yoshida, 2012, Zhu et al., 2013)
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Combining the abilities of promotion of glucose-stimulated insulin secretion
and GLP1 release, a number of synthetic agonists of GPR119 have been
investigated. Since the first synthetic GPR119 agonist (PSN375963) was
reported, more than dozens of GPR119 agonists have been identified.
Furthermore, because of the clear therapeutic potential for treating type 2
diabetes, efforts have been made to optimize GPR119 agonists with oral
availability. Up to date, several GPR119 agonists including MBX-2982, GSK-
1292263 and PSN-821 have been tested in Phase II clinical trials and shown
a promising prospect for type 2 diabetes treatment (figure 1-10) (Jones et al.,
2009).
Figure 1-10 Chemical structures of GPR119 agonists used in phase 2 clinical
trials. The structure of PSN-821, another GPR119 agonist in phase 2 clinical trials
has not been revealed from Prosidion (Hansen et al., 2012, Zhu et al., 2013).
6) GPR120
Human GPR120 gene was firstly reported by Fredriksson et al., in 2003,
which is located on human chromosome 10q23.33 (Fredriksson et al., 2003).
GPR120 is highly conserved in many species, such as mouse, rat and fugu
(pufferfish) (Fredriksson et al., 2003). Interestingly, human GPR120 shares
50
10% identity with human GPR40, which is another GPCR recognizing
medium- and long-chain fatty acids.
A series of medium- and long- chain free fatty acids, including saturated free
fatty acids with C14 - C18 and unsaturated free fatty acids with C16 - C22,
were identified as endogenous ligands of GPR120. This similarity also
reflects on the synthetic agonists. Several GPR40 agonists were also found
as the agonists of GPR120 (Suzuki et al., 2008, Hara et al., 2009).
The expression distribution of GPR120 also shares a somewhat similarity to
GPR40. Pancreatic β-cells and enteroendocrine L-cells have been identified 
as the sites of GPR120 expression (Hirasawa et al., 2005). Besides, the
expression of GPR120 was also found in taste buds, indicating GPR120 may
function in taste sense (Martin et al., 2012). Notably, extensive tissue
expression analysis also demonstrated GPR120 is highly expressed both in
macrophages and mature adipocytes (Talukdar et al., 2011). The functions
of GPR120 both in macrophages and adipocytes (including anti-inflammatory
and glucose transport regulation) have been extensively studied (figure 1-11)
(Gotoh et al., 2007, Oh et al., 2010).
Recently, a genetic analysis conducted in obese children and adults revealed
a striking finding. About 3% of obese patients carry a loss-of-function,
nonsynonymous GPR120 mutation (R270H), which was believed as a factor
causing obesity and insulin resistance (Oh and Olefsky, 2012). Therefore,
GPR120 selective agonists have become potential drugs to improve insulin
resistance and treat obesity related diseases.
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Figure 1-11 Proposed mechanisms of GPR120-mediated insulin sensitization
and anti-inﬂammatory mechanism. GPR120 activates Gα(q/11) G-protein and
increases glucose uptake via PI3K / Akt pathway in white adipocytes, while GPR120
also inhibits TLR and TNF-α inflammatory signalling pathways after forming 
internalized GPR120-β-arrestin 2 complex in macrophages (Oh et al., 2010). 
1.3 Energy Homeostasis
The balance of energy storage and release, also known as energy
homeostasis is crucial for overall health and even survival (Woods et al.,
1998). It has been well characterized that obesity, the result of long-term
positive energy balance, increases the risk for many diseases such as type 2
diabetes, heart disease, hypertension, stroke, liver disease, colon cancer,
and osteoarthritis (Must et al., 1999). Similarly, long-term negative energy
balance also contributes to several severe body-disorders, including decline
in metabolism, loss of bone mass, decreases in thyroid hormones, and
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reduction in physical performance (Pollock et al., 2010). Therefore, the ability
to adapt to variety of energy intakes and outputs is vital. Currently, the widely
accepted model of energy homeostasis consists that fluctuation of energy
status generates complex peripheral signals, which become integrated in
neural systems; and in turn, regulate behavioural and endocrine output to
balance the nutrients intake, storage and expenditure for given
environmental conditions (Gale et al., 2004).
Due to the high importance of energy homeostasis, it is estimated that
thousands of genes are involved in this process. Several genes coding
energy ‘homeostatic’ regulators have been discovered by investigating
monogenic obesity models. Up to date, mutations in 11 different genes,
including leptin, leptin receptor, POMC (Proopiomelanocortin), PC1
(proconvertase 1), MC4R (Melanocortin-4-receptor), SIM1 (Single-minded
homolog 1), NTRK2 (Neurotropic tyrosine kinase receptor type 2), CRHR1
(corticotropin-releasing hormone receptor 1), CRHR2, GPR24, MC3R
(Melanocortin-3-recptor) have been identified to cause monogenic obesity
(Farooqi and O'Rahilly, 2005). Among them, the most striking example
appears to be the discovery of leptin, which presents a good model that how
the peripheral tissue (white adipose tissue) send signals (status of energy
storage) to central nervous system (hypothalamus) to decrease energy
intake via inhibiting neuropeptide Y (NPY) / Agouti-related peptide (AgRP)
and activating proopiomelanoortin (POMC) / cocaine- and amphetamine-
regulated transcript (CART) neurons (Jang et al., 2000, Cowley et al., 2001,
Elias et al., 1998). In addition to the monogenic obesity, there is another
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rarely-occurred syndromic obesity, which arise from discrete genetic defects
or chromosomal abnormalities, such as Prader-Willi syndrome (PWS),
Bardet-Biedl syndrome (BBS), and Alström syndrome (Chung, 2012). In
human, polygenic obesity occurs more commonly, which is the synergistic
effect of individual’s genetic makeup and obesogenic environment that
promotes energy intake over energy expenditure (Hinney and Hebebrand,
2008).
Appetite regulation is a major part of energy homeostasis regulation (Woods
et al., 1998). Since the efficiency of energy digestion and absorbance has
evolved into a very high level (normally more than 90%), therefore, in all
higher life-forms, the way to regulate energy intake mainly relies on the
appetite regulation, which is controlled by a complicated interplay between
adipose tissue, pancreas and gastrointestinal tract and the brain (mainly
hypothalamus) (Calder, 2015). The hypothalamus play a pivotal role in
controlling appetite, where the complex peripheral signals are integrated and
the neuropeptides are send out to stimulate (orexigenic) or inhibit
(anorexigenic) appetite and regulate metabolism of peripheral organs,
including adipose tissues, the gastrointestinal tract, the pancreas, the liver
and the muscle (Liao et al., 2012). Dozens of peptides / proteins have been
demonstrated to be involved in this process (figure 1-12). Hypothalamic
nuclei play central roles in the control of both hunger and satiety. Several
nuclei in hypothalamic (including the arcuate nucleus (ARC), paraventricular
nucleus (PVN), dorsomedial hypothalamic nucleus (DMH), lateral
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hypothalamic area (LHA) and the ventromedial hypothalamic nucleus (VMH))
are key areas responsible for appetite regulation (Yeo and Heisler, 2012).
Figure 1-12 Schematic diagram of the hypothalamic nuclei and other relevant
higher brain regions in appetite regulation. The ARC (arcuate nucleus) is the
crucial nuclei for the regulation of appetite. The ARC in hypothalamus lies
immediately above the medianeminence where peripheral peptides and proteins
can cross the specially modiﬁed blood-brain barrier. The ARC contains two discrete 
populations of neurones expressing orexigenic neuropeptides (including AGRP
(agouti-related peptide), NPY (neuropeptide Y), and GABA (gamma-Aminobutyric
acid)) or anorexigenic neuropeptides (including POMC (proopiomelanocortin) and
CART (cocaine and amphetamine- regulated transcript)), respectively. The ARC
has extensive reciprocal connections with other hypothalamic appetite regulating
regions including the VMN (ventromedial nucleus), DMH (dorsomedial
hypothalamus), PVN (paraventricular nucleus), and LH (lateral hypothalamus). NTS
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(nucleus of the solitary tract), DRN (Dorsal raphe nucleus) in the brainstem, VTA
(ventral tegmental area) in the midbrain and Striatum also mediate appetite by
projections to other nuclei in hypothalamus. Projections between nuclei are
indicated with arrows (Yeo and Heisler, 2012).
Notably, in addition to homeostatic eating, which primarily keeps energy
balance and meets the energy requirement, hedonic eating also contributes
to the energy intake, which arise from anticipation of eating for pleasure
instead of energy or nutrient requirement (Lowe and Butryn, 2007).
Activation of dopamine-containing neurons in the ventral tegmental area is
believed to be involved in many aspects of hedonic eating (figure 1-12)
(Lowe and Butryn, 2007). However, it is still difficult to draw a clear-cut line
separating “homeostatic” and “hedonic” eating.
Similar to the regulation of appetite, the energy expenditure, another aspect
of energy homeostasis regulation, also could be divided into basal and
adaptive energy expenditure (Bianco et al., 2005). The basal expenditure is
vital for maintaining basic metabolic and physiologic activities, such as
maintenance of body temperature, blood flow, ionic and substrate cycles,
and basal glands secretion, etc.; while the adaptive energy expenditure
mainly consists of physical activity and adaptive thermogenesis (Rosenbaum
and Leibel, 2010). Besides, excess energy will be stored. Triglyceride is the
most common format to store excess energy in body, while glycogen also
serves as a form of energy storage in liver and muscle (Dashty, 2013). In the
overfeeding experiment, almost two thirds of the weight gain is stored as
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increased fat mass in body (Bouchard et al., 1990, Diaz et al., 1992,
Tremblay et al., 1992, Lammert et al., 2000).
Although the detailed mechanism is still vague, however, the energy
expenditure also participates in the body weight maintenance and energy
balance regulation. As shown by underfeeding or overfeeding studies in
rodents, certain energy expenditure mechanisms, such as diet-induced
thermogenesis and leptin-induced thermogenesis, contribute to burning up of
excess energy as a specific response to increased body weight and fat
storage (Dulloo et al., 2002, Westerterp, 2004, Ukropec et al., 2006). In
human, overfeeding or obesity also leads to increased energy expenditure
via increasing sympathetic nervous system (SNS) activity and non-exercise
activity thermogenesis (NEAT), together with decreasing parasympathetic
nervous system activity (Welle and Campbell, 1983, Levine et al., 1999).
However, there is still not decisive evidence to support the hypothesis that
relatively low energy expenditure is main cause of the development of
obesity, since the controversial results have reported (Ramsey et al., 1998,
Brehm et al., 2005, Hamilton et al., 2007).
Regulation of energy expenditure is a complex system involving
endocrinological and biochemical mechanisms (Bukowiecki, 1985). Up to
date, many factors have been found to affect the energy expenditure, such
as physical activity, diet intake, body energy status, hormones (e.g. thyroid
hormones) levels, sympathetic nervous system and parasympathetic
nervous system activities, futile cycles, and intermediary metabolism genes
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(Westerterp, 2013, Reed and Hill, 1996, McAninch and Bianco, 2014,
Messina et al., 2013, Qian and Beard, 2006).
Many peripheral tissues have the metabolic potential to mediate
thermogenesis. For example, brown adipose tissue, a key thermogenic
tissue involved in energy expenditure regulation, contribute to the energy
expenditure via heat production (Dawkins and Scopes, 1965). Besides,
brown adipose also shows obvious hypertrophy and increased energy
expenditure in response to high fat feeding, suggesting a role of brown
adipose tissue in resisting obesity via mediating adaptive thermogenesis
(Mercer and Trayhurn, 1987). Indeed, the rats with interscapular brown
adipose tissue being lesioned had abnormal body weight (Connolly et al.,
1982). Leptin was also found to have direct effects on brown adipose tissue
such as increasing glucose utilization and lipolysis, also suggesting brown
adipose tissue responses to body energy status (Siegrist-Kaiser et al., 1997).
Short-chain fatty acids have been found to widely mediate energy
homeostasis through multiple mechanisms. For example, Frost et al., found
short-chain fatty acid acetate reduces appetite via a central homeostatic
mechanism (Frost et al., 2014). Meanwhile, den Besten et al., reported
protective effects of short-chain fatty acids against HFD-induced obesity in
mice; which comes from a PPARγ-dependent switch from lipogenesis to 
oxidation in liver (den Besten et al., 2015). Up to date, there are increasing
evidence to support the hypothesis that serum level of short-chain fatty acids
reflects nutrient status, thereby, which might feedback regulates the energy
metabolism according to body nutrient status. Therefore, it is worthy to
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investigate the effects of short-chain fatty acids on other aspects of energy
homeostasis, such as brown adipose tissue activities.
1.4 White adipose tissue
White adipose tissue is major form of adipose tissues in human, which
accounts for 10% - 25% of total body weight in a non-obese young adult; and
this number can reach to nearly 50% in an obesity patient (Heymsfield, 2005).
WAT is mainly composed by large number of white adipocytes and other cell
types including macrophage, leukocytes, fibroblast, endothelia cells, and
adipocyte progenitor cells (Caspar-Bauguil et al., 2009). The main function of
white adipose tissue is the storage of excess energy in the form of
triglycerides in white adipocytes. Meanwhile, it also serves as the thermal
insulation layer of the body and physical protection pad around important
internal organ (Anderson and Martin, 1994). However, with the discovery of
hormones and adipokines secreted by white adipocytes, the perspective
towards white adipose tissue has been profoundly updated (Scherer, 2006).
Nowadays, the white adipose tissue is regarded as an endocrine organ
(Fonseca-Alaniz et al., 2007).
To maximum the lipid conservation, white adipocytes have a distinctive
morphology with a single lipid droplet occupying nearly 90% cell volume and
squeezing the nucleus and mitochondria into the periphery of the cell
(Napolitano, 1963). Other organelles such as Golgi complex, rough
endoplasmic reticulum, smooth endoplasmic reticulum, and lysosomes also
stay at poorly development status in mature white adipocytes (Cinti, 2009).
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White adipocytes appear in a bright colour, which is believed related with
their low mitochondria density (Mescher, 2009). Besides, the mitochondria in
white adipocytes do not contain UCP1 protein, which is a distinguishing
feature of brown adipocytes (Lean and James, 1983, Pecqueur et al., 2001,
Ricquier and Bouillaud, 2000). However, recent studies showed mitochondria
in white adipocytes also played an important role in biochemical processes
including preadipocyte differentiation (adipogenesis) and lipid metabolism
(lipogenesis, lipolysis and fatty acids re-esterification). The enhanced
mitochondrial metabolism during the early stage of adipogenesis increases
cellular reactive oxygen species (ROS) levels, which is vital for the adipocyte
differentiation via an mTORC1-dependant pathway (Tormos et al., 2011).
Besides, mitochondria in white adipocytes also provide sufficient energy for
adipocyte differentiation. Furthermore, the results from clinical research also
highlighted the significance of mitochondria in white adipocytes. The
abundance of mitochondria and mtDNA in white adipocytes showed a
significant decrease in severe obesity and type 2 diabetes patients
(Yuzefovych et al., 2013); this phenomenon was also observed in ob/ob mice,
db/db mice, diabetic mice, and high-fat diet (HFD)-fed mice (Choo et al.,
2006, Rong et al., 2007). In vitro experiments prompted the hypothesis that
excessive glucose or free fatty acids causes mitochondria dysfunction, which
in turns severely impairs the function of white adipocytes (Gao et al., 2010).
As the pool of lipid in body, the lipid metabolism in white adipocytes plays an
important role in body energy homeostasis maintenance. The lipid storage
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and release are tightly controlled to keep the balance of energy intake and
expense of the body (figure 1-13).
Figure 1-13 Schematic diagram of lipid metabolisms in white adipose tissue.
White adipocytes take up fatty acids mainly from chylomicron or VLDL in the plasma
via fatty acid transporters. Lipoprotein lipase hydrolyses triglycerides in
chylomicrons and VLDL into free fatty acids and glycerol. White adipocytes also can
synthesize triacylglycerol from carbohydrates via lipogenesis. To release the energy
from triacylglycerol, triacylglycerol is mobilized through lipolysis process, which is
mainly dependent on three lipase including ATGL, HSL, and MGL. The key factors
and signalling pathways involved in lipid metabolisms regulation, such as insulin
signalling, adrenergic receptors signalling, PKA and PKG activities, GLUT4
expression and location have also been marked. (Gesta and Kahn, 2012)
Synthesis of fatty acids from glucose begins with excess glucose entering
into white adipocytes mainly through GLUT4, followed by glycolysis process
into pyruvate (Mashima et al., 2009). In mitochondria, pyruvate is oxidized
into acetyl-CoA by pyruvate dehydrogenase (Kersten, 2001). Acetyl-CoA is
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then transported back into cytosol in the form of citrate, which will be broken
down into acetyl-CoA again and catalysed by acetyl-CoA carboxylase into
malonyl-CoA (Kersten, 2001). Afterwards, fatty acids synthesis will be
catalysed in a cascade from malonyl-CoA (Ganguly, 1960). However, this de
novo lipogenesis in adipocytes is not main source for lipid storage in white
adipose tissue in human. Main source for lipid storage in white adipocytes
comes from chylomicron and very-low-density lipoproteins (VLDL) in the
plasma.
During the gap between meals or the period of fasting, white adipocytes
utilize triglycerides as energy source by mobilizing stored triglycerides. The
triglycerides can be broken down into free fatty acids and glycerol in a
cascade by a series of enzymes named lipases. The key lipases involved in
these hydrolysis steps consist of adipose triglyceride lipase (ATGL),
hormone-sensitive lipase (HSL), and monoacyl glycerol lipase (MGL).
Adipose triglyceride lipase (ATGL) was discovered as a novel TAG lipase in
2004 (Jenkins et al., 2004, Villena et al., 2004, Zimmermann et al., 2004).
Interestingly, adipose tissue is the only site with abundant expression of
ATGL gene (Kershaw et al., 2006). Besides, ATGL expression was also
found to be induced by fasting or glucocorticoids stimulation while to be
suppressed by feeding or insulin stimulation (Nielsen et al., 2011, Kershaw et
al., 2006). Furthermore, ATGL knock-out mice show massive accumulation
of triglycerides (Lammers et al., 2011). These evidences together suggest
ATGL might be a key lipase for triglycerides hydrolysis in vivo.
62
Hormone-sensitive lipase is the first identified lipase in 1960s, which can
catalyse both diglycerides and triglycerides hydrolysis in vivo, with 10-fold
higher activity for the diglycerides (Vaughan et al., 1964, Strand et al., 1964,
Fredrikson et al., 1986). Furthermore, evidence from HSL knock-out mice
showed deletion of HSL gene could not abolish the triglyceride hydrolysis
(Osuga et al., 2000, Wang et al., 2001) but cause a significant accumulation
of diglycerides in many organs in mice, which indicated HSL play a central
role in diglycerides catabolism as rate-limiting enzyme (Yeaman, 2004). HSL
activity is tightly regulated by hormones. The hormones such as
catecholamine, which levels up intracellular cAMP concentration and
activates cAMP-dependent PKA activity, leads to the phosphorylation of HSL
at three serine residues (Ser563, Ser659, and Ser660) (Krintel et al., 2009).
Monoacylglycerol lipase (MGL) is the lipase in charge of monoglycerides
breakdown (Karlsson et al., 1997). MGL is abundant expressed in adipose
tissue (Karlsson et al., 1997). Studies have demonstrated this step of
monoglycerides breakdown is less regulated compared to diglycerides and
triglycerides hydrolysis.
Since the discovery of leptin, more than dozens of adipokines have been
identified in white adipocytes (Fonseca-Alaniz et al., 2007). The adipokines
appear to be involved in a wide range of physiological processes including
metabolism, immunity, insulin sensitivity and angiogenesis.
Short-chain fatty acids have been found to mediate both lipid metabolism
and adipokines secretion in white adipose tissue. For example, Hong et al.
have demonstrated that short-chain fatty acids acetate and propionate
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stimulated adipogenesis of 3T3-L1 cells via GPR43 (Hong et al., 2005).
Besides, it has been found that activation of GPR43 by short-chain fatty
acids led to inhibition of lipolysis in white adipocytes in vitro. In vivo studies
also suggested acetate treatment suppressed plasma free fatty acids without
inducing the flushing side effect via GPR43 (Ge et al., 2008). Short-chain
fatty acids were also found to stimulate the expression of leptin in white
adipocytes (Xiong et al., 2004, Zaibi et al., 2010). Studies also indicated
propionate significantly stimulated leptin expression and decreased resistin
expression in human adipose tissue depots, suggesting short-chain fatty
acids are involved in adipokines secretion in human (Al-Lahham et al., 2010).
Recent study also revealed acetate modulated cytoplasmic leptin in bovine
pre-adipocyte (Yonekura et al., 2014).
1.5 Brown adipose tissue
Brown adipose tissue, also known as BAT or brown fat, is another type of
adipose tissues firstly found in rodents and human infants. In a long history, it
was thought brown adipose tissue was lost quickly after birth, however, both
molecular and histological evidence discovered recently supported brown
adipose tissue is present in adult humans. Brown adipose tissue has drawn
attention as a novel preventive and therapeutic target for the treatment of
obesity and other metabolic diseases due to its ability to generate heat by
burning calories. In both rodents models and adult humans, increase in
brown adipose tissue has been associated with a lean and healthy
phenotype (Kopecky et al., 1995, Ghorbani et al., 1997, Guerra et al., 1998,
64
Cypess et al., 2009, Virtanen et al., 2009). The mass of brown adipose tissue
negatively correlates with body mass index and positively with metabolism in
resting state, making stimulation of brown adipose tissue in humans to be a
possible approach for anti-obesity therapy (Pfannenberg et al., 2010,
Yoneshiro et al., 2011, Matsushita et al., 2014).
Figure 1-14 Schematic diagram of thermogenesis in brown adipocytes. Upon
stimulation by cold or β-adrenergic receptor ligands, triglyceride is broken down into 
glycerol and free fatty acids, the latter one then enter into mitochondria and oxidized
via β-oxidation to release the energy. The PKA-CREB-PGC1α signalling pathway 
activated by β-adrenergic receptor mainly mediates the mitochondrial regeneration 
in brown adipocytes. Glucose uptake by brown adipocytes via Glut4 can also be
converted into triglyceride for energy-generation. Besides used for normal ATP
production, majority energy released from oxidation is used to produce heat through
UCP1 (COSMO Bio Co., Ltd).
In contrast to white adipocytes which originate from myf5- precursors, brown
adipocytes stem from myf5+ embryonic precursors (figure 1-15) (Stephens et
al., 2011). However, a revised myf5 lineage model has been proposed
recently that white adipocytes, especially in retroperitoneal white adipose
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tissue (rWAT) and anterior subcutaneous white adipose tissue (asWAT)
develop from both myf5- and myf5+ lineage (Sanchez-Gurmaches and
Guertin, 2014).
Up to date, it has been reported that adipogenesis of brown adipocytes is
highly controlled by several transcription factors. BMP7 and PRDM16 have
been identified as the key regulators of brown adipocytes differentiation in
the early stage (Stephens et al., 2011), followed by C/EBPs and PPARs
continually promoting brown adipogenesis, which finally leads to the
induction of thermogenic genes expression (figure 1-15) (Seale, 2010). A set
of co-activators also play vital roles in the regulation of this process through
their interaction with transcription factors (Rosen et al., 2000). Of note,
PPARγ coactivator-1α (PGC-1α) interacts with the transcription receptor 
PPARγ and regulates the genes expression involved in adipogenesis of 
brown adipocytes (Liang and Ward, 2006).
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Figure 1-15 Schematic diagram of developmental pathway of white adipocytes,
brown adipocytes and skeletal muscle cells differentiation from mesenchymal
stem cells. Stimulatory effects are labelled with green arrows while red arrows
represent inhibitory effects. BMP2 and BMP4 are crucial for white adipocyte
differentiation, while BMP7 and PRDM16 decided the fate of brown adipocyte and
skeletal muscle cells. PPARγ is one of the master regulators for both types of 
adipocytes differentiation. (Stephens et al., 2011)
The increase in mitochondria numbers (mitochondrial biogenesis), is also
one major event during the brown adipogenesis. Indeed, the mitochondrial
density of brown adipocytes ranks highest among any cell type in mammals
(Lindberg et al., 1967). PGC-1α was found to be the major regulator of 
mitochondrial biogenesis, likely through the co-activation of a non-nuclear
hormone receptor transcription factor, nuclear respiratory factor-1 (NRF-1) in
brown adipocytes (Wu et al., 1999a). Since data from clinical trials have
suggested that increased PPARγ activity reduced hyperglycaemia in type 2 
diabetic patients, therefore, increasing the amount and/or activity of PGC-1α 
is considered as a potential pharmacologic strategy for the treatment of
obesity-related diseases (Puigserver, 2005).
The brown adipose tissue possesses several unique structures to perform its
non-shivering thermogenesis function. In contrast to one giant lipid drop and
small amount of mitochondria, brown adipocytes contain many small lipid
droplets and large number of mitochondria, which contribute to its special
dark red to tan colour (Vlachakis, 2007). Besides, brown adipose tissue also
has more capillaries and unmyelinated nerves than white adipose tissue due
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to the oxygen and sympathetic stimulation needed during thermogenesis
(Henrikson et al., 1997).
The most striking character of brown adipocytes is its capability of generating
heat by non-shivering thermogenesis (Cinti, 2012). Mitochondrial uncoupling
protein 1 (UCP1) has been found to be responsible for this process (Matthias
et al., 2000). UCP1 protein locates at inner mitochondrial membrane, playing
a role as a channel transporting proton from mitochondrial intermembrane
space to mitochondrial matrix (Collins et al., 2010). UCP1 mediated proton
transport uncouples the respiratory chain, allowing energy being released as
large amount of heat instead of ATP (Fedorenko et al., 2012).
The browning of white adipocytes, also known as beige adipocytes or brite
adipocytes, also possess thermogenic activities which can suppress weight
gain (Sanchez-Gurmaches and Guertin, 2014). In rodent, cold challenge or
adrenergic agonist stimulation led to the appearance of beige adipose in
white adipose pads (Young et al., 1984). Further study indicated these new-
formed brown adipocytes stemmed from existing white adipocytes, not
traditional myf5+ preadipocytes, confirming the existence of white adipocytes
browning (Shan et al., 2013). Interestingly, the beige adipocytes also showed
a direct link with obesity in humans. Carey Al, et al found beige adipocytes
derived from preadipocytes of subcutaneous white adipose tissue of obese
human contains reduced UCP-1 (Carey et al., 2014).
In conclusion, increasing evidence has shown the importance of brown
adipose tissue in human, therefore, better understanding of the functions of
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brown adipose tissue might open up an exciting new opportunity to combat
obesity and other related diseases.
1.6 Mitochondrial respiration
In eukaryotes, mitochondria are the key organelle to produce ATP via ATP
synthase (complex V) on its inner membrane. The process that ATP
synthase produce ATP relies on the H+ ions gradient from mitochondrial
matrix to intermembrane space (Fillingame, 1997). To generate H+ ions
gradient, complex I, complex III and complex IV move the H+ ions across the
inner membrane coupled with the electron transport chains (oxidative
phosphorylation) pathway, by which electron was transferred from donor
(NADH or succinate) generated in citric acid cycle (TCA) cycles to receptor
(molecular oxygen) via NADH → Complex I → Q → Complex III → 
Cytochrome c → Complex IV → O2 or Succinate → Complex II → FAD → Q 
→ Complex III → Cytochrome c → Complex IV → O2 (figure 1-16). ATP
synthase joins ADP and inorganic phosphate (Pi) together into
ATP(Nakamoto et al., 2008). ATP synthase consists of 2 regions, the FO
portion locates within the inner mitochondrial membrane and the F1 portion
locates inside the matrix of the mitochondria (Kagawa and Racker, 1966). X-
ray crystallography further revealed that F1 portion contains three alpha
subunits and three beta subunits, which surround an asymmetrical gamma
subunit (Fillingame, 1997). According to the current understanding of ATP
synthesis model, the proton flows into mitochondrial matrix via FO region and
drives the subunit C of FO portion rotates. The subunit C is tightly attached to
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the gamma subunit of F1 portion, which rotates within three alpha - beta
subunits of F1 portion and leads to ATP synthesis (Nakamoto et al., 2008).
Figure 1-16 Schematic diagram of electron transport chain and oxidative
phosphorylation. The electrons are passed from citric acid cycle products (NADH
or succinate) to mitochondrial redox carriers until they finally reach molecular
oxygen resulting in the production of H2O. As the Complex I, Complex III, and
Complex IV pass the electrons, H+ ions are transported into the intermembrane
space. The gradient of H+ ions concentration across the intermembrane can be
used to drive ATP synthase (Complex V) to produce ATP.
In brown adipocytes, mitochondria possess a unique uncoupling protein to
provide a mechanism for its enormous heat-generating capacity (Valverde et
al., 2005). Large number of uncoupling protein 1 (UCP1) has been found
only in mitochondria in brown adipocytes as well as beige adipocytes
(Keipert and Jastroch, 2014), which short circuits the electrochemical (H+)
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gradient across the intermembrane and thereby dissipate the large amounts
of chemical energy in the form of heat instead of cellular ATP (Rousset et al.,
2004, Keipert and Jastroch, 2014). Therefore, understanding parameters of
mitochondria respiration in brown adipocytes is important to investigate its
metabolic functions.
By using specific modulators of respiration which target components of the
electron transport chain in the mitochondria, it is possible to interrogate
several key parameters of mitochondria respiration, including basal
respiration (oxygen consumption used to meet energetic demand of the cell
under baseline conditions); ATP production (oxygen consumption used to
produce ATP by the mitochondria); proton leak (remaining basal
mitochondrial respiration not coupled to ATP production); maximal
respiration (the maximum rate of respiration that the cell can achieve upon
metabolic challenge.); spare respiratory capacity (the capability of the cell to
respond to an energetic demand as well as how closely the cell is to
respiring to its theoretical maximum) and non-mitochondrial respiration
(oxygen consumption that persists due to a subset of cellular enzymes that
continue to consume oxygen) (figure 1-17) (Wang et al., 2013a).
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Figure 1-17 The key parameters of mitochondrial respiration measured by
Seahorse XF24 Analyser with XF Cell Mito Stress Test Kit. The sequential
compounds injections (Oligomycin; FCCP; antimycin A & Rotenone) were indicated
with black arrows. Oligomycin blocks ATP synthesis against Complex V, therefore,
the decrease of OCR represents the ATP production; FCCP acts as an uncoupling
agent, therefore, the maximum OCR recorded after FCCP injection represents the
maximum mitochondrial respiration ability. Finally, antimycin A and rotenone totally
block the mitochondrial respiration via inhibiting mitochondrial Complex I and
Complex III, respectively. Therefore, the non-mitochondrial respiration can be
measured by the remaining OCR (Wang et al., 2013a).
Take XF Cell Mito Stress Test kit as an example, the compounds used in XF
Cell Mito Stress Test Kit include oligomycin, FCCP, and a mix of rotenone
and antimycin A. As demonstrated in figure 1-18, oligomycin targets
Complex V, which joins inorganic phosphate and ADP into ATP (Kagawa
and Racker, 1966). Therefore, measuring the decrease in oxygen
consumption following oligomycin injection can reveal mitochondrial
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respiration used for ATP production. FCCP (Carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone) is an uncoupling agent that disrupts
Complex V and collapses the H+ gradient across the intermembrane (Heytler
and Prichard, 1962). Consequently, electron flow through the electron
transport chain and oxygen consumption reach maximum after FCCP
injection. Therefore, FCCP-stimulated oxygen consumption can be
measured as maximal respiration and the spare capacity can be calculated
as the difference between maximal respiration and basal respiration.
Rotenone and antimycin A inhibit the Complex I and complex III, respectively
(Teeter et al., 1969). Combination of these two reagents totally blocks the
electron transport chain and mitochondrial respiration. Therefore, remaining
oxygen consumption after injection of rotenone and antimycin A represents
the non-mitochondrial respiration. The proton leak then can be calculated as
the difference between respiration after oligomycin injection and respiration
after rotenone and antimycin A injection.
Figure 1-18 The targets of compounds used in XF Cell Mito Stress Test Kit.
Oligomycin inhibits ATP synthase (complex V), FCCP dissipate the proton gradient
without ATP production, rotenone and antimycin A inhibit complexes I and III,
respectively (Wang et al., 2013a).
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1.7 Endoplasmic reticulum stress
Endoplasmic reticulum (ER) stress, as a cell self-protective mechanism, is
conserved between all mammalian species (Yang et al., 2014). As an
organelle for folding and sorting of protein inside the cells, ER possess large
number of endoplasmic reticulum chaperone proteins to help the newly made
proteins correct folding (Ma and Hendershot, 2004). However, upon
accumulation of malfolded proteins in the ER, cells activate a defence
mechanism called the ER stress response (Ma and Hendershot, 2004). A
wide range of factors have been identified as the causes of ER stress such
as aging, genetic deficiency, viral infection or the over-expression of proteins
(Yoshida, 2007). It has been revealed that three independent unfolded
protein response sensors (protein kinase RNA (PKR)-like ER kinase (PERK);
inositol-requiring protein-1 (IRE1α); and activating transcription factor-6 
(ATF6)) separately regulate induction unfolded protein response (UPR)
(Kaufman et al., 2010). In unstressed state, BiP/glucose-regulated protein 78
(BiP/GRP78) binds to PERK, IRE1α, and ATF6. Upon activation of unfolded 
protein response, BiP binds to unfolded proteins and dissociates with these
three ER sensors PERK, IRE1α, and ATF6, results in phosphorylation of 
PERK and IRE1α and cleavage of ATF6 (Lee, 2005). Phosphorylated PERK 
then induces phosphorylation of eIF2α, which attenuates global translation 
and selectively induces ATF4 translation (Harding et al., 2000). ATF4
induces expression of ER stress-associated molecules, including
chaperones, amino acid (AA) transporters, ER-associated degradation
(ERAD), CHOP and GADD34 (Harding et al., 2000, Harding et al., 2003, Ma
and Hendershot, 2003). Phosphorylation of IRE1α leads to the splicing of X 
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box binding protein-1 (XBP1) mRNA, which is translated into XBP1s isoform
and increases transcription of chaperones, foldases and ERAD genes
(Yoshida et al., 2001, Acosta-Alvear et al., 2007). ATF6 is activated by site 1
protease and site 2 protease (S1P/S2P) in the Golgi, which then translocates
to the nucleus to activate transcription of chaperones and ERAD genes
(Shen and Prywes, 2004). Recently, studies also suggested that these three
unfolded protein response sensors can form regulatory networks upon
unfolded protein response. For example, PERK/eIF2α/ATF4 pathway is also 
required for activation of ATF6 and its target genes (Teske et al., 2011).
Figure 1-19 The unfolded protein response signalling pathways. In unstressed
conditions, the BiP binds to three unfolded protein response sensors (PERK, IRE1,
and ATF6) to inhibit their activation. Upon accumulation of unfolded proteins, BiP
dissociates with these unfolded protein response sensors and interacts with
unfolded proteins, leading to the activation of PERK, IRE1, and ATF6. PERK
undergoes homodimerization and autophosphorylation, and phosphorylates eIF2α. 
Phosphorylated eIF2α decreases global translation but selectively increases 
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translation of ATF4. ATF4 regulates the transcription of genes involved in
antioxidant response and amino acid transporter synthesis, as well as chaperones,
CHOP and GADD34. IRE1 also autophosphorylates via homodimerization, which
results in the splicing of the XBP1 mRNA to form the transcription factor XBP1s,
which induces expression of ERAD proteins, chaperones and CHOP. ATF6 is
proteolysed by site 1 and site 2 proteases (S1P and S2P). The N-terminal domain of
ATF6 induces expression of chaperones, ERAD proteins and CHOP (Kaufman et al.,
2010).
ER stress has been identified as a characteristic in adipose tissue of obese
individuals, which is believed as one reason to cause chronic inflammation
(Kawasaki et al., 2012). Studies have revealed addition of chemical
chaperones could restore glucose homeostasis in a mouse model of type 2
diabetes via reducing ER stress, suggesting ER stress is a promising target
to treat obesity related diseases such as type 2 diabetes (Ozcan et al., 2006).
ER stress also mediates adipocytes differentiation. Using in vitro models,
Han et al., demonstrated ER stress suppressed adipocyte differentiation in
3T3-L1 cells (Han et al., 2013). ER stress was also found to affect
adipokines expression in adipose tissue. Mondal et al., found the induction of
ER stress was accompanied by a decrease in adiponectin and Iκβ-α 
expression as well as increase in TNF-α mRNA in adult-derived human 
adipocyte stem (ADHAS) cells (Mondal et al., 2012). High-fat diet induced
overexpression of GPR43 in tissues such as white adipose tissue, muscle
and liver (Dewulf et al., 2011, Cornall et al., 2011), suggesting high-fat diet
induced ER stress might also be involved in the regulation of GPR43 (Dewulf
et al., 2011).
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1.8 MAPK signalling pathway
Mitogen-activated protein kinases (MAPKs) are a highly conserved family of
serine/threonine protein kinases. The classical MAPK signalling pathways
are regulated by a three-tiered phosphorylation cascade:
MAPKKK→MAPKK→MAPK (Seger and Krebs, 1995). When cells are 
exposed to wide range of extracellular stimuli including mitogens, cytokines,
growth factors, and cellular stressors, etc., MAPKKK will be activated and
phosphorylate a downstream MAPKK, which will further activate a specific
MAPK by phosphorylation (Goldsmith and Dhanasekaran, 2007). In human,
at least 19 MAPKKK (MAP3K1, MAP3K2, MAP3K3, MAP3K4, MAP3K5(aka
ASK1), MAP3K6(aka ASK2), MAP3K7(aka TAK1), MAP3K8(aka TPL2),
MAP3K9, MAP3K10, MAP3K11(aka MLK3), MAP3K12(aka MUK),
MAP3K13(aka LZK), MAP3K14, MAP3K15(aka TAO1), MAP3K16(aka
TAO2), MAP3K17, RAF1, BRAF, ARAF, ZAK) and 7 MAPKK (MAP2K1,
MAP2K2, MAP2K3, MAP2K4, MAP2K5, MAP2K6, MAP2K7) have been
discovered. Conventional MAPKs include the extracellular signal-regulated
kinase 1 and 2 (ERK1/2), c-Jun N-terminal kinases 1-3 (JNK1-3), p38
isoforms (p38α, β, γ and δ) and ERK5 (figure 1-20) (Cargnello and Roux, 
2011). There are also atypical MAPK including ERK3/4, ERK7/8 and Nemo-
like kinase (NLK) being discovered in recent years (Cargnello and Roux,
2011). Not all atypical MAPKs follow the classical three-tiered MAPK
pathways. For example, ERK3/4 was recently shown to be directly
phosphorylated and activated by PAK kinases (Deleris et al., 2011). This
two-tiered system was believed to be a more ancient system. Although the
details of NLK and ERK7/8 activation remain vague, however, recent studies
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suggested that Thr286 is predicted to be key phosphorylation site in the
activation loop of NLK. Mutation of Thr286 abolished the
autophosphorylation of NLK and downstream c-Myb degradation (Brott et al.,
1998). Meanwhile, ERK7/8 was found to physically associate with c-Src.
Activated c-Src kinases phosphorylate and activate ERK7/8 in Cos7 cells
(Abe et al., 2002, Jin et al., 2015).
Figure 1-20 The cladogram for mitogen-activated protein kinases. Cladograms
were calculated based on the sequences of kinase domains for MAPKs indexed in
KinBase (kinase database) (Glatz et al., 2013).
The MAPKKKs activate MAPKKs in a very diversity way. Many MAPKKKs
own capacity to phosphorylate multiple MAPKKs in vitro and activate many
MAPKs when overexpressed (figure 1-21). Only MAPKKK Raf isoforms
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phosphorylate MEKs in a highly specific way (Rafs→MEK1/2) (Kyriakis et al., 
1992). There are also plenty of crosstalk and signalling switches in MAPKs
phosphorylation by MAPKKs, except MEK1/2 was only found to activate
ERK1/2 (Wortzel and Seger, 2011). Due to this selectivity, MEK1/2 inhibitors
serve as useful tools to investigate the effects of ERK1/2 activation on
various downstream effectors and further illustrate the roles of ERK1/2
pathway in cellular regulation. For example, U0126 directly inhibits MEK1
activity, and greatly impairs ERK1/2 activation in vitro (Favata et al., 1998).
While another widely used MEK1/2 inhibitor PD098059 indirectly blocks
MEK1/2 activation by binding to the inactive enzyme and also deactivates
ERK1/2 (Dudley et al., 1995).
Figure 1-21 Schematic diagram of MAPK cascade. Activated by a diverse array
of stimulus, MAPKK kinases (MAPKKKs) phosphorylate and activate a downstream
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MAPK kinase (MAPKKs), which then phosphorylates and activates MAPKs.
Activated MAPKs leads to the phosphorylation and activation of specific targets of
MAPK, such as members of the RSK, MSK, or MNK family, or induced the
activation of transcription factors including c-Fos, c-Jun, c-Myc, CREB, STAT1, etc..
(GeneCopoeia).
The kinase cascade that transmits signals from MAPKKK to MAPK provides
molecular mechanisms underlying signalling amplification and feedback
regulation. Analysis on the computational model has suggested multi-level
signalling cascades such as MAPK cascades attenuate input signal noise
(Thattai and van Oudenaarden, 2002), and amplify signal transduction
specificity (Swain and Siggia, 2002). MAPK cascades amplifying signalling
relies on the high efficiency of mitogen-activated protein kinases, which can
phosphorylate much more downstream effectors (Khokhlatchev et al., 1997).
Therefore, MAPK signalling cascade easily transmits the signals from small
number of activated receptors to widespread responses in the cells.
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Figure 1-22 Schematic diagram of amplification in signalling cascades. Small
number of upstream kinases are activated by input signals and induce the activation
of more downstream kinases, resulting in the amplified signals and widespread
responses in the cells.
To make MAPK signalling pathways to be controllable, MAPK signalling
cascades normally also contain negative feedback loops, which allows
excessive input signals can be ignored when the effects have reached the
desirable output levels (Katz et al., 2007). Take Raf-MEK-ERK cascade as
an example, activated ERK feeds back to MEK by phosphorylation of MEK1
at Thr292, which inhibits the MEK-ERK complex formation, and thereby
interferes the MEK phosphorylating ERK (Eblen et al., 2004, Shin et al.,
2009).
MAPKs are necessary to modulate adipogenesis in adipose tissue (Bost et
al., 2005a). For example, ERK1 was found to be required for proliferative
stage of adipogenesis. The ERK1 knock-out mice showed decreased
adipose tissue and less adipocytes compared to wild-type mice. Moreover,
the preadipocytes from ERK1 knock-out mice demonstrated impaired
adipogenesis (Bost et al., 2005b). Although the precise mechanisms
underlying the indispensable effects of ERK on adipogenesis is still not fully
understood, however, C/EBPβ, an ERK phosphorylation target, might 
account for the ERK effect on adipocyte differentiation (Park et al., 2004).
Meanwhile, increasing evidence also proved the inhibitory effects of p38
selective inhibitor on adipogenesis, suggesting the indispensable role of p38
in adipogenesis (Engelman et al., 1998). Indeed, p38 is also a key kinase for
the activation of thermogenesis in brown adipocytes (Cao et al., 2004).
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cAMP- and PKA-dependent activation of p38 is an indispensable step in the
transcription of the UCP1 gene in brown adipose tissue in mice (Cao et al.,
2004).
Indeed, it has been found that numerous metabolic regulators mediate brown
adipocyte functions via MAPKs. For example, irisin promotes browning of
white adipocytes via activating p38 and ERK signalling pathway (Wu and
Spiegelman, 2014, Zhang et al., 2014). Cardiac natriuretic peptides such as
atrial NP (ANP) and ventricular NP (BNP) induce PGC-1α and UCP1 
expression in human adipocytes in a p38 MAPK-dependent manner
(Bordicchia et al., 2012). GADD45γ regulates the thermogenic capacity and 
UCP-1 expression in brown adipocytes by activating p38 (Gantner et al.,
2014). These findings highlighted the involvement of MAPKs activation,
especially the ERK and p38 activation, in the regulation of brown adipocyte.
Recently, receptor-specific regulation of ERK1/2 activation by members of
free-fatty acids receptor family has been investigated (Seljeset and Siehler,
2012). The results demonstrated activation of free-fatty acids receptor
GPR40, GPR41 and GPR43 all leads to ERK1/2 activation in HEK293 cells
stable-transfected with these receptors, respectively. Besides, studies on
functions of free-fatty acids receptors also supported that MAPK signalling
pathways was involved in free fatty acids mediated effects. For example, it
has been found that short-chain fatty acids induce acute phosphorylation of
the p38 in MCF-7 human breast cancer cell line via GPR43 and in bovine
mammary epithelial cells via GPR41 and GPR43 (Yonezawa et al., 2007,
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Yonezawa et al., 2009). Collectively, MAPK signalling pathways may play
important roles in short-chain fatty acids mediated effects.
1.9 CREB signalling pathway
CREB, also known as cAMP response element-binding protein, is a cellular
transcription factor (Altarejos and Montminy, 2011). CREB is closely related
in structure and function to CREM (cAMP response element modulator) and
ATF-1 (activating transcription factor-1), which all belong to ATF/CREB
protein family. CREB contains two glutamate-rich domains (Q1 and Q2), a
central kinase-inducible domain (KID), and a carboxyl-terminal basic leucine
zipper (bZip) domain (figure 1-23). The phosphorylation at Ser133 inside the
KID domain mediates the interaction between CREB and CREB-binding
protein (CBP) / p300 (Vo and Goodman, 2001). bZip domain promotes
CREB - DNA binding (Sharma et al., 2007). CREB also can form homo-
dimers as well as hetero-dimers with other members of ATF/CREB family
through their bZip domains (Shaywitz and Greenberg, 1999). Q1 and Q2
domains interact with various co-factors to regulate CREB activity. For
example, Q1 and Q2 domains can interact with TATA binding protein-
associated factor II 135 (TAFII135), which in turn recruits a polymerase
complex and stimulates transcription (Felinski and Quinn, 2001).
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Figure 1-23 Modular organization of CREB. Yellow regions represent two Glu-rich
domains (Q1 and Q2); green region shows a central kinase-inducible domain (KID)
and blue region demonstrates a carboxyl-terminal basic Leu zipper (bZIP) domain.
The amino-terminal transactivation (TAD) domain consist of the KID domain and the
Q2 domain. Phosphorylation of Ser residues in the KID domain mainly mediates the
interaction with CREB-binding protein (CBP) and its paralogue p300.
Phosphorylation at Ser133 promotes this interaction while phosphorylation of other
Ser residues flanking Ser133 acts inhibitory effects. The Q2 domain binds to TBP-
associated factor 4 (TAF4); The bZIP domain mediates CREB binding to DNA and
cAMP-regulated transcriptional co-activators (CRTCs). Arg314 is key residue for the
CRTC binding (Altarejos and Montminy, 2011).
CREB is phosphorylated in response to a wide variety of signals (Mayr and
Montminy, 2001). Ser133 in KID domain is a key residue to stimulate CREB
activity, which could be phosphorylated by numbers of kinases, including
CaMK II, PKA, PKC, MSK, RSK, Akt and MAPKAP kinase 2, etc. (Alberts et
al., 1994, Andrisani, 1999). CREB phosphorylation at Ser133 leads to the
recruitment of CBP/ p300, followed by binding to gene promoters containing
cAMP response element (CRE) (Clark et al., 2015). The typical sequence of
CRE is ‘TGACGTCA’, while half-site ‘TGACG or CGTCA’ are also found to
possess transcriptional activities (Loeken, 1993).
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CREB is a crucial regulator to modulate metabolism (Altarejos and Montminy,
2011). Studies have highlighted the diverse functions of CREB in metabolic
tissues, including the liver, pancreatic islets, skeletal muscle and adipose
tissue. For example, CREB was found to promote β-cell survival. Disruption 
of CREB function in β-cells leads to decreased islet mass (Jhala et al., 2003). 
CREB is also important for skeletal muscle. Overexpression of dominant-
negative CREB in skeletal muscle causes progressive muscle wasting,
muscle inflammation and myonecrosis (Berdeaux et al., 2007). In adipocyte,
CREB activation leads to an increased expression of ATF3, which inhibits
the expression of insulin-sensitive GLUT4 (Qi et al., 2009). Mutation of
adipocyte-CREB in mice increased the expression of GLUT4 in adipocytes
and showed protective effects from development of insulin resistance (Qi et
al., 2009).
CREB has also been found to play crucial roles in adipogenesis and
mitochondrial biogenesis. In 3T3-L1 cells, Reusch et al. found conventional
differentiation inducing agents such as insulin, dexamethasone, and dibutyryl
cAMP stimulated CREB activation throughout the differentiation process
(Reusch et al., 2000). Furthermore, constitutively activation of CREB in
preadipocytes was sufficient to induce adipogenesis while expression of
dominant-negative CREB blocked the differentiation, indicating CREB is
necessary to induce adipogenesis (Reusch et al., 2000). Besides, CREB was
also found to regulate several adipocyte-specific genes transcriptions via
binding to putative CRE sequences in the promoters, such as PEPCK, FAS,
and FABP, etc.. (Reusch et al., 2000). CREB is also a key regulator for
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adipogenesis and thermogenesis in brown adipocytes. Upon activation of β-
adrenergic receptor, intracellular cAMP level, as well as cAMP-dependent
PKA activity are elevated, leading to the phosphorylation of CREB at Ser133.
Activated CREB up-regulates the expression of PGC-1α, which further 
increases the mitochondria biogenesis and brown adipogenesis (Scarpulla,
2011). Activated CERB also directly increases thermogenic genes
transcription such as UCP1 (Xue et al., 2005). In liver, CREB also controls
hepatic lipid metabolism via stimulating expression of PGC-1α. Mice with 
deficiency in CREB activity show a fatty liver phenotype (Herzig et al., 2003).
Collectively, these studies highlight the importance of CREB signalling
pathway in the control of energy homeostasis.
1.10 PPAR signalling pathway
PPARs (Peroxisome proliferator-activated receptors) are a group of nuclear
receptors activated by peroxisome proliferators (Moreno et al., 2010). Until
now, four PPAR isoforms (α; β/δ; γ1; γ2) have been identified in humans 
(Berry et al., 2003, Yanase et al., 1997). They share a similar structure which
contains the following functional domains: N-terminal region; DBD (DNA-
binding domain); flexible hinge region; LBD (ligand binding domain) and C-
terminal region (figure 1-24) (Wadosky and Willis, 2012).
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Figure 1-24 Modular organization of PPAR isoforms. Green region shows DBD
(DNA-binding domain); while orange region demonstrates LBD (ligand binding
domain). The key phosphorylation sites are marked as -P. (Wadosky and Willis,
2012)
PPARs activation requires the formation of heterodimers with another
nuclear receptor: retinoid X receptors (RXRs). Both DBD and LBD of PPARs
are involved in the dimerization with RXRs. (Bourguet et al., 1995). The
PPAR/RXR heterodimers recognize and bind to PPAR-responsive elements
(PPREs) in promoters. The typical PPRE contains direct repeats (DRs) DNA
sequence of AGG(T/A)CA separated by single or two intervening base-pairs
(Miyamoto et al., 1997).
The activation of PPAR/RXR heterodimers normally also requires the
recruitment of coactivators, such as PPARγ coactivator 1 (PGC-1), the 
histone acetyltransferase p300, and the CREB binding protein (CBP), to
induce the transcription of target genes (Viswakarma et al., 2010). This
process often occurs with the histone modification such as acetylation (figure
1-25).
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Figure 1-25 Model of PPAR-RXR coactivator complex. The transcription factors
PPAR and RXR form the heterodimerization via their DBD and LBD domains. After
ligand binding to PPAR, coactivators are assembled into transcription factor
complex and induce histone modifications such as acetylation, which activates the
transcription of target genes (Viswakarma et al., 2010).
Although PPAR isoforms are similar in structure and all play essential roles
in metabolism regulation, however, they have relatively distinct tissue
distribution and functions. For example, PPARα mainly expresses in liver and 
controls cholesterol metabolism and fatty acids oxidation (Burri et al., 2010);
while PPARγ is abundant in adipose tissue and regulates adipocyte 
differentiation (Siersbaek et al., 2010); PPARβ/δ is important for fatty acids 
transport and oxidation, mitochondrial respiration and thermogenesis in
skeletal muscles (Erol, 2007). However, recent studies also revealed that
there are overlaps across the functions of PPAR isoforms. For example,
PPARα also expresses in adipose tissues and promotes adipogenesis (Goto 
et al., 2011). PPARβ/δ activation also promotes triglyceride metabolism and 
UCP1 expression in white and brown adipocytes (Wang et al., 2003).
Although it is widely accepted that PPARγ is one of the master regulators for 
the differentiation of both white and brown adipocytes (Lee et al., 2008).
However, these two types of adipocytes exhibit distinct properties and
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transcriptome, indicating the existence of complex regulation of genes
expression during the differentiation of white and brown adipocytes. Recent
studies have highlighted the importance of coregulators of PPARγ (such as 
PGC-1α) in this process (Viswakarma et al., 2010).  
Due to its important roles in energy metabolism, PPARs, especially PPARγ, 
have become novel drug targets to treat obesity and diabetes. PPARγ 
agonist thiazolidinediones (e.g. rosiglitazone) have been demonstrated to be
effective insulin sensitizers in type 2 diabetes patients (Bailey and Day,
2001). However, due to its side effects on cardiovascular system,
rosiglitazone has been withdrawn from the market in European (Singh et al.,
2007). Similarly, several other thiazolidinediones, such as pioglitazone, and
troglitazone, has also been suspended in some country due to their risks of
causing bladder cancer and hepatitis, respectively (Turner et al., 2014,
Bonkovsky et al., 2002). Although most of the first generation of
thiazolidinediones have been abandoned in clinical treatment due to their
unneglectable side effects, however, because of their significant effects on
improving insulin resistance in type 2 diabetes patients, search for the novel
PPARγ agonists without severe side effects continues. Furthermore, several 
new investigated PPARα/γ dual agonists, such as ragaglitazar (Skrumsager 
et al., 2003), muraglitazar (Nissen et al., 2005), tesaglitazar (Oakes et al.,
2005), LSN862 (Reifel-Miller et al., 2005), naveglitazar (Yi et al., 2007), and
netoglitazone(MCC-555) (Imchen et al., 2013) are reported to improve insulin
resistance as well as decrease atherogenic triglycerides and increase
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cardioprotective HDL levels, which seems to be a promising strategy to
develop anti-diabetic drugs.
Both in vivo and in vitro studies have linked short-chain fatty acids with
PPARγ activity. For example, den Besten et al., found dietary supplement
with short-chain fatty acids induced a PPARγ-dependent switch from lipid 
synthesis to utilization in mice liver (den Besten et al., 2015). Alex et al.,
reported short-chain fatty acids increased angiopoietin-like 4 synthesis in
human colon adenocarcinoma cells by activating PPARγ (Alex et al., 2013). 
Due to the importance of PPARγ in adipocytes, it is reasonable to speculate 
that short-chain fatty acids may also mediate functions of adipocytes.
1.11 PI3K/Akt signalling pathway
Akt, also known as Protein Kinase B (PKB), is a serine/threonine-specific
protein kinase (Yang et al., 2004). Akt consists of three domains: the PH
(pleckstrin homology) domain at N-terminal, the kinase domain and the
regulatory domain at C-terminal (Hanada et al., 2004).
Figure 1-26 Modular organization of the AKT. AKT possesses three domains: the
PH (pleckstrin homology) domain, the kinase domain and the C-terminal regulatory
domain. The PH domain and the kinase domain are linked with a helix structure.
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The residues Thr308 in kinase domain and Ser473 in the hydrophobic motif of
regulatory domain are phosphorylated when AKT become active (Song et al., 2012).
Akt is mainly involved in the PI3K/AKT pathway (Downward, 1998). Activated
PI3K catalyses the phosphorylation of phosphatidylinositol into
phosphatidylinositol 3,4,5-trisphosphate (PI(3,4,5)P3) (King et al., 1997).
PI(3,4,5)P3 binds to Akt PH domain and induces conformational changes of
Akt, followed by exposure of phosphorylation sites Thr308 and Ser473
(Hanada et al., 2004). Phosphorylation of these two residues leads to fully
activation of Akt.
Phosphatase and tensin homolog (PTEN) antagonises PI3K functions by
converting PI(3,4,5)P3 into PI(4,5)P2. Because PI(3,4,5)P3 is the key
secondary message to activate Akt (Maehama and Dixon, 1999), therefore
PTEN also inhibits PI3K/Akt signalling pathway (Stambolic et al., 1998).
The PI3K-Akt pathway plays important roles in multiple cellular processes,
including brown adipogenesis. Recently, it has been demonstrated that Akt
pathway negatively regulated UCP1 transcription in brown adipocytes
(Ortega-Molina et al., 2012). Increasing PTEN activity or attenuating Akt
activity was found to up-regulate expression of brown adipocyte markers
UCP1 in brown adipocytes (Ortega-Molina et al., 2012). However, in vivo
experiment also demonstrated the necessity of Akt for the normal
differentiation of brown adipocytes. Akt1/2 knock-out mice displayed
impaired brown adipogenesis. (Peng et al., 2003). Akt was also found to
regulate adipocyte differentiation in very early stage (mitotic clonal expansion)
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(Nogueira et al., 2012). Therefore, the relationship between Akt and brown
adipogenesis still need more work to explore.
1.12 XBP1 signalling pathway
XBP1, the abbreviation for X-box binding protein 1, is a transcription factor
that regulates the mammalian unfolded protein response (He et al., 2010).
XBP1 contains a bZIP domain allowing it binds to the cis-acting X box
present in the promoter regions of human major histocompatibility complex
class II genes (Liou et al., 1990). Moreover, XBP1 also binds to ER stress
response element (ERSE) in response to ER stress (Yoshida et al., 2001).
The typical sequence of ERSE is CCAAT-N9-CCACG (Yoshida et al., 1998).
As discussed above, XBP1 mRNA splicing was induced after activation of
IRE1α, resulting in a frame-shift and an isoform XBP1s. Although both 
XBP1u and XBP1s can bind to ERSE in the presence of NF-Y, however, only
spliced form of XBP1 shows significant transcriptional activity and induces
target genes expression (Yoshida et al., 2001).
92
Figure 1-27 mRNA splicing of XBP1 in response to ER Stress. Grey and blue
regions represent two ORFs of XBP1; pink region shows a carboxyl-terminal basic
Leu zipper (bZIP) domain; green region demonstrates hydrophobic region and
yellow region shows transcriptional activator domain. Only the XBP1s form contains
the transcriptional activator domain in the C-terminal region when XBP1 mRNA
splicing occurs in response to ER Stress (Yoshida et al., 2001, Nagashima et al.,
2011).
As a key regulator in ER stress, abnormalities in XBP1 normally link with
increased ER stress response and subsequent susceptibility to inflammatory.
It has been suggested that XBP1 malfunction contributed to Alzheimer's
disease and inflammatory bowel diseases (such as Crohn’s disease) (Casas-
Tinto et al., 2011, Kaser et al., 2008).
XBP1 is indispensable for the differentiation of various cell types in vivo,
such as plasma cells, pancreatic and salivary exocrine cells (Reimold et al.,
2001, Lee et al., 2005). XBP1 is also crucial for the development of liver cells.
Mice lacking XBP1 displayed hypoplastic fetal livers (Reimold et al., 2000).
Besides, Xbp1 also mediates lipogenesis in the liver (Lee et al., 2008).
Furthermore, XBP1 is also found to be necessary for adipogenesis in vitro.
Suppressing XBP1 expression in preadipocytes in vitro led to severe
inhibition of adipogenesis (Sha et al., 2009). However, in vivo study showed
deletion of adipocyte XBP1 had little effect on adipose tissue formation and
metabolic functions in mice, suggesting the complex roles of XBP1 in
adipogenesis still need more evidence to elucidate (Gregor et al., 2013).
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1.13 STAT signalling pathway
STAT (signal transducer and activator of transcription) proteins are a family
of transcription factors. STAT proteins share a highly conserved Src
homology2 (SH2) domain, which mediates dimerization of STATs via
phosphotyrosine. The dimerization of STATs is an essential pre-requisite for
the classical STAT signalling pathways. Interestingly, STATs could form both
homodimers and heterodimers via their SH2 domains. For example, in type I
interferon signalling, STAT1-STAT2 heterodimers together with IRF9 can
bind to ISRE to induce target genes expression. Several widely-used STAT
inhibitors (e.g. 6-Nitrobenzo[b]thiophene-1,1-dioxide, N’-((4-Oxo-4H-
chromen-3-yl)methylene) nicotinohydrazide, etc.) target SH2 domain
phosphorylation and dimerization events, which also highlights the
irreplaceable roles of SH2 domain in STAT signalling.
It has been recognized for more than decades STATs proteins play important
roles in the transcriptional control of adipogenesis. The first evidence to
support this idea is that increase in expression levels of members of STATs
family such as STAT3, STAT5A and STAT5B occurs during differentiation of
3T3-L1 adipocytes and human primary adipocytes (Stephens et al., 1996).
Among them, STAT5s has been identified with strong pro-adipogenic
activities (Stewart et al., 2011). Knock-out transgenic mice models provide
more evidence to support the indispensable role of STATs proteins in
adipose tissue in vivo. Deletion of STAT5A or STAT5B leads to severe
impaired adipose tissue in mice, while double knock-out of STAT5A and
STAT5B causes loss of about 80% of fat pad (Teglund et al., 1998).
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Interestingly, there are wide cross talk between STAT5 signalling pathway
and PPARγ signalling pathway during adipogenesis. In several preadipocyte 
models, activated STAT5 have been shown to induce PPARγ expression in 
early stage of adipogenesis, suggesting that STAT5 can promote adipocyte
differentiation by regulating PPARγ. Intriguingly, during adipogenesis of 
human bone marrow-derived stromal cells, PPARγ binds to the STAT5A 
promoter (Olsen and Haldosen, 2006). Given the tight relationship of PPARγ 
and adipogenesis, elucidating the complex interplay of STAT5-PPARγ in 
mediating adipogenesis would advance our understanding towards the
transcriptional control of adipogenesis
1.14 Aims of the study
Short-chain fatty acids and their receptors have been proved to play
important roles in keeping body metabolic homeostasis. In addition to well-
studied function of mediating inflammation, GLP-1 secretion, and appetite,
short-chain fatty acids sensing GPCRs, especially GPR43, are also involved
in the regulation of white adipocytes differentiation and metabolism. However,
the implication of short-chain fatty acids and their receptors in brown adipose
tissue is little investigated. This research will focus on the functions of
acetate and its receptors in the brown adipose tissue and brown adipocytes
and illustrate signalling and biological actions of short-chain fatty acid
sensing GPCRs in brown adipocytes. In particular, this study will consist of:
To confirm the expression of short-chain fatty acids sensing GPCRs in brown
adipose tissue and brown adipocytes.
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To identify the expression pattern of short-chain fatty acids sensing GPCRs
in brown adipocytes during differentiation and in response to stimuli.
To investigate the role of acetate in brown adipogenesis and mitochondrial
biogenesis.
To illustrate activation of short-chain fatty acids sensing GPCRs induced
signalling cascades in brown adipocytes.
To study the role of acetate in lipid metabolism of brown adipocytes.
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Chapter 2: Material and methods
97
2.1 Material
2.1.1 General laboratory reagents
Methanol, Ethanol, Paraformaldehyde: VMR
Isopropanol: Sigma-Aldrich
Tris, SDS, Glycine, EDTA: Fisher Chemical
2.1.2 Molecular biology reagents and kits
Fetal Bovine Serum: Invitrogen
Dimethyl sulfoxide (DMSO): Sigma-Aldrich
Penicillin/Streptomycin (Pen/Strep): Gibco
Trypsin-EDTA solution: Sigma-Aldrich
DEPC-treated water: Invitrogen
Puromycin: Sigma-Aldrich
G-418 Solution: Sigma-Aldrich
TransIT®-2020 Transfection Reagent: Mirus Bio LLC
Lipofectamine® RNAiMAX Reagent: Invitrogen
QIAzol Lysis Reagent: QIAGEN
GenElute Mammalian Total RNA Kit: Sigma-Aldrich
Precision DNase: Primerdesign Ltd
nanoScript 2 Reverse Transcription kit: Primerdesign Ltd
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Taq DNA Polymerase: Invitrogen
dNTP Set: Thermo Scientific
SYBR Green PCR Mater Mix: Applied Biosystems
Agarose: VMR
GeneRuler 100 bp Plus DNA Ladder: Thermo Scientific
6 × DNA Loading Dye: Thermo Scientific
Ethidium Bromide: Sigma-Aldrich
ProtoGel 30% (37.5:1 Acrylamide: Bisacrylamide): Geneflow
4 × Resolving Buffer: Geneflow
4 × Stacking Buffer: Geneflow
Ammonium Persulphate (APS): Sigma-Aldrich
N,N,N’,N’-Tetramethylethylenediamine (TEMED): Sigma-Aldrich
Radioimmunoprecipitation lysis buffer (RIPA): Millipore
Protease/Phosphatase Inhibitor Cocktail: Roche
Phenylmethanesulfonyl Fluoride (PMSF): Sigma-Aldrich
Bicinchoninic Acid (BCA) Kit: Sigma-Aldrich
PageRuler Prestained Protein Ladder: Thermo Scientific
2× Laemmli Sample Buffer: Bio-rad
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Immobilon-P PVDF Transfer Membrane: Millipore
Bovine Serum Albumin (BSA): Sigma-Aldrich
ECL Plus reagents: GE Healthcare
TBST (10X) (Tris buffered saline w/Tween-20): Fisher Scientific
Adipogenesis kit: Millipore
Lipolysis Assay Kit (Fluorometric): Abcam
Free Fatty Acid Uptake Assay Kit (Fluorometric): Abcam
Glucose Uptake Assay Kit (Fluorometric): Abcam
CellTiter 96 Aqueous One Solution Cell Proliferation Assay kit: Promega
Immunohistochemical detection Kit: ImmunoCruz™ rabbit ABC Staining
Systems
Gill’s formulation #2 hematoxylin: Santa Cruz
2.1.3 Agonist, antangonist and inhibitor
4-CMTB: Tocris Bioscience
Acetate: Sigma-Aldrich
Palmitic Acid: Sigma-Aldrich
Pertussis toxin (PTX): Tocris Bioscience
U0126: Tocris Bioscience
U73122: Tocris Bioscience
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Gallein: Tocris Bioscience
Nʹ-((4-Oxo-4H-chromen-3-yl)methylene)nicotinohydrazide: Merck Millipore 
GW9662: Tocris Bioscience
HX 531: Tocris Bioscience
Rosiglitazone: Sigma-Aldrich
2.1.4 Antibody
Phospho-p44/42 MAPK (Erk1/2) Rabbit mAb: Cell Signaling (#9101)
P44/42 MAPK (Erk1/2) Rabbit mAb: Cell Signaling (#4695)
Phospho-Akt Rabbit mAb: Cell Signaling (#4060)
Akt Rabbit mAb: Cell Signaling (#9272)
Phospho-CREB (Ser133) Rabbit mAb: Cell Signaling (#9198)
CREB Rabbit mAb: Cell Signaling (#9197)
PGC-1α Rabbit Ab: Santa Cruz (sc-13067) 
UCP-1 Rabbit Ab: Sigma-Aldrich (U6382)
Phospho-PTEN (Ser380/Thr382/383) Rabbit Ab: Cell Signaling (#9554)
PTEN Rabbit mAb: Cell Signaling (#9559)
Horseradish peroxidase (HRP) conjugated anti-β-Actin antibody: Santa Cruz 
(sc-47778 HRP)
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2.1.5 Cell culture media
DMEM/Ham’s F-12 (1:1) with L-Glutamine, 15 mM Hepes, and 3.151 g/L
Glucose: Lonza
DMEM/Ham’s F-12 (1:1) w/o L-Glutamine w/o Hepes w/o Glucose: Generon
Ltd.
L-glutamine solution (200 mM): Sigma-Aldrich
XF Assay Medium: Seahorse Bioscience
XF Calibrant Solution: Seahorse Bioscience
2.1.6 Primers
All DNA oligos used for real-time PCR were synthesized by Sigma-Aldrich
and listed in Table below:
Table 2-1 Primer sequences for real-time PCR
Sequence (5'-3') Product
length
NCBI Reference
Sequence
mGPR43-Forward CCACTGTATGGAGTGATCGCTG 142 NM_146187.4
mGPR43-Reverse GGGTGAAGTTCTCGTAGCAGGT
mBMP7-Forward GGAGCGATTTGACAACGAGACC 158 NM_007557.3
mBMP7-Reverse AGTGGTTGCTGGTGGCTGTGAT
mPRDM16-Forward ATGCGAGGTCTGCCACAAGT 180 NM_027504.3
mPRDM16-Reverse CTGCCAGGCGTGTAATGGTT
mPPARγ-Forward GGCTTCCACTATGGAGTTCA 105 NM_011146.3/
mPPARγ-Reverse GATCCGGCAGTTAAGATCAC
mPGC1a-Forward TGCAGCCAAGACTCTGTATG 163 NM_008904.2
mPGC1a-Reverse ATTGGTCGCTACACCACTTC
mUCP1-Forward CACTCAGGATTGGCCTCTAC 151 NM_009463.3
mUCP1-Reverse CTGACCTTCACGACCTCTGT
mAP2-Forward ATCACCGCAGACGACAGGAA 132 NM_024406.2
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mAP2-Reverse TTCCACCACCAGCTTGTCAC
mRPL19-Forward GGAAAAAGAAGGTCTGGTT 72 NM_009078.2
mRPL19-Reverse TGATCTGCTGACGGGAGT
2.1.7 siRNA & shRNA
XBP1 siRNA were purchased from Santa Cruz.
GPR43 shRNA were ordered from Thermo Fisher.
2.1.8 Software
ABI 7500 Software: Applied biosystems
RTCA software: ACEA Biosciences, Inc.
GeneSys: Syngene, Division of Synoptics Ltd.
GeneTool: Syngene, Division of Synoptics Ltd.
GraphPad Prism 6: GraphPad software
2.2 Methods
2.2.1 Animals care
Male C57BL/6J (4 weeks old) mice were purchased from Dakewe Biotech
Co., Ltd (Beijing, China). After a 2-week quarantine, the C57BL/6J mice were
fed normal diet/chow until 12 weeks of age. For acetate administration, 6-
week-old mice were treated with sodium acetate (150 mM) in drinking water
for 6 weeks (n = 5 for control, n = 5 for acetate administration). For testing
the effect of rosiglitazone on GPR43 expression, mice (12 weeks old) were
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intraperitoneally injected daily with 10 mg/kg rosiglitazone for 7 days (n = 5
for control, n = 5 for rosiglitazone injection). All of the mice were housed in
the animal facility with a 12 h light/dark cycle and constant temperature (22–
24°C). The mice had free access to water and diet. Adipose tissue was
isolated as described as previous reports (Mann et al., 2014). All samples
were immersed in liquid nitrogen immediately before RNA extraction. The
animals care and samples collection were accomplished with the help from
Dr. Xiaoyu Chen and Msc. Xin Cai (Jining Medical University, Jining). All
procedures were approved by Jining Medical University and met the
standards of the Guide for the Care and Use of Laboratory Animals issued
by the Ministry of Science and Technology of the People’s Republic of China
in 2006.-
2.2.2 Cell culture
1) Isolation and immortalization of mice brown adipocyte cell line (IM-
BAT)
The immortalized brown adipocyte cell line (IM-BAT) from mice was
constructed by Dr. Mark Christian (University of Warwick, Coventry). Briefly,
primary cultures of brown adipose tissues were generated by first digesting
the interscapular BAT with Tissue Dissociation Buffer (DMEM:F12 medium
containing collagenase (10 mg/ml) and DNase (10 mg/ml)) and pelleting the
stromal vascular fraction (SVF) by centrifugation at 170 × g for 10 min.
Preadipocytes were purified by collecting the cells that passed through 100
µM of mesh. Next, brown preadipocytes were selected by collecting the cells
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that passed through 70 µM of mesh and were cultured in DMEM:F12
medium containing 10% fetal bovine serum and 1% antibiotic-antimycotic for
2 days before being immortalized by retroviral-mediated expression of
temperature-sensitive SV40 large T antigen H-2kb-tsA58. Cells were
continually cultured at 33 ˚C and selected with G418 (100 mg/ml) for 2 weeks. 
The established immortalized brown preadipocytes were maintained in
DMEM:F12 medium containing 10% fetal bovine serum, 1%
Penicillin/Streptomycin, and 50 µg/ml of G418. The mycoplasma
contamination was also checked by using kit before the cell line was used for
assays.
2) Maintenance and differentiation of IM-BAT cells
The IM-BAT cells were maintained in DMEM:F12 medium containing 10%
fetal bovine serum, 1% Penicillin/Streptomycin, and 50 µg/ml of G418. The
cells were passaged by using trypsin-EDTA treatment when they reach 80-
85% confluent. All experiments were performed between passages 12 and
22.
For differentiation of IM-BAT cells into adipocyte, cells were treated with
differentiation medium I (DMEM:F12 containing 500 µM 3-isobutyl-1-
methylxanthine (IBMX), 250 nM dexamethasone, 170 nM insulin, 1 nM
3,3’,5-triiodo-l-thyronine (T3) and 10% fetal bovine serum) for 48 h, followed
by incubation with differentiation medium II (DMEM:F12 containing 170 nM
insulin, 1 nM T3 and 10% fetal bovine serum) until day 7 when lipid droplet
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formation was observed. The differentiation medium II was replaced every 2-
3 days.
3) Maintenance and differentiation of T37i cells
The T37i cells were maintained in DMEM medium containing 10% fetal
bovine serum, and 1% Penicillin/Streptomycin. The cells were passaged by
using trypsin-EDTA treatment when they reach 70-80% confluent. For
differentiation of T37i cells into adipocyte, cells were cultured to confluence
and treated with differentiation medium (DMEM medium containing 10% fetal
bovine serum, 20 nM insulin, 2 nM 3,3’,5-triiodo-l-thyronine (T3)) until day 7
when lipid droplet formation was observed. The differentiation medium was
replaced every 2-3 days (Penfornis et al., 2000).
4) Maintenance and differentiation of 3T3-L1 cells
The 3T3-L1 cells were maintained in DMEM medium containing 10% new-
born calf serum, and 1% Penicillin/Streptomycin. The cells were passaged by
using trypsin-EDTA treatment when they reach 70-80% confluent. For
differentiation of 3T3-L1 cells into adipocyte, cells were cultured to
confluence and treated with differentiation medium (DMEM medium
containing 10% fetal bovine serum, 1.0 µM dexamethasone, 0.5 mM IBMX,
1.0 µg/ml insulin) for 48 h, followed by incubation with Adipocyte
Maintenance Medium (DMEM medium containing 10% fetal bovine serum
and 1.0 µg/ml insulin) until day 7 when lipid droplet formation was observed.
The Adipocyte Maintenance Medium was replaced every 2-3 days.
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2.2.3 siRNA transfection of IM-BAT adipocytes
To introduce siRNA into un-differentiated IM-BAT cells, siRNA were
transfected with Lipofectamine RNAiMAX according to manufacturer's
manual. Briefly, IM-BAT cells were seeded to be 60-80% confluent at the
time of transfection. siRNA-lipid complexes were prepared and incubated at
room temperature for 10 min before added into cells. The cell culture
medium was changed back into DMEM:F12 containing 10% FBS and 1%
Penicillin/Streptomycin after 6h. 24h post transfection, the cells were
differentiated as described above.
To introduce siRNA into fully differentiated adipocytes, a modified version of
‘reverse transfection’ was applied according to the method reported by Kilroy
et al. (Kilroy et al., 2009). Briefly, adipocytes were differentiated according to
the description above and trypsinized to detach from the plate. The detached
adipocytes were pelleted and gently resuspended in DMEM:F12 medium
containing 10% FBS without antibiotics. The siRNA-lipid complexes were
prepared inside the wells of cell culture plates as below: 12 pmol siRNA were
diluted in 100 µl Opti-MEM medium and mixed gently. Then, 2 µl
Lipofectamine RNAiMAX were added into each well containing the diluted
RNAi molecules and mixed gently. After 20 mins incubation at room
temperature, 1 ml suspended adipocytes (5 × 105 cells/ml) were plated in
wells containing siRNA-lipid complexes. The cells were incubated at 37˚C in 
a CO2 incubator for 24 h before down-streaming assays were carried out as
indicated. The efficiency of gene knock-down was measured by real-time
PCR or Western blots.
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2.2.4 Oil Red O staining
Lipid accumulation of differentiated adipocytes was visualized and
determined by quantitative Oil Red O staining kit (Millipore ECM950).
Briefly, the preadipocytes were differentiated as described above. Seven
days after induction, the medium was carefully discard and the cells were
washed with PBS, and ﬁxed by 3.7% formaldehyde for 15 min, followed by 
stained with Oil Red O solution for 15 min. After staining, plates were
washed twice with water and photographed. Oil Red O was eluted using Dye
Extraction Solution (100% isopropanol), and absorbance at 490 nm was
measured by microplate reader.
2.2.5 Real time analysis using the xCELLigence system
1) xCELLigence System Principle
The xCELLigence system consists of RTCA station (RTCA Analyser and
RTCA Control Unit) and E-Plate/CIM-Plate. The E-Plate/CIM-Plate
incorporates a gold sensor electrode array that allows cells in the well to be
cultured on the top of these electrode while the RTCA station was used to
collect and process electrical impedance of sensing electrode signals from E-
Plate/CIM-Plate (figure 2-1).
Then, the electrical impedance of gold sensing electrode underneath the
cultured cell layer monitored by RTCA station can be calculated as arbitrary
cell index (CI) units as below:
CI = (Zi-Z0) / 15,
108
in which Zi represents the electrical impedance at given time points and Z0
means the background of electrical impedance.
Since the electrical impedance is affected by the number, shape, adhesion,
or mobility of the adherent cells, therefore, the changes of CI could reflect the
primary events of adipocyte differentiation.
2) xCELLigence RTCA DP System Set up
The xCELLigence RTCA DP system was calibrated as manufacturer’s
instructions prior to the measurements. Briefly, the resistor plate was placed
into DP station cradle and the Resistor Plate Verification program (-10
sweeps every 30 seconds) was initiated in RTCA software. The results were
checked before the start of the experiment. Cell index (CI) value should be
lower than 0.063. The raw data should be as below: Row A & Row H: 40.0 ±
2.0; Row B & Row G: 67.5 ± 2.5; Row C & Row F: 93.6 ± 2.9; Row D & Row
E: 117.6 ± 3.3.
3) Establish the background reading
E-plate was filled with basal medium (100 µL/ well) and placed into DP
station cradle (housed in a humidified incubator at 37 ˚C with a 5% CO2
atmosphere) to establish the background reading. The program for
background measurement was set as Step 1 = 1 sweep for 1min.
4) Real-time monitoring the primary morphological changes in IM-BAT
cells differentiation
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IM-BAT cells were seed into E-plate at 5 × 104 cells per well in 100 µl
aliquots. The E-plate was equilibrated at room temperature for 30 min before
moved back into DP station cradle. The program was set as 6 sweep every
20 min followed by 100 sweeps every 1 h.
Figure 2-1 The principle of xCELLigence system. The presence of adherent cells
on top of the electrodes will affect the local ionic environment at the
electrode/solution interface, leading to an increase in the electrode impedance. The
increase in electrode impedance is positively correlated to the number of cells
attached on the electrodes. Besides, the electrode impedance is also affected by
the quality of the cell interaction with the electrodes such as cell adhesion or
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spreading. By monitoring electrode impedance, cell viability, number, morphology,
and adhesion degree could be measured in a number of cell-based assays.
When cells reached confluence, E-plate were taken out and cells were
treated with Differential medium I as described above at 36 h post-seeding
for 2 days, followed by incubation with Differential medium II only or with
acetate/ 4-CMTB until days 7 post-induction. The program for each
measurement was both set as 6 sweep every 20 min followed by 100
sweeps every 1 h.
The arbitrary Cell Index (CI) was monitored by electrical impedance
measurements. The differentiation of IM-BAT cells in E-plate was confirmed
by optical microscope observation at days 7 post-induction.
5) Data analysis
After the experiment, the Cell Index (CI) curves were normalized to the last
time point before the addition of the differentiation medium by using the
RTCA software included in xCELLigence system. For cooperation of two
groups, P values were calculated using Student’s t-tests.
2.2.6 Immunohistochemistry
1) IHC staining of differentiated IM-BAT cells
Preparation of coverslips
Circle coverslips were sterilized by 70% ethanol for 30 min and dried in cell
culture hood. After sterilization, the cover slips were placed in 12-well plates
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and coated with 2% Gelatin solution for 30 min followed by being dried for 15
mins prior to use.
Preparation of cells on coverslips
Preadipocytes were seeded into 12-well plates containing Gelatin coated
coverslips at the density of 1 × 105 /well. When cells reached confluence,
preadipocytes was treated with differentiation medium I for 2 days followed
by incubation with Differential medium II until days 7 post-induction before
staining.
Fixation of cells on coverslips
When adipocytes have reached differentiated status, the culture medium was
removed and the cells were washed twice with PBS before incubated with
4% formaldehyde fixative solution for 20 mins at room temperature.
IHC staining for cultured cells on coverslips
The fixed cells were washed twice with PBS. To avoid endogenous
peroxidase interference, endogenous peroxidase was neutralized using 0.1%
hydrogen peroxide for 5 min. After wash with PBS twice, the cells were
blocked with 1.5% blocking serum for 5 min and washed with PBS twice
again. The cells were incubated with primary antibodies (anti-GPR43(H-120),
Santa Cruz, sc-32906) at 1:100 overnight at 4 ˚C followed by washing with 
PBS for three times. The cells were incubated with biotin-conjugated
secondary antibody and avidin-biotin enzyme reagent (AB enzyme reagent)
for 30 mins sequentially with 3 washes for each step. The staining was
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developed with DAB chromogen for 2.5 mins followed by counterstaining
with Gill’s formulation #2 hematoxylin (Santa Cruz, sc-24973) for 10 seconds.
2) IHC staining of Paraffin-embedded mice BAT tissue
Sectioning formalin-fixed, paraffin-embedded mice brown adipose
tissues
Formalin-fixed, paraffin-embedded mice brown adipose tissues were kindly
provided by Dr. Manjunath Ramanjaney (Hamad Medical Corporation, Doha).
Slides with paraffin-embedded sections were prepared by Mr. Sean James
(West Midlands Genomic Medical Centre, Coventry). Briefly, paraffin-
embedded adipose tissue was cut into 3 µm thick tissue sections using a
rotary microtome Lecia RM2235. The sections were mounted onto
histological slides in a 45 °C water bath. Slides with paraffin-embedded
sections were dried overnight in oven.
Removal of Paraffin and Rehydration
The paraffin-embedded sections were deparaffinized and rehydrated as
follow: 3 × xylenes for 5 mins each, 2 × 100% isopropanol for 3 mins each, 1
× 70% isopropanol for 3 mins.
Antigen Retrieval
The slides were placed in a Slide Chamber filled with 10 mM sodium citrate
buffer (pH=6.0) and heated in 2100 Antigen Retriever to unmask antigen.
ABC staining
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GPR43 were detected in formalin-fixed, paraffin-embedded human tissue by
immunoperoxidase staining using anti-GPR43(H-120) antibody (Santa Cruz,
sc-32906) and ImmunoCruz rabbit ABC staining system (Santa Cruz sc-2018)
according to the manufacturer’s instructions. Briefly, the section was blocked
in 1.5% blocking serum for 1 h before incubated with primary antibody (1:100)
overnight at 4 ˚C. The sections were washed with PBS three times and 
stained with biotinylated secondary antibody (1 µg/ml) followed by PBS
washes three time for 5 mins each. The staining was developed using DAB
chromogen for 2.5 mins followed by hematoxylin (Gill’s formulation #2
hematoxylin, Santa Cruz, sc-24973) counterstaining for 10 seconds.
2.2.7 Real-Time Quantitative Reverse Transcription PCR (Two-Step)
1) RNA isolation
For extraction RNA from cultured cells, cells were lysed directly in cell culture
plates by adding 500 µl QIAzol lysis reagent per 107 cells. Total RNA was
purified according to the manual provided by Sigma GenElute Mammalian
Total RNA Kit.
For extraction RNA from adipose tissue, the sample was quickly sliced into
pieces up to 25 mg followed by addition of 500 µl QIAzol lysis reagent and
homogenization immediately until no visible pieces remain. Total RNA was
then purified according to manufacturer's instructions.
All RNA samples were quantified by NanoDrop 1000 UV-Vis
Spectrophotometer and treated with RNase-free DNase I digestion at 37˚C 
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for 30 mins to exclude the contamination of genomic DNA before down-
streaming assays.
2) Reverse transcription
All the first-strand cDNA synthesis was performed using purified total RNA
with nanoScript 2 Reverse Transcription kit by reverse transcription.
For the reverse transcription:
Template RNA (1 µg); 0.5 µl random nonamer primers and 0.5 µl oligo-dT
primers were mixed with RNase/DNase free water to final volume of 10 µl,
and incubated at 65 ˚C for 5 min, and placed on ice immediately. The RT 
reaction mix were made up according to total number of reactions as below:
nanoScript2 4 × Buffer (5 µl / reaction); 10 mM dNTP (1 µl / reaction);
RNase/DNase free water (3 µl / reaction); nanoScript2 enzyme (1 µl /
reaction).
10 µl RT reaction mix were added into samples containing template RNA and
random nonamer / oligo-dT primers; and incubated 5 min at 25˚C followed by 
20 min at 42˚C. The reaction was terminated by heating at 75˚C for 10 min. 
The cDNA was stored at -20 ˚C. The cDNA was diluted 1:5 before used for 
quantitative real-time PCR.
3) Quantitative real-time PCR (qPCR)
The following components (2 × SYBR Green PCR Master Mix: 10 µl /well;
Forward Primer (10 µM): 0.5 µl /well; Reverse Primer (10 µM): 0.5 µl /well;
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template cDNA: 1 µl / well; RNase/DNase free water: 8 µl /well) were added
to an ABI 96-well plate sitting on ice:
The plate was centrifuged at 300 × g for 3 min before put into ABI 7500 fast
real-time PCR system. The ABI 7500 software were set as follows:
Holding stage: Pre-denature: 95˚C 20 s 
Cycling Stage: Denature: 95˚C 3 s 
Extend: 60˚C 30 s 
Melt Curve Stage: 95˚C 15 s 
60˚C 1 min 
The amplification products were analysed by DNA agarose gel
electrophoresis. The gel was loaded with 20 µl DNA samples or DNA ladders
in each well. The DNA was separated at 100 V until dye is closed to the end
of gel. The results were captured by UV transilluminator equipped inside
G:BOX Chemi XX6 system.
2.2.8 Measurement of Mitochondrial DNA
Genomic DNA and mitochondrial DNA were isolated from mature IM-BAT
brown adipocytes using QIAamp DNA Mini Kit according to manufacturer’s
instruction.
The mitochondrial DNA level was determined with primers targeted for
mouse mitochondrial D-Loop region and normalized against the genomic
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DNA measured with 18S primers using the comparative CT method with ABI
7500 fast real-time PCR system as described above.
2.2.9 Western Blots
1) Cell / Tissue lysate preparation
For release the protein from cultured cells, cells were lysed directly in cell
culture plates by adding 200 µl ice-cold RIPA lysis buffer per 107 cells and
agitation at 4˚C for 30 min. The cell lysate was then transferred into a 1.5 ml 
Eppendorf tube followed by 12,000 × g centrifuge at 4 ˚C for 15 min. The 
supernatant was aspirated into another new 1.5 ml Eppendorf tube before
protein quantification.
For extraction protein from tissue, the sample was quickly dissected into
pieces followed by addition of 300 µl RIPA lysis buffer per 5 mg and
homogenization immediately. The tissue lysates were than agitated at 4˚C 
for 2 h followed by centrifuge at 12,000 × g for 15 mins. The supernatant was
aspirated into another new 1.5 ml Eppendorf tube before protein
quantification.
All protein samples were mixed in a 1:1 ration with 2 × Laemmli buffer and
denatured by heating at 95 ˚C for 5 min before loading into gels. 
2) Protein concentration determination
Protein concentration was measured by bicinchoninic acid (BCA) methods
according to the manufacturer’s instruction. In brief, the assay based on the
reduction of Cu2+ to Cu1+ from Cu2+-protein complex under alkaline conditions
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with the detection of purple-blue Cu1+-BCA complex by reading the
absorbance at 562 nm (Olson and Markwell, 2001). The standard curve was
drawn by plotting the average absorbance at 562 nm vs. the concentration of
BSA standard at each measurement, and the concentration of protein lysate
was calculated according to the standard curve.
Figure 2-2 A typical standard curve for BSA standards in BCA protein
quantification assay. The standard curve was calculated using linear regression
and only results with R2>0.99 will be used to calculate protein concentration.
3) Sodium-dodecyl-sulphate polyacrylamide (SDS-PAGE) gel
electrophoresis
The resolving gel (12 % Acrylamide, for separating proteins with 10 -200 kDa
MW) was made following the receipt below:
ProtoGel 30% 4.0 ml;
4 × Resolving Buffer 2.5 ml;
Deionized H2O 3.4 ml;
10% APS 0.1 ml;
TEMED 0.01 ml
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The resolving gel casting solution was poured into gel casting cassette and
overlaid with distilled water to provide a sharp interface.
After the resolving gel set, the stacking gel was made following the receipt
below:
ProtoGel 30% 1.3 ml;
4 × Stacking Buffer 2.5 ml;
Deionized H2O 6.1 ml;
10% APS 0.1ml;
TEMED 0.01 ml
The stacking gel casting solution was poured into gel casting cassette and
inserted with the comb to form the well.
After the stacking gel set, the gel cassette was installed into the tank
apparatus. The tank was filled with 1 × SDS Running buffer and load 20 µl
protein samples or 1 × Laemmli buffer into each well. The protein was
separated at 15 mA per gel until dye is all the way at end of gel.
4) Membrane Transfer
The transfer stack was set up in the following orientation (from top to
bottom: Clear clap; Sponge; Filter Paper × 2; PVDF Membrane; Gel; Filter
Paper × 2; Sponge; Black clap) and installed into the tank apparatus. The
tank was filled with ice-cold 1 × Tris-glycine buffer. The protein was
transferred from the gel to the PVDF membrane at 100V for 1 h.
5) Blocking, Antibody incubation, and Detection
119
After transfer, the PVDF membrane was washed twice in TBST solution and
blocked in 5% non-fat milk at room temperature for 1 h. The PVDF
membrane was then incubated with relevant primary antibody diluted in 5%
BSA solution at optimized dilution overnight at 4 ˚C followed by three times 
washing with TBST solution before the PVDF membrane was incubated with
HRP-conjugated secondary antibody at room temperature for 1 h. ECL
Western Blotting Substrate (Pierce) was used to visualize the signal of
protein bands. The chemiluminescence were captured by X-ray films (Fujifilm
Super RX) or G:BOX Chemi XX6 system. All X-ray films were digitized by
Cannon 700F scanner. All the Western blots results were quantitated and
analysed by using GeneTools software.
2.2.10 Phospho-Kinase Antibody Array Assay
1) Phospho-Kinase Antibody Array Principle
The Proteome Profiler phospho-kinase array (R&D Systems) were spotted
with capture antibodies against 43 different kinases and 2 related total
proteins. Cell lysate samples are diluted and incubated with the array. Target
proteins are bound by its cognate immobilized capture antibody on the
membrane. Detection Antibody Cocktail recognize target proteins and form
protein / detection antibody complex. Streptavidin-Horseradish Peroxidase
and chemiluminescent detection reagents were added to generate signals
which are proportional to the amount of proteins bound. Chemiluminescence
is detected in the same manner as Western blots.
2) Screening the effects of acetate treatment on kinases
phosphorylation in IM-BAT cells
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IM-BAT cells were differentiated and treated with or without acetate (10 mM)
for 15 min. Cell lysates were prepared and quantified as described above.
After blocked with Array Buffer 1 for 1 h, of cell lysate were applied to
phospho-kinase array and incubated at 4˚C overnight. The phospho-kinase 
array was washed with wash buffer for three times and incubated with
Detection Antibody Cocktail at room temperature for 2 h before washed for
three times again. The phospho-kinase array was then incubated with
Streptavidin-HRP for 30 min at room temperature and washed three times
before developed by adding Chemi Reagent Mix. The results were captured
by G:BOX Chemi XX6 system (Sysgene) and quantitated using GeneTools
software (Sysgene).
2.2.11 Cell viability assay (MTS assay)
The effect of acetate treatment on proliferation of brown adipocytes was
measured by CellTiter 96® AQueous One Solution Cell Proliferation Kit.
Briefly, cells were seeded into 96 well plate at the density of 5 × 103 cells per
well and cultured in the medium free of phenol red with or without acetate for
24 h. Following treatment, 20 µl CellTiter 96 Aqueous One Solution Reagent
was add to each well and the plate was incubated at 37 ˚C for 1-4 h. The 
absorbance was detected at 490 nm using a plate reader.
2.2.12 Oxygen consumption rate (OCR) measurement
The Seahorse Bioscience XF24 extracellular flux analyser was used to
determine the cellular oxygen consumption. O2 tension in an extremely small
volume (less than 7 µl) of medium above the monolayer of cells in the XF24
culture microplates were measured by a solid state sensor probes hanging
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200µm above the cell. The Oxygen consumption rate (OCR) was calculated
by plotting the O2 tension of the medium in the microenvironment above the
cells as a function of time. Baseline (Basal) OCRs were measured firstly
followed by oligomycin, FCCP and rotenone + antimycin A being
pneumatically injected into the media in each well sequentially through an
integrated drug delivery system to assess the ATP turnover, maximum
respiratory capacity and non-mitochondrial respiration, respectively. Total
protein was extracted by RIPA buffer directly in XF24 culture microplates
after OCR measurement. The protein content was quantified by BCA assay
as described above and used to normalize the OCR.
2.2.13 Flowcytometry analysis of mitochondrial mass
IM-BAT cell were differentiated as described above for ≥7 days. Acetate or 4-
CMTB was supplemented with the differentiated medium II from day 2 during
differentiation in experimental group.
When IM-BAT cells were fully differentiated, the cells were trypsinized by
0.25% trypsin and pelleted by centrifuge. The supernatant was aspirated and
the cell pellet was re-suspended in DMEM:F12 medium with equal volume of
the dye-working solution. The cells were then incubated in a 37 ˚C, 5% CO2
incubator for 30 min before the cells were washed with pre-warmed (37 ˚C) 
HBBS buffer for three times.
For each measurement, data from 10,000 single-cell events were collected
using FC500 flow cytometers (Beckman Coulter), and CytoPainter MitoNIR
Indicator Reagent ﬂuorescent intensity was measured in FL4 channel.  
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2.2.14 Construction of GPR43 knock-down stable cells
1) Optimization of Antibiotic Selection
IM-BAT cells were seeded at 6 × 105 cells per well in DMEM/F-12 medium
supplemented with 10% fetal bovine serum in a 6-well plate and incubated at
37°C with a humidified atmosphere at 5% CO2 overnight. On next day, the
cell culture medium was replaced with complete media containing puromycin
at 6 different concentrations (0, 2, 4, 6, 8 and 10 µg/ml). The cells were
continuously cultured for next 7 days with medium being change every 2-3
days. Cell viability in each well was determined by either cell counting on day
7. The minimum concentration of puromycin resulting in complete cell death
after 7 days of selection with puromycin would be used for that transduction
with shRNA plasmids to construct GPR43 knock-down stable cells.
2) shRNA plasmid DNA transfection
IM-BAT cells were seeded at 3 × 105 cells per well in DMEM:F-12 medium
supplemented with 10% fetal bovine serum in a 6-well plate and incubated at
37°C with a humidified atmosphere at 5% CO2 overnight. On next day,
GPR43 shRNA plasmids were transfected into IM-BAT preadipocytes by
TransIT-2020 Reagent. The TransIT-2020 Reagent: DNA complex was
prepared in Opti-MEM I Reduced-Serum Medium and distributed to cells
drop-wisely.
The medium was replaced with DMEM:F12 medium containing 10% fetal
bovine serum and 8 µg/ml puromycin after 48 h post-transfection and the
cells were fed every 3 days with this medium until the colony formation.
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3) Validation of GPR43 knock-down
Following selection by puromycin, selected cells were differentiated as
described above for 7 days and lysed with Qiazol. The mRNA expression of
GPR43 was subjected to real-time PCR analysis.
2.2.15 Lipolysis Assay
IM-BAT cells were differentiated for 7 days and seeded into 96-well clear
bottom cell culture plate at 5 × 104 cells / well for 4 h before washed with
lipolysis wash buffer twice. After wash, the cells were incubated in 150 µl
lipolysis assay buffer and treated with test compounds for 3 h. Conditioned
medium media was collected and transferred into a new 96-well plate. The
final volume was adjusted with lipolysis assay buffer to 50 µl / well. The
reaction mix (glycerol assay buffer 42 µl / well; glycerol enzyme mix 2 µl /
well; glycerol developer 2 µl / well; picoprobe 4 µl / well) was prepared and
added into 96-well plates (50 µl/ well) containing standard and test samples.
The plate was incubated at room temperature for 60 mins before the
fluorescence (Ex/Em = 535/587 nm) was measured by microplate reader.
2.2.16 Free fatty acids uptake assay
IM-BAT cells were differentiated for 7 days and seeded into 96-well clear
bottom cell culture plates at 5 × 104 cells / well for 4 h before serum deprived
for 1 h. After serum starvation, the cells were treated with test compounds for
30 min followed by incubated with 100 µl fatty acid dye-loading solution
(containing TF2-C12 fatty acid). The fluorescence (Ex/Em = 485/515 nm)
was measured by microplate reader.
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2.2.17 Glucose uptake assay
IM-BAT cell were differentiated for 7 days as described above. Upon
differentiation, the cells were starved in DMEM:F12 medium without glucose
and FBS for 3 h. The cells were harvest, washed and re-suspended in
glucose-free DMEM:F12 medium containing 150 µg/ml 2-NBDG with or
without insulin at 1 × 105 cells / ml for 30 min. The 2-NBDG uptake reaction
was stopped by removing the incubation medium and washing the cells with
pre-cold PBS.
For each measurement, 2-NBDG ﬂuorescent intensity were collected using 
FC500 flow cytometers (Beckman Coulter) in FL1 channel or plate reader
(Ex/Em = 485/535 nm)
2.2.18 Statistical analysis
Results are presented as the mean ± S.E.M of at least triplicate samples in
each experimental group; experiments were replicated to ensure consistency.
Statistical significance of difference was determined using student t-test
when comparing 2 groups or one-way ANOVA followed by post hoc Tukey’s
multiple comparison test when comparing more than 3 groups. Values were
considered to be statistically significant if their P value was lower than 0.05.
All statistical calculations were analysed in GraphPad Prism 6.
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Chapter 3: Short-chain fatty acid receptor GPR43
expression in brown adipose tissue and brown
adipocytes
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3.1 Preamble
So far, two GPCRs (GPR41 and GPR43) have been demonstrated to be
receptors for short-chain fatty acids (Brown et al., 2003). The expression of
GPR43 in white adipocytes and white adipose tissue has been confirmed by
real-time PCR, fluorescence in situ hybridization (FISH), and
immunohistochemistry in several independent studies (Zaibi et al., 2010,
Cornall et al., 2011, Kimura et al., 2013), however, the existence of GPR43
in brown adipose tissue and brown adipocytes were only confirmed by real-
time PCR (Zaibi et al., 2010, Regard et al., 2008).
Regarding the controversial reports of GPR41 expression in adipose tissue,
Xiong et al. showed that short-chain fatty acids stimulate leptin release from
white adipose tissue through GPR41 (Xiong et al., 2004), suggesting GPR41
exists in white adipose tissue. However, at least three other studies reported
that GPR41 could not be detected in differentiated 3T3-L1 cells or in mouse
white adipose tissue (subcutaneous, perirenal, mesenteric, and epididymal
fat pads) (Hong et al., 2005, Zaibi et al., 2010, Kimura et al., 2013). GPR43
mRNA, rather than GPR41 mRNA, was found to be detected in these studies.
Furthermore, using GPR41 knock-out mice, Zaibi et al. further confirmed that
short-chain fatty acids induced leptin secretion was only slightly affected after
the loss of GPR41, suggesting the promotive effect of short-chain fatty acids
on leptin secretion is GPR43-dependenet but not GPR41-dependent (Zaibi et
al., 2010). The discrepancies between reports from Xiong et al. and Zaibi et
al. might because the loss of GPR41 also affects GPR43 expression in
GPR41 knock-out mice (Zaibi et al., 2010). Indeed, increasing evidence
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supports the hypothesis that GPR43 mainly mediates the effects of short-
chain fatty acids in adipocytes and adipose tissue (Kimura et al., 2013).
However, the implication of GPR41 and GPR43 in brown adipocytes are still
not clearly investigated.
Recently, the promoter structure of GPR43 gene in human monocytes has
been illustrated. XBP1 was identified as a core cis element controlling
GPR43 transcription in human monocytes, while several other transcription
factors including CREB, CHOP, NFAT and STAT5 act as enhancers in
mediating GPR43 expression (Ang et al., 2015). LPS, TNFα, and GM-CSF 
increase GPR43 expression in human monocytes via augment of XBP1s
level (Ang et al., 2015). However, the link between XBP1 and GPR43 is still
not clear in adipocytes.
To elucidate the biological properties of short-chain fatty acids in brown
adipocytes, existence of short-chain fatty acids receptors (GPR41 and / or
GPR43) was firstly measured in differentiated IM-BAT cells as well as murine
interscapular brown adipose tissue. Furthermore, to investigate the possible
roles of short-chain fatty acids in brown adipogenesis, the expression of
short-chain fatty acids receptors was also quantified during the adipogenesis
of brown adipocytes. Besides, the effects of pro-adipogenic agents (such as
PPARγ agonist) and anti-adipogenic agents (such as STAT5 inhibitor) on 
short-chain fatty acids receptors expression in brown adipocytes and brown
adipose tissue were also determined in this study.
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3.2 Results
3.2.1 Identification of GPR43 expression in brown adipose tissue
GPR41 and GPR43 have been de-orphaned as short-chain fatty acids
receptors in last decades. To test the hypothesis that GPR41 and/or GPR43
mediate the regulatory effects of short-chain fatty acids in brown adipose
tissue, reverse transcription PCR analysis was performed on interscapular
brown adipose tissue of C57BL/6 mice to measure the mRNA expression
levels of GPR41 and GPR43. The results demonstrated that GPR43 mRNA
expression reached a clearly detectable level in interscapular brown adipose
tissue (figure 3-1(A)). To exclude the possibility of gDNA contamination, the
minus-reverse transcriptase ‘-RT’ controls were introduced. The significant
decrease of amplification products in -RT controls confirmed the PCR
amplification was mostly attributable to the presence of GPR43 cDNA (figure
3-1(A)). To confirm the findings from reverse transcription PCR, real-time
PCR was also applied to measure the difference of Ct values between +RT
test samples and ‘-RT’ controls. The results also showed a significant
increase of Ct values in ‘-RT’ controls group, indicating the gDNA
contamination was neglectable (figure 3-1(B)). Besides, in agreement with
previous reports, our results also indicated GPR41 were not detected in
interscapular brown adipose tissue since the Ct values between test samples
and controls were similar.
We also compared the expression levels of GPR43 in subcutaneous white
adipose tissues and interscapular brown adipose tissue. Consistent with
previous reports, the GPR43 expression level in interscapular brown adipose
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tissue was found to be much less (around 10-fold lower) than that in
subcutaneous white adipose tissues (figure 3-1 (A) and (C)).
Figure 3-1 Identification of GPR43 mRNA transcription in interscapular brown
adipose tissue of C57BL/6 mice. (A) RT-PCR to envisage GPR43 transcription
from interscapular brown adipose tissue. (B) Transcription of GPR43 in
interscapular brown adipose tissue measured by real-time PCR. (C)
Transcription level of GPR43 in subcutaneous white adipose tissue and
interscapular brown adipose tissue. Interscapular brown adipose tissue and
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white adipose tissue were removed from mice immediately after sacrifice and
immersed in RNAlater RNA Stabilization Reagent. RNA was isolated using
commercial total RNA isolation kit and used for cDNA synthesis. The target genes
transcription was detected by PCR (A) or measured by real-time PCR (B and C).
Data presented as mean ± S.E.M.. * P <0.05 compared to control by student’s t-test.
Immunohistochemical staining was also used to demonstrate the existence
of GPR43 in interscapular brown adipose tissue. As shown in figure 3-2,
immunoperoxidase staining of formalin-fixed, paraffin-embedded
interscapular brown adipose tissue using anti-GPR43 antibody showed
membrane and cytoplasmic staining, while in no primary antibody control,
only negligible staining could be found.
Figure 3-2 Expression of GPR43 in interscapular brown adipose tissue of
C57BL/6 mice examined by Immunohistochemistry. Interscapular brown
adipose tissue was stained with anti-GPR43 antibody and haematoxylin (40X
magnification shown). No primary antibody was served as negative control.
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3.2.2 Identification of GPR43 expression in immoralized brown
adipocytes
To clarify that GPR43 were expressed in brown adipocytes instead of
stromal vascular fraction, immortalized brown adipocytes (IM-BAT)
constructed by Dr. Mark Christian (University of Warwick) were differentiated
into mature adipocytes as a cell model to analyse the mRNA expression of
GPR43 in brown adipocytes.
In keeping with previous report, IM-BAT cells (which have a fibroblast-like
appearance under standard culture condition) can differentiate into large,
spherical cells, accumulating multiple lipid droplets of various sizes as
revealed by the Oil Red O staining after incubated with differentiation
medium I for 2 days followed by differentiation medium II for another 5 days
(figure 3-3(A)).
Furthermore, the gene expression of the brown adipocyte marker UCP1 was
highly induced in IM-BAT cells after differentiation (figure 3-3(B)). Besides,
the UCP1 and mitochondrial DNA levels in differentiated IM-BAT were also
significantly higher than differentiated white adipocyte cell line 3T3-L1 (figure
3-3(C))
Moreover, differentiated IM-BAT cells maintained the ability to express large
amount of UCP1 after β-adrenergic stimulation; an acute (6 h) treatment with 
CL-316,243 led to a significant increase of UCP1. A series of functional
metabolic assays were also performed to identify and confirm the
characteristics of the IM-BAT cells as a brown adipocyte model. Glucose
uptake, assessed with a fluorescent glucose analog (2-NBDG), was also
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increased after CL-316,243 treatment in mature adipocytes (figure 3-3(E)),
indicating that the β3-adrenergic signalling pathway is fully functional in 
terminal differentiated and full matured IM-BAT cells (figure 3-3(D)).
In addition, Akt phosphorylation was increased by insulin stimulation in
differentiated IM-BAT cells, indicating that insulin signalling was also intact in
mature IM-BAT adipocytes (figure 3-3(F)).
Figure 3-3 Identification of IM-BAT as brown adipocytes model in vitro. (A)
Lipid accumulation in differentiated IM-BAT cells visualized by Oil Red-O
staining. Macroscopic pictures of Oil Red-O staining of immortalized BAT (IM-BAT)
cells differentiated for 7 days. (B) Expression levels of UCP1 mRNA in the
course of adipogenesis of IM-BAT cells. IM-BAT cells were differentiated and cell
lysate were collected at day 0, day 3, day 6 and day 9. Transcription of UCP-1 was
detected by real-time PCR. (C) UCP-1 and mitochondrial DNA levels in
differentiated IM-BAT cells and differentiated 3T3-L1 cells. IM-BAT and 3T3-L1
cells were differentiated; total RNA and total DNA was isolated by GenElute™
Mammalian Total RNA Miniprep Kit and QIAamp DNA Mini kit, respectively. UCP-1
transcription and mitochondrial DNA to genomic DNA ratio were measured by real-
time PCR. (D) Effects of CL-316,243 (CL) treatment on expression levels of
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UCP1 in differentiated IM-BAT cells. IM-BAT cells were differentiated then treated
with CL-316,243 (10 µM) for 6 h. Expression of UCP1 was measured by real-time
PCR. (E) Effects of CL-316,243 (CL) treatment on glucose uptake in differentiated
IM-BAT cells. IM-BAT cells were differentiated and starved in glucose-free, serum-
free DMEM:F12 medium for 3 h. The cells then were treated with CL-316,243 (10
µM) for 3 h and stained with 2-NBDG (150 µg/ml). Fluorescence (Ex/Em = 465/540
nm) was measured by flow cytometry. (F) Effects of insulin treatment on Akt
activation in differentiated IM-BAT cells. IM-BAT cells were differentiated and
serum-starved overnight. The cells then were treated with insulin (1 µM) for 15 min.
The phosphorylated Akt and total Akt were measured by Western blots. Data are
presented as mean ± S.E.M.. *P <0.05, **P<0.01, ***P<0.001.
After confirmed the IM-BAT cells were able to exhibit the main characteristics
of brown adipocytes, next, we measured the GPR43 expression in
differentiated IM-BAT cells by real-time PCT. As shown in figure 3-4(A),
transcription of GPR43 were clearly detected in differentiated IM-BAT cells,
while relatively less expression was found in preadipocytes as well as ‘-RT’
controls. The RT-PCR also visualised the transcription of GPR43 in
differentiated IM-BAT cells (figure 3-4(B)).
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Figure 3-4 Identification of GPR43 mRNA transcription in IM-BAT cells. (A)
Transcription of GPR43 in immortalized brown adipocytes measured by real-
time PCR. (B) RT-PCR to envisage GPR43 transcription from undifferentiated
and differentiated IM-BAT. Total RNA was isolated from differentiated IM-BAT
cells and used for cDNA synthesis. GPR43 transcription was measured by real-time
PCR using SYBR green I (A) or visualized by agarose gel electrophoresis after PCR
(B).
Western blots were also applied to visualise the protein expression of
GPR43 in differentiated immortalized brown adipocytes. As shown in figure
3-5, a distinct band at around 45kD were detected in differentiated IM-BAT
cells compared to undifferentiated cells (figure 3-5 (A)), which is close to the
theoretical molecular weight of GPR43.
Immunohistochemical staining was also used to demonstrate the existence
of GPR43 in IM-BAT cells. Similarly, immunoperoxidase staining of formalin-
fixed, differentiated IM-BAT cells using anti-GPR43 antibody showed
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membrane and cytoplasmic staining, while in no primary antibody control,
only negligible staining could be found (figure 3-5 (B)).
Figure 3-5 Identification of GPR43 protein expression in IM-BAT cells. (A)
Expression of GPR43 in undifferentiated and differentiated IM-BAT adipocytes
examined by Western blots. IM-BAT cells were differentiated then lysed with RIPA
buffer. Expression of GPR43 was detected by Western blots using anti-GPR43
antibody. (B) Expression of GPR43 in IM-BAT cells examined by
Immunohistochemistry. Representative immunohistochemistry staining GPR43 in
differentiated IM-BAT cells. No primary antibody group and undifferentiated group
were served as negative control (40X and 100X magnification shown).
3.2.3 GPR43 expression pattern during differentiation of brown
adipocytes
To better understand the possible role of GPR43 in brown adipocyte
differentiation, we began our study by investigating GPR43 expression
pattern during the differentiation of cultured brown adipocytes IM-BAT. The
mRNA levels of GPR43 were quantified by real-time PCR during the course
of adipose differentiation until days 9 post-induction, at which time point the
hypertrophic brown adipocytes filled with plenty of lipid droplets. The results
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showed that GPR43 mRNA expression was scarcely detected in
preadipocytes (Day 0) but clearly escalated at day 3 post-induction, and
significantly increased at days 6 after differentiation, and maintained at high
expression levels afterwards (Figure 3-6 (A)). These data demonstrated that
GPR43 expression increased during brown adipocyte differentiation in vitro.
As positive controls, gene expressions of adipogenic-related gene (PGC-1α) 
and thermogenesis-related gene (UCP1) were also quantified by real-time
PCR during the differentiation of IM-BAT cells. The results showed the
significant elevation of genes expression reaches significance at day 6 and
maintains until day 9 (Figure 3-6 (B) and (C)). These patterns were
consistent with previous studies and also demonstrated the successful
differentiation of IM-BAT cells.
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Figure 3-6 Expression patterns of GPR 43 during the differentiation of IM-BAT
cells. (A) Expression levels of GPR43 mRNA in the course of adipogenesis of
IM-BAT cells. (B) Expression levels of UCP1 mRNA in the course of
adipogenesis of IM-BAT cells. (C) Expression levels of PGC-1α mRNA in the 
course of adipogenesis of IM-BAT cells. IM-BAT cells were differentiated and cell
lysate were collected at day 0, day 3, day 6 and day 9. Transcription of target
genes were detected by real-time PCR. Data presented as mean ± S.E.M.. * P
<0.05, **P<0.01, ***P<0.001 compared to day 0 by one-way ANOVA followed by
post-hoc tests.
3.2.4 XBP1 is crucial for GPR43 expression in brown adipocytes
XBP1 has been identified as key regulator of GPR43 transcription in human
monocytes (Ang et al., 2015). Interestingly, it has also been reported that
both XBP1 and GPR43 expression increase during the adipogenesis of white
adipocytes, indicating a possible link between XBP1 and GPR43 expression
in adipocytes.
Here, to interrogate the role of XBP1 in GPR43 expression in brown
adipocytes, XBP1 expression pattern during brown adipogenesis was initially
detected. The results demonstrated XBP1 expression showed a similar
increasing trend as GPR43 during differentiation, suggesting the possibility
that XBP1 plays an important role in GPR43 expression in brown adipocytes
(figure 3-7).
138
Figure 3-7 Expression levels of XBP1 mRNA in the course of adipogenesis of
IM-BAT cells. IM-BAT cells were differentiated and cell lysate were collected at day
0, day 3, day 6 and day 9. Transcription of XBP1 were detected by real-time PCR.
Data presented as mean ± S.E.M. **P<0.01 compared to day 0 by one-way ANOVA
followed by post-hoc tests.
To further investigate the role of XBP1 in GPR43 expression in brown
adipocytes, we knocked-down XBP1 expression by introducing siRNA
targeting XBP1 into pre-adipocyte and then differentiated IM-BAT from 24 h
post-transfection as described above.
To make sure the duration of silencing after siRNA transfection, the
expression of XBP1 was checked from day 1 to day 7 post-differentiation.
The XBP1 mRNA transcription levels were checked by real-time PCR and
compared to cells transfected with control siRNA. The result showed that the
knock-down efficiency reached >60% at 48 h post-transfection (24 h post-
differentiation). Moreover, the knock-down efficiency kept at >70% until day 5
post-differentiation and persisted at >70% at day 7 (figure 3-8 (A)), indicating
the XBP1 gene silencing effect can last through the differentiation process of
IM-BAT cells.
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To reach the desirable knock-down efficiency, all the assays were carried out
at day 5 post-induction. As expected, knock-down of XBP1 severely impairs
the differentiation process. The oil accumulation in IM-BAT cells transfected
with XBP1 siRNA was significantly lower after 5 days differentiation
compared to the cells transfected with control siRNA (figure 3-8(B)), which is
similar to the effect of XBP1 knock-down / knock-out in white adipocytes
reported by previous studies. More interestingly, GPR43 expression were
also severely decreased in IM-BAT cells transfected with XBP1 siRNA
compared to control group (figure 3-8(C)), suggesting XBP1 plays a crucial
role in GPR43 expression in brown adipocytes.
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Figure 3-8 Effects of XBP1 knock-down on adipogenesis and GPR43
expression in IM-BAT cells. (A) Duration of XBP1 silencing after XBP1 siRNA
transfection. IM-BAT cells were transfected with XBP1 siRNAs (Santa Cruz, # sc-
38628) or Control siRNA (sc-37007) at 200 nM. The next day, cells were
differentiated as indicated. Cells were lysed day 0 through day 7 post-differentiation
and XBP1 transcription levels were measured using the real-time PCR. Knock-down
efficiency is expressed relative to expression from cells transfected with control
siRNA. (B) XBP1 knock-down impairs the lipid accumulation in IM-BAT cells.
IM-BAT cells were transfected with control siRNA or XBP1 siRNA and differentiated
for 5 days. Lipid accumulation was measured with Oil-Red O staining. (C)
Expression levels of GPR43 and XBP1 mRNA in IM-BAT cells transfected with
control siRNA or XBP1 siRNA after 5 days differentiation. IM-BAT cells were
transfected with control siRNA or XBP1 siRNA and differentiated for 5 days. Target
genes transcription levels were measured by real-time PCR. Data presented as
mean ± S.E.M. *P<0.05 compared to control siRNA group by student’s t-test.
Similarly, using ‘reverse transcription’ to knock-down the expression of XBP1
also led to a significant decrease of GPR43 expression. The differentiated
IM-BAT cells were trypsinized to detach and transfected with XBP1 siRNA
when suspended in DMEM:F12 medium containing 10% FBS without
antibiotics. As shown in figure 3-9 (A) and (B), introducing XBP1 siRNA into
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differentiated IM-BAT cells led to GPR43 expression decreasing to around
50% after 48h incubation.
Figure 3-9 Effects of XBP1 knock-down on GPR43 expression in differentiated
IM-BAT cells. Expression levels of XBP1 (A) and GPR43 (B) mRNA in
differentiated IM-BAT cells transfected with control siRNA or XBP1 siRNA. The IM-
BAT cells were differentiated for 7 days and transfected with control siRNA or XBP1
siRNA. The cells were lysed after 48 h with QIAzol and the transcription levels of
GPR43 and XBP1 were measured by real-time PCR. Data presented as mean ±
S.E.M. *P<0.05, ****P<0.0001 compared to control siRNA group by student’s t-test.
3.2.5 Rosiglitazone up-regulated GPR43 mRNA expression in brown
adipocyte.
To further investigate the links between adipogenesis and GPR43
expression, we also tested the impact of rosiglitazone treatment on GPR43
expression in brown adipocytes in vitro. Rosiglitazone, a well-known highly
active adipogenic agent increasing PPARγ activity, were supplemented 
during the differentiation (day 2 to day 7). The results demonstrated that
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treatment of rosiglitazone during differentiation significantly increased
GPR43 mRNA level up to 3.5-folds as compared to the control condition
(figure 3-10(A)). Besides, differentiated IM-BAT cells stimulated with
rosiglitazone for short-time (24h) also display significantly augmented
GPR43 expression compared to un-treated cells (figure 3- 10(B)).
Meanwhile, we also tested the effects of β-adrenergic receptor agonist and 
GPR43 agonist on GPR43 expression in differentiated IM-BAT cells.
However, treatment with these agonists did not show significant increase in
GPR43 expression, although an upward trend was observed when treated
with isoproterenol (figure 3- 10(C)).
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Figure 3-10 Rosiglitazone treatment up-regulates GPR43 expression in IM-
BAT cells. (A) Effects of rosiglitazone treatment on GPR43 mRNA
transcription in IM-BAT cells. The IM-BAT cells were differentiated for 7 days with
or without rosiglitazone (1 µM, from day 2 to day 7). The cells were lysed with
QIAzol and the transcription levels of GPR43 were measured by real-time PCR.
Data presented as mean ± S.E.M. **P<0.01 compared to control siRNA group by
student’s t-test. (B) Effects of rosiglitazone treatment on GPR43 mRNA
transcription in differentiated IM-BAT cells. The IM-BAT cells were differentiated
for 7 days followed by treated with rosiglitazone (1 µM) for 24 h. The cells were
lysed with QIAzol and the transcription levels of GPR43 were measured by real-time
PCR. Data presented as mean ± S.E.M. **P<0.01 compared to control siRNA group
by student’s t-test. (C) Effects of 4-CMTB and Isoproterenol on GPR43 mRNA
transcription in differentiated IM-BAT cells. The IM-BAT cells were differentiated
for 7 days followed by treated with 4-CMTB (1 µM), or isoproterenol (1 µM) for 24 h.
The cells were lysed with QIAzol and the transcription levels of GPR43 were
measured by real-time PCR. Data presented as mean ± S.E.M.
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3.2.6 Rosiglitazone up-regulated GPR43 mRNA expression in brown
adipose tissue.
Male C57BL/6J mice (12-week-old) were intraperitoneally injected daily with
10 mg/kg rosiglitazone for 7 days. Brown adipose tissue was isolated
immediately after mice were sacrificed. The expression of GPR43 was
determined by real-time PCR. The results confirmed the effects of
rosiglitazone in IM-BAT cells also applied in vivo. GPR43 expression in
brown adipose tissue increased around 3-folds compared with control group
(figure 3-11(A)). As a positive control, UCP-1 was used to confirm the effects
of rosiglitazone on brown adipose tissue. The real-time PCR data showed
rosiglitazone significantly up-regulated UCP-1 expression in brown adipose
tissue as reported previously (figure3-11 (B)).
Figure 3-11 Rosiglitazone treatment up-regulates GPR43 expression in
interscapular brown adipose tissue of C57BL/6J mice. Effects of rosiglitazone
treatment on GPR43 (A) and UCP-1 (B) mRNA transcription in brown adipose
tissue of C57BL/6J mice. C57BL/6J mice was bred until 12 week of age before
intraperitoneally injected daily with 10 mg/kg rosiglitazone for 7 days. Interscapular
brown adipose tissue was immediately sliced into pieces after the mice were
sacrificed and immersed into RNAlatter solution. GPR43 and UCP1 mRNA
transcription levels were measured by real-time PCR. Data presented as mean ±
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S.E.M. *P<0.05, ***P<0.001 compared to control group injected with saline by
student’s t-test.
3.2.7 PPARγ and RXR involved in rosiglitazone-induced transcriptional 
upregulation of GPR43 in brown adipocytes
Recent studies have identified that the effects of thiazolidinediones (TZDs) in
adipocytes can be categorized into PPARγ-dependent and PPARγ-
independent. To elucidate the involvement of PPARγ in rosiglitazone induced 
increase in GPR43 expression, PPARγ selective antagonist GW9662 was 
pre-incubated before rosiglitazone treatment for 24 h. The results indicated
significant up-regulation of GPR43 expression was only observed in cells
treated with rosiglitazone but not in cells pre-treated with GW9662,
suggesting rosiglitazone upregulated GPR43 is PPARγ dependent.  
Similarly, RXR antagonist HX531 was also applied to test the effects of
heterodimerization of PPARγ and RXR on GPR43 expression. The results 
also showed pre-treatment of HX531 effectively inhibited rosiglitazone
induced GPR43 expression in differentiated brown adipocytes.
Taken together, these evidence suggested increase in GPR43 transcription
induced by rosiglitazone treatment might require the formation of
heterodimerization between PPARγ and RXR. 
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Figure 3-12 PPARγ and RXR are required for rosiglitazone-induced GPR43 
expression in IM-BAT cells. (A) Effects of PPARγ antagonist GW9662 on 
GPR43 mRNA transcription stimulated by rosiglitazone treatment in IM-BAT
cells. (B) Effects of RXR antagonist HX531 on GPR43 mRNA transcription
stimulated by rosiglitazone treatment in IM-BAT cells. The IM-BAT cells were
differentiated for 7 days. The cells were pre-treated with GW9662 or HX531 for 4 h
before treated with or without rosiglitazone (1 µM). The cells were lysed with QIAzol
and the transcription levels of GPR43 were measured by real-time PCR Data
presented as mean ± S.E.M. ***P<0.001 compared to control siRNA group by one-
way ANOVA followed by post-hoc tests.
3.2.8 Rosiglitazone overcame the effects of XBP1 knock-down on
GPR43 expression in brown adipocyte.
As we demonstrated above, XBP1 seems to be indispensable for the normal
expression of GPR43 in brown adipocytes. In addition, we also observed
rosiglitazone significantly up-regulated GPR43 expression in brown
adipocytes.
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Next, we tried to identify the roles of XBP1 in rosiglitazone-induced
transcriptional upregulation of GPR43 in brown adipocytes. We firstly
transfected siRNA targeting XBP1 into preadipocytes and differentiated the
cells into brown adipocytes with or without the existence of rosiglitazone from
day 2 to day 5 post-induction. In accordance to previous findings, the
efficiency of XBP1 knock-down could keep at >~70% to day 5 post-induction
(figure 3-13 (A)), at which time point GPR43 expression levels were
measured by real-time PCR. The results also confirmed that GPR43 mRNA
transcription was significantly impaired by the knock-down of XBP1
compared to cells only transfected with control siRNA (figure 3-13 (B)). More
interestingly, compared with no rosiglitazone treated cells, the rosiglitazone
treated brown adipocytes still showed a significant increase in GPR43
expression at normal level, indicating the promotion effect of rosiglitazone on
GPR43 expression is not abolished by XBP1 knock-down.
Besides, since activation of XBP1 requires the splicing of XBP1 mRNA, we
also tested the effect of rosiglitazone treatment on XBP1 mRNA splicing by
reverse transcription PCR. The results showed that in positive control group,
treatment with tunicamycin, a N-linked glycoproteins synthesis inhibitor and
commonly used ER stress inducer, led to a clear XBP1 splicing as two bands
shown on the gel, while there was no obvious XBP1 mRNA splicing detected
after rosiglitazone treatment (figure 3-13 (C)), supporting the hypothesis that
XBP1 activation might not involve in rosiglitazone induced GPR43
expression.
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Figure 3-13 Rosiglitazone overcomes the effects of XBP1 knock-down on
GPR43 expression in IM-BAT cells. (A) Validation of shRNA-mediated knock-
down of XBP1. IM-BAT cells were transfected with control siRNA or XBP1 siRNA,
on next day, the cells were differentiated for 5 days with or without rosiglitazone (1
µM) from day 2 to day 5. The transcription level of XBP1 was measured at day 5
after differentiation. (B) Effects of rosiglitazone treatment on GPR43 mRNA
transcription in XBP1 knock-down IM-BAT cells. IM-BAT cells were transfected
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with control siRNA or XBP1 siRNA, on next day, the cells were differentiated for 5
days with or without rosiglitazone (1 µM) from day 2 to day 5. The transcription level
of GPR43 were measured at day 5 after differentiation. (C) Effects of
rosiglitazone treatment on XBP1 mRNA splicing in differentiated IM-BAT cells.
IM-BAT cells were differentiated and treated with rosiglitazone (1 µM). The splicing
of XBP1 were measured by RT-PCR. The cells treated with tunicamycin were used
as positive control. Data presented as mean ± S.E.M. *P<0.05, **P<0.01 compared
to control siRNA group by one-way ANOVA followed by post-hoc tests.
3.2.9 STAT5 involved in rosiglitazone-induced transcriptional
upregulation of GPR43 in brown adipocytes
STAT5 has been identified as an enhancer in GPR43 expression. Besides,
STAT5 expression and activation also significantly increased during brown
adipogenesis. Previous reports also demonstrated that PPARγ binds to the 
STAT5A promoter and increase the STAT5A expression, therefore, the
rosiglitazone-mediated GPR43 expression might attribute, at least partially,
to the increase of STAT5A expression and activation.
To test this hypothesis, we differentiated IM-BAT cells with adipogenic
cocktail plus rosiglitazone and / or STAT5 inhibitor. The mRNA levels of
GPR43 were examined by real-time PCR at day 5 post-induction. As shown
in figure 3-14, rosiglitazone treatment showed an apparent stimulatory effect
on GPR43 transcription, while GPR43 expression displayed a significant
decrease both in cells treated with STAT5 inhibitor only and cells treated with
the combination of rosiglitazone and STAT5 inhibitor. These results
suggested STAT5 is indispensable for rosiglitazone induced GPR43
expression in brown adipocytes.
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Figure 3-14 Effects of STAT5 inhibitor on rosiglitazone-induced GPR43
expression in IM-BAT cells. IM-BAT cells were differentiated with 1 µM
rosiglitazone and or STAT5 inhibitor from day 2 to day 5, GPR43 mRNA
transcription in IM-BAT cells was measured by real-time PCR. Data presented as
mean ± S.E.M. **P<0.01 compared to control group by one-way ANOVA followed by
post-hoc tests.
3.3 Discussion
Brown adipose tissue has emerged as an important endocrine organ in
energy homeostasis. Immortalized brown adipocyte is a powerful tool to
investigate the functions of brown adipose tissue in vitro. Klein et al. have
proposed several criteria to characterize brown adipose cell lines: 1)
expression of a tissue-specific protein UCP-1; 2) high sensitivity to
adrenergic stimulation; 3) signalling and metabolic response to insulin
stimulation (Klein et al., 2002). Here, our results showed that IM-BAT cells
(which have a fibroblast-like appearance under standard culture conditions)
can be differentiated into large, spherical cells, accumulating multiple lipid
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droplets of various sizes as revealed by the Oil Red O staining and express
brown adipocytes marker UCP1. Moreover, differentiated IM-BAT cells
maintained the ability to increase UCP1 expression and glucose uptake after
β-adrenergic stimulation, while insulin treatment rapidly induced a strong Akt 
phosphorylation in differentiated IM-BAT cells, indicating that β-adrenergic 
signalling and insulin signalling were intact in the differentiated IM-BAT
adipocytes. Taken together, the above data showed that IM-BAT cells used
in our study demonstrated highly phenotypic and functional similarities with
brown adipocytes models in previous reports, which have been widely used
as a tool to investigate functions of brown adipocytes in vitro.
GPR43 shares 38% identity with GPR41 in amino acid sequence and
recognizes short-chain fatty acids (Sawzdargo et al., 1997). Based on our
experiments, we could not observe GPR41 expression at detectable levels in
brown adipocytes as well as in interscapular brown adipose tissue. This
finding is consistent with previous data reporting that nearly all identified
physiological functions of short-chain fatty acids in white adipocytes were
mediated by GPR43 (Kimura et al., 2013).
Although pro-adipogenic and anti-lipolytic properties of GPR43 have been
extensively studied in white adipocytes, little information has been known for
the implication of this receptor in brown adipocytes. To identify the
expression of GPR43 in brown adipose tissue and brown adipocytes, we first
utilized real-time PCR, Western blots and immunohistochemistry to explore
the expression of GPR43 in brown adipocyte and brown adipose tissue. Our
results indicated the GPR43 expression can be detected in interscapular
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brown adipose tissue as well as in immortalized brown adipocytes from day 3
post-induction.
Besides, our finding is also consistent with previous reports by Zaibi et al.
that GPR43 expression is relatively lower in brown adipose tissue than white
adipose tissue in mice (Zaibi et al., 2010). However, the expression patterns
of GPR43 during differentiation share many similarities in brown adipocytes
and white adipocytes. For example, it was found in several white adipocyte
models (e.g. 3T3-L1) that GPR43 expression significantly increased in the
later stages of differentiation, suggesting the involvement of GPR43 in the
process of adipogenesis. Here, our results also demonstrated the GPR43
expression was rapidly and reproducibly increased during the adipogenesis
process of IM-BAT cells. Indeed, the fact that GPR43 only being detected in
the later phase of adipocyte differentiation makes it a good candidate for a
novel adipogenic marker.
Moreover, it has been reported that treatment of PPARγ agonist significantly 
increased the expression of GPR43 in white adipose tissue in vivo and in
white adipocytes in vitro. Here the promotive effect of PPARγ agonist on 
GPR43 expression in brown adipose tissue and brown adipocyte was also
observed both in vivo and in vitro. Acute treatment of rosiglitazone led to a
rapid increase of GPR43 in differentiated IM-BAT cells and interscapular
brown adipose tissue, while treatment of rosiglitazone during the
differentiation further up-regulated its expression, which is similar to the
effects of thiazolidinedione in white adipocytes in previous studies. This
observation also supported the hypothesis that GPR43 exists in brown
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adipocytes and shares a similar mechanism of expression control during the
adipogenesis.
As transcription factor, PPARγ binds to cis-element PPRE in promoter region
to directly mediate target genes expression. Although our results clearly
demonstrated PPARγ activation led to the up-regulation of GPR43 
expression in brown adipocytes as well as brown adipose tissue, however,
using computer programme to analyse the structure of GPR43 genes
promoter, we could not found putative PPRE. Besides, in report form Ang et
al., the PPRE was neither identified in the GPR43 promoter region.
Therefore, the promotive effect of PPARγ agonist on GPR43 expression 
might be attributed to more complex transcription controls during the
differentiation of brown adipocytes. However, more evidence is needed to
confirm this hypothesis.
Recent studies have shown PPARγ agonists not only function via receptor-
dependent mechanism at the genomic level, but also may operate via
receptor-independent effects (Kulkarni et al., 2012). Here, our results
revealed that pre-treatment of PPARγ antagonist or PXR antagonist nearly 
abolished the effect of rosiglitazone on GPR43 expression in IM-BAT cells,
suggesting the effect of rosiglitazone on GPR43 expression is PPARγ 
dependent and requires the dimerization between PPARγ and PXR.  
Indeed, XBP1 has been elucidated as core cis element controlling the
GPR43 transcription in human monocytes by Ang et al. (Ang et al., 2015).
Here, our results also demonstrated knock-down of XBP1 significantly
impaired the expression of GPR43 in brown adipocytes, indicating XBP1 also
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plays a crucial role in GPR43 expression in brown adipocytes. Since XBP1
has been identified as an important sensor in ER stress response, it is
reasonable to speculate there might be a relationship between ER stress and
GPR43 expression. Actually, there has been some evidence to support this
hypothesis. It was reported that GPR43 expression was elevated in adipose
tissue, muscle and liver in high-fat diet-fed mice (Cornall et al., 2011), while
Dr. Manjunath Ramanjaney (Hamad Medical Corporation, Doha, Qatar) also
communicated that high-fat diet-fed mice showed augment of GPR43
expression in interscapular brown adipose tissue in mice. Notably, the links
between obesity and ER stress, especially in adipose tissues, have been
elucidated in both mouse experiments and human studies. Chronic excess
nutrient intake has been shown to cause ER stress as well as insulin
resistance and inflammation in adipose tissue in mice fed high-fat diets and
in ob/ob mice (Kawasaki et al., 2012). Recently, increased ER stress has
also been observed in subcutaneous adipose tissue of obese human
subjects (Gregor et al., 2009). Hence, based on our findings that XBP1 is an
important controller of GPR43 expression in brown adipocyte, the increased
activity of XBP1 in ER stress status might be the underlying mechanism by
which obesity leads to the increase of GPR43 expression.
Meanwhile, it was also observed that rosiglitazone induced augment of
GPR43 was not significantly affected by knock-down of XBP1. Interestingly,
although deletion of XBP1 inhibits adipogenesis in vitro, Gregor et al. found
this inhibitory effect could be overcome by stronger pro-adipogenic stimuli,
such as thiazolidinedione (Gregor et al., 2013). Deletion of adipocyte-XBP1
155
in vivo did not affect body weight, adipose tissue mass, serum insulin, or
glucose homeostasis, indicating XBP1 might not be an indispensable
contributing factor to the formation or expansion of adipose tissue in vivo
(Gregor et al., 2013). Here, consistent to these findings, our results also
suggested rosiglitazone increased GPR43 transcription seems to be XBP1-
independent. Studies based on XBP1 knock-out cells or mice may provide
more conclusive evidence to prove this hypothesis.
Notably, Choi et al. reported that co-culture of adipocytes with myoblasts
promoted C/EBPβ and PPARγ gene expression in differentiated myoblasts 
and GPR43 expression in adipocytes, also suggesting the involvement of
GPR43 in adipogenesis via mediating PPARγ activity (Choi et al., 2013). 
Anti-adipogenic compound STAT5 inhibitor was found to decrease the
expression of GPR43, providing more evidence to support the hypothesis
that GPR43 might reflect the differentiation status of adipocytes. Furthermore,
we also observed that rosiglitazone treatment could not overcome the effects
of STAT5 inhibitor on GPR43 expression. Therefore, our findings indicated
STAT5 as an important regulator for GPR43 expression in brown adipocytes.
Intriguingly, in several pre-adipocyte models, PPARγ was shown to bind to 
the STAT5A promoter and increase the STAT5A-luciferase reporter
expression, while activated STAT5A increased the PPARγ expression during 
differentiation of adipocytes, indicating a coordinated role between STAT5A
and PPARγ in adipogenesis.  
Finally, together with the evidence that GPR43 was only detected in
differentiated brown adipocytes, as well as the impaired differentiation
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caused by knock-down of XBP1 or treatment of STAT5 inhibitor was
accompanied by the decrease of GPR43, suggesting GPR43 might be a
novel adipogenic marker for brown adipocytes and play important roles in
brown adipogenesis.
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Chapter 4: Acetate promotes adipogenesis and
mitochondrial biogenesis in brown adipose tissue via
GPR43
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4.1 Preamble
Although it is still not fully understood the molecular mechanism underlying
the adipogenesis in vivo, however, in vitro immortalized cell lines such as
3T3-L1 and 3T3-F442A or primary preadipocytes freshly isolated from
stromal vascular fraction of adipose tissue have been widely used as in vitro
models, which allow researchers to investigate the signalling pathways
involved in adipogenesis or to screen the pro-adipogenic and anti-adipogenic
potential of hormones, growth factors and various pharmacological
compounds.
Based on the findings obtained from in vitro models, adipogenesis is
recognized as the multi-step process involving a cascade of many different
signalling pathways and transcription factors. Up to date, it has been
revealed that the adipocytes differentiation was initialized by treatment with
adipogenic cocktail (normally includes insulin, dexamethasone and cAMP
elevating agents (e.g. IBMX)) when cells reach growth arrest after
confluence (Reichert and Eick, 1999). This growth arrest by contact inhibition
has been proved to be required for adipocyte differentiation. Within 1 h after
the addition of adipogenic cocktail induction, preadipocytes show a transient
high expression of c-Fos, c-Jun, JunB, c-Myc until 2-6 h post-induction
(Cornelius et al., 1994). These oncogenes promote preadipocytes to re-enter
cell cycles and undergo several rounds of cell cycles post-confluent, known
as mitotic clonal expansion (Tang et al., 2003). This special mitosis is also
indispensable for adipogenesis. Preventing this mitotic clonal expansion by
blocking the cell entering S phase at this time point results in the absence of
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lipid accumulation and glycerol-3-phosphate dehydrogenase (GPDH) activity,
suggesting adipogenesis is severely impaired (Tang et al., 2003). During this
step, the genomic DNA is also unwound to allow transcription factors access
to regulatory response elements of genes involved in modulating the terminal
differentiation (Cornelius et al., 1994). The transcription factors regulated
genes expression during adipogenesis is a multi-step cascade. Several key
transcription factors in this process have been identified. Among them,
members of PPAR family and C/EBP family are found to play central roles
(Mandrup and Lane, 1997). Initially, C/EBPβ and CEBPδ transiently increase 
within 4 h after induction with adipogenic cocktail, which further mediate the
expression of PPARγ and C/EBPα (Wu et al., 1999b). PPARγ and C/EBPα 
expression reach detectable levels from day 2 post-stimulation and peaked
at day 2-5 (Christy et al., 1991). Phosphorylated C/EBPα shows strong 
growth-inhibiting activity and promotes cells to exit cell cycles and start
terminal differentiation (Darlington et al., 1998). Interestingly, PPARγ and 
C/EBPα increase the expression of each other, to amplify the signals of 
adipogenesis (Shao and Lazar, 1997). PPARγ and C/EBPα are critical for 
the expression of the late markers of adipogenesis, which consist of
lipogenic and lipolytic enzymes, as well as other proteins responsible for
modulating the mature adipocyte phenotype (Lefterova et al., 2008). The
dramatic morphology changes and formation of lipid droplets inside the cells
normally occurred by day 5-7 post-differentiation, by the time cells become
terminally differentiated (Fan et al., 1983). Changes of extracellular matrix
components and cytoskeletal components are also involved in this
morphology changes (Mariman and Wang, 2010). However, there are many
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limitations of conventional methods to monitor the cell morphology changes
during the differentiation of adipocytes in real-time. Recent studies have
shown the potential of xCELLigence system to monitor the differentiation of
adipocytes in real-time (Kramer et al., 2014).
Although brown adipogenesis shares plenty of similarities with white
adipogenesis, brown adipogenesis also possess its uniquity in many ways,
such as large amount of mitochondria biogenesis, transcription of genes for
thermogenesis (such as UCP-1), etc.. PPARγ co-activators, especially PGC-
1α, are crucial for these unique processes (Farmer, 2008). PGC-1α interacts 
with the transcription receptor PPARγ and regulates the genes involved in 
brown adipogenesis. Of note, PGC-1α is highly expressed in brown, but not 
in white adipocytes (Puigserver et al., 1998). Ectopically expressing PGC-1α 
in white adipocytes induces ‘browning’ phenotype, indicating that PGC-1α 
plays an important role in the control of brown adipocyte differentiation and
the converting of white adipocytes into beige cells (Bostrom et al., 2012).
Since short-chain fatty acids have been demonstrated to promote white
adipogenesis (Hong et al., 2005), therefore, here we aimed to investigate the
possible pro-adipogenic effects of short-chain fatty acid acetate in brown
adipocytes and in brown adipose tissue. The results may provide useful
evidence to understand the links between short-chain fatty acids and brown
adipose tissues.
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4.2 Results
4.2.1 Acetate showed no significant cytotoxicity towards immortalized
brown adipocytes
As an end product of anaerobic fermentation in gut, acetate is expected to
show little cytotoxic effects towards brown adipocytes at physiological
concentration. To test this hypothesis, the cytotoxicity of acetate was
measured by MTS assay using CellTiter 96® AQueous One Solution. As can
be seen from figure 4-1(A), incubation with acetate ranging from 1 nM to 10
mM showed no significant effect on cell viability in mature adipocytes. Indeed,
considering the pH value of DMEM:F12 medium containing 100 mM acetate
dramatically changed, the cytotoxicity of acetate at this concentration may
attribute, at least partially, to the changes of acidity of the medium.
Meanwhile, to test the effects of long-term treatment of acetate during
differentiation, IM-BAT cells were differentiated as described above while
acetate was added into differentiation medium II from day 2 post-induction at
final concentration of 10 mM, which is the same acetate concentrations as
Kimura et al used for the cellular work in 3T3-L1 cells (Kimura et al., 2013).
The cell viability was measured at day 7 after differentiation and compared
with the cells differentiated in the absence of acetate. The results also
demonstrated no significant changes of cell viability with 10 mM acetate
treatment during the differentiation (figure 4-1 (B)). Taken together, these
results suggested that in the range of below 10 mM, acetate showed little
effects on cell viability or cell proliferation for IM-BAT cells.
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Figure 4-1 The toxicity effects of acetate on IM-BAT cells measured by MTS
assay. (A) The effect of acetate treatment on differentiated IM-BAT cell
viability. IM-BAT cells were differentiated for 7 days and treated with acetate (10
nM to 100 mM) for 24 h. The cell viability was measured by MTS assay and
compared with cells without acetate treatment. Data presented as mean ± S.E.M.
****P<0.0001 compared to control by one-way ANOVA followed by post-hoc tests.
(B) The effect of acetate treatment during differentiation on IM-BAT cell
viability. The IM-BAT cells were differentiated for 7 days with or without acetate (10
mM, from day 2 to day 7). The cell viability was measured by MTS assay and
compared with cells without acetate treatment. Data presented as mean ± S.E.M.
N.S means ‘Not Significantly Different’.
4.2.2 Acetate treatment during differentiation increased lipid
accumulation of brown adipocytes
In order to examine the effects of acetate on differentiation of brown
adipocytes, IM-BAT cells were treated with or without acetate (10 mM)
throughout the course of the differentiation process from day 2 until day 7
post-induction, at which time the hypertrophic brown adipocytes filled with
plenty of lipid droplets. The differentiated IM-BAT cells were then stained by
Oil-Red O (Millipore Oil-Red O staining kit). The lipid accumulation in
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differentiated brown adipocyte was then measured semi-quantitatively. As
shown in figure 4-2, acetate increased Oil Red O staining of IM-BAT cells
after differentiation relative to normally-differentiated control cells, indicating
acetate as a positive modulator of brown adipocyte development.
Figure 4-2 Effect of acetate treatment on lipid accumulation in IM-BAT cells
measured by adipogenesis kit (Oil-Red O). The IM-BAT cells were differentiated
for 7 days with or without acetate (10 mM, from day 2 to day 7). The lipid
accumulation was measured by Oil-Red O staining and compared with cells without
acetate treatment. Data presented as mean ± S.E.M. *P<0.05 compared to control
by student’s t-tests.
4.2.3 Acetate treatment during differentiation up-regulated AP2, PPARγ, 
PGC-1α and UCP1 expression in brown adipocytes 
Next, the effects of acetate treatment during differentiation on the expression
of several adipogenesis-related and thermogenesis-related genes were also
examined by real-time PCR. As shown in figure 4-3 (A), acetate treatment
during IM-BAT cells differentiation (from day 2) significantly increases the
mRNA transcription levels of AP2, PPARγ, PGC-1α, and UCP1, while no 
significant changes of BMP7 and PRDM16 mRNA transcription were
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observed. The protein expression of PGC-1α and UCP1 in brown adipocytes 
was also tested after acetate treatment by Western blots. Our results
demonstrated that the protein levels of PGC-1α and UCP1 amounts 
exhibited ~1.9 fold and ~2.3 fold increases, respectively, in acetate treated
cells compared to normally-differentiated cells (figure 4-3 (B) and (C)).
Also the concentration-dependent effects of acetate treatment on PGC-1α 
and UCP1 transcriptions in IM-BAT cells were investigated by real-time PCR.
As shown in figure 4-4, compared to the effects of 10 mM acetate treatment
during differentiation, acetate at 1 mM also induced a pronounced increase
of PGC-1α and UCP1 while lower concentration of acetate induced relatively 
weaker response on PGC-1α and UCP1 expression (figure 4-4). 
Besides, to establish that the observed effects are not cell line dependent,
we also performed experiments using an additional brown adipocyte model
(T37i) in which we also documented increased AP2, PPARγ, PGC-1α and 
UCP1 expression upon acetate stimulation (figure 4-5).
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Figure 4-3 Effects of acetate treatment during differentiation on the
expression of brown adipogenesis markers in immortalized brown adipocytes.
(A) The effects of acetate treatment on transcription of BMP7, PRDM16, AP2,
PPARγ, PGC-1α, and UCP1 in IM-BAT cells detected by real-time PCR. (B) The
effects of acetate treatment on expression of PGC-1α in IM-BAT cells detected 
by Western blots. (C) The effects of acetate treatment on expression of UCP1
in IM-BAT cells detected by Western blots. The IM-BAT cells were differentiated
for 7 days with or without acetate (10 mM, from day 2 to day 7). The cells were
lysed with QIAzol (A) or RIPA buffer (B and C). The transcription levels of BMP7,
PRDM16, AP2, PPARγ, PGC-1α, and UCP1 were measured by real-time PCR. The 
protein expression levels of PGC-1α and UCP1 were measured by western blots. 
Data are presented as mean ± S.E.M. *P<0.05, **P<0.01, ***P<0.001, ****P<0.0001
compared to control by student’s t-tests.
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Figure 4-4 Concentration-dependent effects of acetate treatment during
differentiation on the expression of PGC-1α and UCP1 in immortalized brown 
adipocytes. The IM-BAT cells were differentiated for 7 days with or without acetate
at different concentrations (0.01 - 10 mM, from day 2 to day 7). The cells were lysed
with QIAzol. The transcription levels of PGC-1α, and UCP1 were measured by real-
time PCR. Data are presented as mean ± S.E.M. *P<0.05, ***P<0.001 compared to
control by student’s t-tests.
Figure 4-5 Effects of acetate treatment during differentiation on the
transcription of brown adipogenesis markers in T37i cells detected by real-
time PCR. The T37i cells were differentiated for 7 days with or without acetate (10
mM, from day 0 to day 7). The cells were lysed with QIAzol. The transcription levels
of BMP7, PRDM16, AP2, PPARγ, PGC-1α, and UCP1 were measured by real-time 
PCR. Data are presented as mean ± S.E.M. *P<0.05, **P<0.01 compared to control
by student’s t-tests.
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4.2.4 Acetate treatment affects the morphological shifts of brown
adipocytes during differentiation
To further investigate the effects of acetate treatment on IM-BAT
differentiation, xCELLigence system was used to monitor the Cell Index (CI)
value of IM-BAT cells during the differentiation in real-time. As can been
seen from figure 4-6 (A), the CI value of IM-BAT cells significantly drop after
the incubation with differentiation medium I. A similar CI curve of 3T3-L1
differentiation detected by the xCELLigence system was also reported by
Kramer et al. (Kramer et al., 2014). Interestingly, the CI curves of IM-BAT
cells rapidly increased followed by a slightly decrease after incubation with
differentiation medium II. Meanwhile, the acetate treatment during the
incubation with differentiation medium II significantly decreased the augment
of CI value compared to control group.
To find out whether acetate induced the decrease of CI value in IM-BAT cells
was caused by change of cell numbers, the cell viability was also checked by
microscopic analysis and MTS assay. The results confirmed that cell death
was ruled out as a cause for this decreased CI values since there was
almost the same cell viability in both assays (figure 4-6 (B) and (C)).
Meanwhile, it also confirmed from microscopic analysis that gold sensing
electrodes did not affect the differentiation (lipid accumulation) significantly
(figure 4-6 (B)).
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Figure 4-6 Effects of acetate treatment on morphological shifts of IM-BAT
cells during differentiation. (A) Effects of acetate treatment on IM-BAT cell
growth CI curves during differentiation. IM-BAT cells were treated with
differential medium I followed by Insulin + T3 (control); or Insulin + T3 + Acetate
(green) at the same time to compare the resulting CI growth curves. All curves were
plotted as an average of quadruplicate treatments. Error bars show S.E.M. (n = 4). *
P <0.05; ** P <0.01 compared to control by student’s t-test. (B) Terminally
differentiated IM-BAT cells in E-plate were visualized by microscopy. IM-BAT
cells were differentiated in E-plate and continuously monitored the CI index. After
measurement, the cells were checked under microscopy (40X magnification shown).
(C) Cell viability of IM-BAT cells during differentiation was measured by the
MTS assay. Values presented as mean ± S.E.M.. The IM-BAT cells were
differentiated for 7 days with or without acetate (10 mM, from day 2 to day 7). The
cell viability was measured by MTS assay and compared with cells without acetate
treatment. Data presented as mean ± S.E.M. N.S means ‘Not Significantly Different’.
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4.2.5 Acetate treatment during differentiation increases mitochondrial
biogenesis in brown adipocytes
Mitochondrial biogenesis has been associated with brown adipocyte
differentiation and thermogenesis. PGC-1α is a key co-activator to turn on 
this process in brown adipocyte. Since previous results have shown the
increase in PGC-1α after acetate treatment, therefore, next we examined the 
effects of acetate treatment on mitochondrial biogenesis in brown adipocytes.
As shown in figure 4-7 (A), the mitochondrial DNA / nuclear DNA ration
significantly increased after IM-BAT cells treated with acetate during the
periods of differentiation from day 2 until day 7.
In agreement with this result, flowcytometry assay also indicated the
augment of mitochondrial in brown adipocytes after acetate treatment during
differentiation (figure 4-7 (B)).
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Figure 4-7 Effects of acetate treatment during differentiation on mitochondrial
biogenesis of IM-BAT cells. (A) Relative mitochondrial DNA levels in IM-BAT
cells treated with or without acetate during differentiation. DNA was isolated
from IM-BAT cells using QIAamp DNA Mini Kit. The mitochondrial DNA level was
measured with primers targeted for mouse mitochondrial D-Loop with 2 × SYBR
green PCR master mix as described above. The mitochondrial DNA levels were
normalized against the nuclear DNA level measured with 18S primers using the
comparative CT method. Data are presented as mean ± S.E.M. *P<0.05 compared
to control by student’s t-tests. (B) Mitochondrial mass of IM-BAT cells treated
with acetate during differentiation measured by flow cytometry. The IM-BAT
cells were differentiated for 7 days with or without acetate (10 mM, from day 2 to
day 7) and stained with CytoPainter MitoNIR Indicator Reagent. The fluorescence
levels (Ex/Em = 640/695 nm) were measured by flowcytometry and compared with
untreated cells.
4.2.6 Acetate treatment during differentiation incrased mitochondrial
basal and reserve respiratory capacity of brown adipocytes
To further assess the potential for acetate treatment during differentiation to
increase mitochondrial oxidative capacity, mitochondrial respiration was
measured using Seahorse XF24 Extracellular Flux Analysers and XF Cell
Mito Stress Test Kit. The results showed the basal oxygen consumption rate
171
(OCR) and spare respiratory capacity (stimulated by FCCP) in acetate
treated cells were increased by 17%, and 24%, respectively (figure 4-8).
Figure 4-8 Effects of acetate treatment during differentiation on mitochondrial
respiratory capacity of IM-BAT measured by the XF24 analyser. Group mean
oxygen consumption rate (OCR) in pMol/min/µg protein of IM-BAT cells treated with
or without acetate at 10 mM during differentiation from day 2 to day 7. Vertical lines
indicate time of addition of mitochondrial inhibitors (a) oligomycin (1 μM), (b) FCCP 
(0.5 μM), or (c) antimycin A (1 μM) & rotenone (1 μM). Basal OCR, maximum OCR, 
spare capacity of cells treated as described above. Data are presented as mean ±
S.E.M. * P <0.05 (Student’s t-test).
4.2.7 Acetate treatment during differentiation incrased oxygen
consumption rates of brown adipocytes upon β-adrenergic receptor 
agonist stimulation
Since β-adrenergic receptors are important regulator for energy expenditure 
in brown adipocytes, therefore, we also tested the effects of acetate
treatment during differentiation on the response of IM-BAT cells to β-
adrenergic receptors agonists. As shown in figure 4-9, both basal OCR and
maximum response after CL-316,243 injection were up-regulated in cells
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differentiated with acetate. This result is consistent with the increased
mitochondrial biogenesis and increased mitochondrial respiratory capacity
demonstrated above.
Figure 4-9 Effects of acetate treatment during differentiation on the
mitochondrial respiratory capacity in IM-BAT cells in response to β-
adrenergic stimulation. The x axis represents the applied XF24 protocol
measurements and the vertical line indicates the time of addition of CL316,234 (CL).
Data are expressed as the percentage of the basal value measured at the time point
3 (four replicates) in the control group. OCR: oxygen consumption rate. Data are
presented as mean ± S.E.M. * P <0.05 (Student’s t-test).
4.2.8 4-CMTB treatment during differentiation induced pro-adipogenic
effects similar to acetate treatment in brown adipocytes
As shown in Chapter 3.2.2, GPR43 was successfully detected in
differentiated IM-BAT cell while GPR41 was scarcely detected. Therefore, it
is highly likely that GPR43, not GPR41, is mainly involved in acetate-
mediated pro-adipogenic effects in brown adipocytes. To test this hypothesis,
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IM-BAT cells were also treated with 4-CMTB, a synthesized selective agonist
for GPR43, during the differentiation of IM-BAT cells from day 2 to day 7
post-induction. The expression of BMP7, PRDM16, AP2, PPARγ, PGC-1α 
and UCP1 were also measured by real-time PCR. As shown in figure 4-10
(A), similar to acetate treatment, 4-CMTB also significantly increased the
transcription levels of AP2, PGC-1α and UCP1 in brown adipocytes, while 
PPARγ also showed an increase trend after 4-CMTB treatment. The BMP7 
and PRDM16 mRNA levels were also not altered significantly by 4-CMTB
treatment. Furthermore, Western blots also confirmed a significant increase
of PGC-1α and UCP1 at protein level in 4-CMTB treated IM-BAT cells 
compared to normal differentiated cells (figure 4-10 (B) and (C)).
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Figure 4-10 Effects of 4-CMTB treatment during differentiation on the
expression of brown adipogenesis markers in immortalized brown adipocytes.
(A) The effects of 4-CMTB treatment on transcription of BMP7, PRDM16, AP2,
PPAR, PGC-1α, and UCP1 in IM-BAT cells detected by real-time PCR. (B) The
effects of 4-CMTB treatment on expression of PGC-1α in IM-BAT cells 
detected by Western blots. (C) The effects of acetate treatment on expression
of UCP1 in IM-BAT cells detected by Western blots. The IM-BAT cells were
differentiated for 7 days with or without 4-CMTB (1 µM, from day 2 to day 7). The
cells were lysed with QIAzol (A) or RIPA buffer (B and C). The transcription levels of
GPR43 were measured by real-time PCR. The protein expression levels of PGC-1α 
and UCP1 were measured by Western blots. Data are presented as mean ± S.E.M.
*P<0.05, **P<0.01 compared to control by student’s t-tests.
Similarly, we also test the effects of 4-CMTB treatment during the
differentiation on CI value measured by xCELLigence. The results showed 4-
CMTB also elicited the similar CI value changes during the differentiation.
The CI value of IM-BAT cells significantly drop after the incubation with
differentiation medium I but rapidly increased after incubation with
differentiation medium II followed by a slightly decrease. Meanwhile, the CI
value is significantly lower in cells treated with differentiation medium II plus
4-CMTB than that in control group treated with differentiation medium II only
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(figure 4-11 (A)). Furthermore, the cell viability and lipid accumulation after 4-
CMTB treatment were also checked by MTS assay and microscopic analysis
(figure 4-11 (B) & (C)). The results confirmed that cell death was not
significantly increased after 4-CMTB treatment, indicating morphology
change was the main reason for this decrease of CI values.
Mitochondrial biogenesis has also been determined in 4-CMTB treated IM-
BAT cells. As shown in figure 4-12 (A), the mitochondrial DNA to nuclear
DNA ratio also significantly increased after IM-BAT cells treated with 4-
CMTB during the periods of differentiation from day 2 until day 7.
Furthermore, the effects of 4-CMTB treatment on mitochondrial respiration in
brown adipocytes were also measured by Seahorse XF24 Extracellular Flux
Analysers and XF Cell Mito Stress Test Kit. The results revealed that more
pronounced increases of the basal OCR and reserve respiratory capacity
were also observed after 4-CMTB treatment during the differentiation of IM-
BAT cells (figure 4-12 (B)).
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Figure 4-11 Effects of 4-CMTB treatment on morphological shifts of IM-BAT
cells during differentiation. (A) Effects of 4-CMTB on IM-BAT cell growth CI
curves during differentiation. IM-BAT cells were treated with differential medium I
followed by Insulin + T3 (control); or Insulin + T3 + 4-CMTB (blue) at the same time
to compare the resulting CI growth curves. All curves were plotted as an average of
quadruplicate treatments. Error bars show S.E.M. (n = 4). * P <0.05; ** P <0.01
compared to control by student’s t-test. (B) Terminally differentiated IM-BAT cells
in E-plate were visualized by microscopy (40X magnification shown). (C) Cell
viability of IM-BAT cells during differentiation was measured by the MTS
assay. Values presented as mean ± S.E.M..
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Figure 4-12 Effects of 4-CMTB treatment during differentiation on
mitochondrial biogenesis and mitochondrial respiratory capacity of IM-BAT
cells. (A) Relative mitochondrial DNA levels in IM-BAT cells treated with or
without 4-CMTB during differentiation. DNA was isolated from IM-BAT cells
using QIAamp DNA Mini Kit. The mitochondrial DNA level was measured with
primers targeted for mouse mitochondrial D-Loop with 2 × SYBR green PCR master
mix as described above. The mitochondrial DNA levels were normalized against the
nuclear DNA level measured with 18S primers using the comparative CT method.
(B) The effect of 4-CMTB treatment on mitochondrial respiratory capacity of
IM-BAT during differentiation measured by the XF24 analyser. Group mean
oxygen consumption rate (OCR) in pMol/min/µg protein of IM-BAT cells treated with
or without 4-CMTB at 1 µM during differentiation from day 2 to day 7. Vertical lines
indicate time of addition of mitochondrial inhibitors (a) oligomycin (1 μM), (b) FCCP 
(0.5 μM), or (c) antimycin A (1 μM) & rotenone (1 μM). Basal OCR, maximum OCR, 
spare capacity of cells treated as described above. * P <0.05 (Student’s t-test).
4.2.9 Pro-adipogenic effects of acetate treatment were impired in
GPR43 knock-down brown adipocytes
To further assess the role of GPR43 in acetate-induced effects on brown
adipocytes, we also measured the effects of knock-down GPR43 on acetate-
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induced brown adipogenic gene (UCP1) expression and mitochondria
biogenesis.
IM-BAT cells were transfected with GPR43 shRNA and selected with
puromycin at optimized concentration (figure 4-13(A)). Then, the cells were
differentiated as described above and GPR43 expression were measured.
The results showed that we successfully decreased GPR43 transcription to
less than 30% of its baseline value in differentiated adipocytes by
transfecting shRNA targeting GPR43 (figure 4-13(B)). While the stimulatory
effect of acetate on UCP1 mRNA was apparent in control cells transfected
with control shRNA, this effect was impaired in cells transfected with shRNA
for GPR43 (figure 4-13(C)). Similarly, the increase of mitochondrial DNA ratio
was also only observed in control cells (figure 4-13(C)).
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Figure 4-13 Effects of GPR43 knock-down on pro-adipogenic effects of
acetate in IM-BAT cells (A) Optimization of puromycin selection condition. IM-
BAT cells were seeded at in 96-well plates. On the next day, the culture media were
replaced with DMEM:F12 containing 0-10 puromycin. After 7 days selection, the cell
viability was checked by microscopy. The optimal concentration was chosen at the
lowest concentration that kills 100% of non-transduced cells. (B) Validation of
shRNA-mediated knock-down of GPR43. Undifferentiated immortalized BAT (IM-
BAT) cells were transfected with shRNA non-targeting control (#RHS6848) or
shRNA targeting GPR43 (sh-GPR43-1: TRCN0000027581; sh-GPR43-2:
TRCN0000027541; sh-GPR43-3: TRCN0000027562 sh-GPR43-4:
TRCN0000027552). Following selection by puromycin, cells were lysed with Qiazol
after 7 days of differentiation and subjected to real-time PCR analysis. (C) The
effects of GPR43 knock-down on acetate induced UCP1 increase and
mitochondria biogenesis. IM-BATs transfected with non-targeting shRNA control
or shRNA targeting GPR43 were treated with or without acetate during
differentiation. Relative mRNA levels of UCP1 and relative mitochondrial DNA levels
were analysed by real-time PCR. Data are presented as mean ± S.E.M.. *P <0.05,
**P<0.01, ****P<0.0001 compared to sh-control by one-way ANOVA followed by
Post-Hoc tests (A) or by student’s t-test (B and C).
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4.2.10 The effects of acute acetate treatment on PGC-1α and UCP1 
expression in differentiated brown adipocytes
In parallel, the effect of acute acetate treatment on gene expression in
mature brown adipocytes was determined. The IM-BAT cells were
differentiated as described above and then treated with 10 mM acetate for 6
h. As shown in figure 4-14, acute acetate treatment (6 h) on differentiated IM-
BAT cells also significantly increased PGC-1α and UCP1 transcription. 
Meanwhile, as positive control, CL-316,243 also elicited dramatically
increase in both PGC-1α and UCP1 transcription (figure 4-14) 
Figure 4-14 Effects of acute acetate treatment on PGC-1α and UCP1 
expression in differentiated IM-BAT cells. IM-BAT cells were differentiated for 7
days followed by acetate treatment (10 mM) for 6 h. β-adrenergic receptor agonist 
CL-316,243 (CL) was used as positive control. The expression levels of PGC-1α 
and UCP1 were determined by real-time PCR. Data are presented as mean ±
S.E.M.. *P <0.05, **P<0.01 by student’s t-test compared with no acetate treated
controls.
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4.2.11 The effects of acetate administration on brown adipose tissue in
vivo
Moreover, we also examined the effects of acetate on the expression of two
thermogenesis-related genes (PGC-1α and UCP1) in brown adipose tissue 
in vivo. The results demonstrated a significant increase in PGC-1α after 6 
weeks acetate administration (figure 4-15 (A)), while the increase in UCP1
expression just failed significance (figure 4-15 (B)), which might suggest the
control of UCP1 expression in vivo is more complex than in vitro.
Figure 4-15 Effects of acetate administration on PGC-1α and UCP1 expression 
in interscapular brown adipose tissue of C57BL/6J male mice. C57BL/6J male
mice were fed with sodium acetate (150 mM) in drinking water for 6 weeks (n = 5 for 
control, n = 5 for acetate administration). Mice were sacrificed at week 12. The
expression levels of PGC-1α (A) and UCP1 (B) were determined by real-time PCR.
Data are presented as mean ± S.E.M.. *P <0.05 compared to control by student’s t-
test.
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4.3 Discussion
So far, it has been discovered that plenty of transcription factors are involved
in the regulation of adipogenesis. Among these transcription factors, the
nuclear receptor PPARγ is a key player in transcriptional cascade during 
adipocyte differentiation (Siersbaek et al., 2010). Previous studies have
demonstrated that PPARγ is a master regulator of adipogenesis, ectopic 
overexpression of PPARγ in non-adipogenic 3T3 fibroblasts cells leads to 
their differentiation into adipocytes with the accumulation of lipid droplets and
the induction of adipogenic marker genes expression, such as C/EBPα, aP2, 
and GLUT4 (Hamm et al., 1999); while overexpression of PPARγ in 
adipogenic 3T3-L1 preadipocytes leads to increased lipid accumulation and
up-regulation of adipocyte markers (Tamori et al., 2002). Furthermore, no
additional factors have been found to induce adipogenesis in the absence of
PPARγ (Rosen and MacDougald, 2006). In mice, PPARγ is not only critical 
for adipogenesis but also important for the maintenance of the fully
differentiated state. However, PPARγ could not induce adipogenesis alone in
vivo (Bastie et al., 1999). Transcription co-activators, such as C/300, PGC-1α, 
also mediate the activities of PPARγ in vivo. Among them, PGC-1α has been 
identified as a key molecule that stimulates brown adipocytes differentiation
by interacting with PPARγ and direct gene transcription involved in both 
adipogenesis and mitochondrial biogenesis (Puigserver et al., 1998).
Increased PGC-1α enhances the transcription of NRF-1 and NRF-2, leading 
to increased expression of mtTFA (Wu et al., 1999a), as well as other
nuclear-encoded mitochondria subunits of the electron transport chain
complex (e.g. β-ATP synthase, cytochrome c, and cytochrome c oxidase IV) 
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(Scarpulla, 2011). mtTFA translocates to the mitochondrion and stimulates
mitochondrial DNA replication and gene expression (Larsson et al., 1998).
PGC-1α also interacts with PPARγ or other nuclear hormone receptors in 
brown adipocytes to up-regulate the expression of brown fat-specific UCP1
(Cassard-Doulcier et al., 1994, Barbera et al., 2001). Moreover, ectopic
expression of PGC-1α in white fat cells also induces expression of 
mitochondrial and thermogenic genes (Puigserver et al., 1998, Tiraby et al.,
2003). Our results showed that increased PGC-1α and PPARγ expression, 
as well as increased mitochondrial mass and UCP1 expression were
observed after acetate treatment in brown adipocytes, supporting the
importance of PGC-1α in brown adipocyte differentiation. Based on these 
findings, it could be hypothesized that dietary supplementation of acetate or
fibre could potentially promote brown adipose tissue by increasing the
amount and/or activity of PGC-1α in brown adipose tissue, thus offering an 
additional target for the treatment of obesity and related metabolic diseases.
Indeed, Gao et al., have demonstrated that dietary supplementation of
butyric acid increase brown adipose energy expenditure in mice (Gao et al.,
2009). However, further studies are needed to address this hypothesis.
Notably, PRDM16 activity is mainly mediated through protein stabilization by
PPARγ in brown adipogenesis (Ohno et al., 2012), which might be another 
possible reason that little change of PRDM16 at transcription level was
observed.
During the adipogenesis, pre-adipocyte undergoes post confluent mitosis,
growth-arrest, morphology change and lipid droplets accumulation, all of
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which induce the change of cell shape, adhesion, and mobility. However,
traditional measurements have plenty of limitations to observe these
changes continuously and in real-time. Recently, the xCELLigence system,
which could measure the electrical impedance of gold sensing electrode
underneath the cultured cell layer has been reported to successfully monitor
the differentiation process of 3T3-L1 cells in vitro. Compared to the traditional
ways (such MTT assay or Boyden Chamber Assays) to measure cell
proliferation, invasion or migration, the biggest advantage of xCELLigence
system is providing a way to monitor cell proliferation, invasion or migration
and cell morphology changes in real-time. Besides, xCELLigence system is a
label-free cellular analysis assay, which minimizes the effects of exogenous
labels on cell growth and differentiation. Therefore, xCELLigence system can
capture data throughout the entire time course of adipogenesis and reflect
more physiologically relevant data. Here, we applied this system to observe
brown adipocyte differentiation with different compounds treatment.
Compared to the results from Kramer et al., that treatment with a similar
differentiation cocktail (containing insulin, IBMX, Dexamethasone, and
Rosiglitazone) leads to rapid drop of CI curve of 3T3-L1 adipocytes (Kramer
et al., 2014), a similar CI curve was also observed after IM-BAT being
treated with differentiation medium I containing insulin, IBMX,
Dexamethasone, and T3 in our study. Kramer et al. have further established
that among the components of the full differentiation cocktail, treatment with
IBMX is crucial to result in significant decrease of CI values, indicating that
IBMX mainly mediates the morphological change of 3T3-L1 during the
differentiation (Kramer et al., 2014). Our results are also in accordance with
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this finding, since increased CI value was observed after the incubation with
differentiation medium II, which does not contain IBMX. In addition, our
results also demonstrated that acetate treatment could keep the CI value at
lower levels compared to normal differentiated cells. Based on the previous
data from 3T3-L1 cells, documenting that the most efficient differentiation
caused by full differentiation cocktail results in the most decreased CI value,
our results indicate that acetate promotes the differentiation of IM-BAT cells
(decreased CI value). Meanwhile, using MTS assay, no significant difference
of cell viability was observed between groups. This result strongly suggested
that the changes of CI values after acetate treatment attribute more to the
morphological shifts of IM-BAT cells instead of the difference of cell numbers.
Taken together, the evidence gathered here imply IM-BAT undergo
morphological shifts during the differentiation, which share high levels of
similarity to that in white adipocytes, and acetate treatment could affect this
process.
Since the mitochondria are key organelle for the main function of brown
adipocytes (thermogenesis), therefore, functional mitochondrial
measurements are useful for understanding brown adipocytes differentiation
and metabolism profiles. Here, using Seahorse XF24 Analyser with XF Cell
Mito Stress Test Kit, we assessed the key parameters of mitochondria in
brown adipocytes differentiated with acetate. The results showed an increase
in basal and maximum respiration, which is consistent to the results that
increased mitochondria mass were achieved after acetate treatment during
adipogenesis in IM-BAT cells.
186
Interestingly, the pro-adipogenic effect of short-chain fatty acids was not only
found in murine adipocytes (3T3-L1), it has also been demonstrated in
porcine adipose tissue that short-chain fatty acids enhance adipocyte
differentiation (Li et al., 2014), suggesting pro-adipogenic effect of short-
chain fatty acids might widely exits in many species, which probably
indicates short-chain fatty acids could also stimulate brown adipogenesis in
human, however, more clinical trials are needed to support this hypothesis.
Furthermore, we also sought to determine the effects of administration of
acetate on brown adipose tissue in C57BL/6 mice. Although immortalized
adipocyte cell lines provided numerous advantage for adipose tissue
research, which eliminate the frequent need to re-establish fresh cultures
from adipose tissue and provide a consistent homogeneity in cellular
population and differentiation stage, however, during the establishment of
immortalized cell lines, oncogenes such as simian virus 40 large T antigen
are introduced into primary cells to overcome the normal cell cycle control
points, which will inevitably affect the biological properties of normal cells.
Therefore, although clonal cell lines are an important complementary tool to
animal models for the study of adipocytes functions, but it still could not
totally replace in vivo experiments to investigate brown adipose tissue
functions.
Besides, as a key organ involved in the control of energy homeostasis,
brown adipose tissue not only responses to the changes of energy and
nutritional status by itself alone, but also incorporates all the signals from
other tissue in whole body (Lee et al., 2014). Therefore, it is also worth to
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investigate the function of acetate in vivo. Here, we deliver acetate via
drinking water instead of traditional intravenous injection. It has been
demonstrated that addition of acetic acid in drinking water can deliver
acetate into circulation and significantly affects insulin sensitivities of white
adipose tissue and muscle and liver in vivo (Kimura et al., 2013). Compared
to intravenous injection, oral administration is a convenient, self-
administered, and pain free route of drug administration.
It has been reported that short-chain fatty acids butyrate, an agonist for
GPR43, also increase adaptive thermogenesis, mitochondrial biogenesis,
and UCP-1 expression in brown adipose tissue in vivo (Gao et al., 2009).
Meanwhile, Bjursell et al., reported HFD-fed GPR43 knock-out mice
demonstrated decreased lipid droplets in brown adipose compared to HFD-
fed WT mice (Bjursell et al., 2011). These evidence highlights the possible
role of GPR43 in brown adipose tissue. Here our findings also support the
existence of GPR43 in brown adipose tissue and the possible roles for
adipogenesis.
Notably, acetate treatment has been demonstrated different effects on
immune system in different type of mice. For example, enhanced polyclonal
antibody responses were observed in C57BL/6 mice treated with acetate
(single intraperitoneal administration, 5 mg per mouse), but not in DBA/2
mice with the same treatment (Ishizaka et al., 1990). Therefore, the effects of
acetate treatment on brown adipose tissue are also worth to be investigated
in other models in future, which would provide better understanding towards
the possible benefit of acetate administration.
188
Besides, most studies also revealed the protective effects of short-chain fatty
acids in mice models under HFD conditions (Puddu et al., 2014, den Besten
et al., 2015), which also indicated the effects of short-chain fatty acids on
brown adipose tissue might be more significant when challenged by high-fat
diet. However, this hypothesis also needs more evidence to support.
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Chapter 5: The effects of acetate treatment on signal
transduction pathways in brown adipocytes
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5.1 Preamble
Protein kinases are a family of enzymes performing post-translational
modification in cells, which are involved in almost all cellular processes.
Protein kinases can transfer phosphate groups from ATP to their targets
(normally proteins or peptides), thereby regulating the activity, localization, or
other functions of the targets (Hunter, 1995, Adams, 2001). This reaction is
also known as phosphorylation. Protein kinases mediated phosphorylation
provides a rapid and reversible mechanism by which extracellular signals
regulate intracellular responses, which in particular plays crucial roles in a
wide range of cellular signalling (Cohen, 2000, Adams, 2001). Analysing the
phosphorylation profiles of kinases and their protein substrates can provide
important information for understanding how cells recognize and respond to
extracellular stimulus (Zhong et al., 2007). Phospho-specific antibodies and
mass spectrometry are both valuable tools for detection and characterization
of the status of phosphoproteins (DiGiovanna et al., 2002, Salih, 2005).
GPCRs transduce a range of downstream signalling, of which the majority
were mediated by kinases, such as PKA and PKC, which are the most well-
known protein kinase enzymes regulated by Gαs-, Gα(i/o)- or Gαq-coupled
GPCRs, respectively (Tuteja, 2009). Protein kinases are also crucial for
turning off excessive GPCRs signalling. G protein-coupled receptor kinases
(GRKs) phosphorylate intracellular domains of GPCRs to recruit β-arrestin 
and prevent reassocitation of GPCRs with G-proteins (Ritter and Hall, 2009).
β-arrestin desensitizes GRK-phosphorylated GPCRs, and causes the 
internalization of receptors (Pierce and Lefkowitz, 2001).
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Previous studies have shown that GPR43 activation by short-chain fatty
acids elicits activation of various protein kinases and phosphorylation of a
range of protein substrates in different types of cells. For example, using
HEK293 cells expressing GPR43, it has been demonstrated that activation of
GPR43 leads to the activation of all major MAPK signalling pathways
including ERK1/2, p38 and JNK (Seljeset and Siehler, 2012). Furthermore,
evidence also suggested that phosphorylation of p38 is required for the anti-
proliferitic effect of GPR43 in human breast cancer cell line MCF-7 and
GPR43-induced neutrophilic granulocytes migration (Yonezawa et al., 2007,
Sina et al., 2009). It has also been reported that short-chain fatty acids
mediate CREB phosphorylation. For example, short-chain fatty acids up-
regulate TH transcription via ERK-dependent activation of CREB (Shah et al.,
2006).
Since p38, ERK1/2, CREB and Akt have been identified as key signalling
pathways in adipogenesis process (Engelman et al., 1998, Reusch et al.,
2000, Park et al., 2014), therefore, it is worthy to investigate the effects of
acetate treatment on phosphorylation profiles of kinases and their targets in
brown adipocytes, which can provide useful information for understanding
the roles of acetate in brown adipogenesis.
Proteome Profiler phospho-kinase array utilized in our assays is based on
the sandwich immunoassay principle. Instead of checking the relative site-
specific phosphorylation of kinases by performing numerous immune-
precipitations and Western blots, the Proteome Profiler phospho-kinase array
detects the relative levels of phosphorylation of 43 kinase phosphorylation
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sites in one assay, therefore providing a high-throughput way for detecting
phosphorylation profiling semi-quantitatively.
Furthermore, there is another benefit of using Proteome Profiler phospho-
kinase array since all the target proteins spotted on the membrane can be
validated by phospho-specific antibodies. For example, Western bolts using
phospho-specific antibodies can be applied to further determine the time-
course of target protein(s) phosphorylation after acetate stimulation.
In addition, kinase inhibitors targeting various nodes of signalling pathways
may also assist in elucidating the mechanisms involved in acetate-induced
signalling pathways in brown adipocytes.
5.2 Results
5.2.1 Screening phospho-kinase activities after acetate stimulation in
differentiated IM-BAT cells
Because phosphorylation is fundamental to many aspects of cell signalling,
Proteome Profiler phospho-kinase array were applied to determine the
signalling pathways activated following acetate exposure in brown
adipocytes. The differentiated IM-BAT cells were treated with acetate for 10
min before lysed by lysis buffer. The lysate was incubated with Array
membranes spotted with capture antibodies. The levels of phosphorylated
proteins were detected by chemiluminescence. As shown in figure 5-1, of all
43 phospho-proteins interrogated in parallel, the phosphorylation of ERK1/2
and the phosphorylation of CREB (S133) increased by ~2.0 fold and ~2.6
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fold vs. untreated cells, respectively, after 10 mM acetate treatment for 10
min in differentiated brown adipocytes, suggesting increased activation of
these two kinases by acetate. In contrast, one spot on the membrane (Akt
1/2/3 (S473)) showed a clear decreased signal after acetate treatment,
indicating acetate treatment might decrease Akt 1/2/3 phosphorylation at
Ser473 in IM-BAT cells.
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Figure 5-1 Screening protein kinase activated by acute acetate treatment in
IM-BAT cells by phospho-kinase array. (A) The effects of acetate treatment on
phosphorylation of 43 protein kinase phosphorylation sites in IM-BAT cells
determined by phospho-kinase array. Differentiated immortalized BAT (IM-BAT)
cells were either left untreated or treated with acetate for 10 minutes. Site-specific
phosphorylation of 43 kinases were analysed by R&D Proteome Profiler Phospho-
Kinase Array Kit. Data are presented as mean ± S.E.M. (B) Phospho-Kinase Array
Layout. The location of controls and targets are listed in the table 5-1 below. (C)
Relative change in phosphorylated kinase proteins between control and
acetate-treated samples. Pixel density of the pair of duplicate spots representing
phosphorylated kinase protein were quantified and subtracted the signal of negative
control spots.
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Table 5-1 Layout of Phospho-Kinase Array
Membrane/ Coordinate Target/Control Phosphorylation Site
A-A1, A2 Reference Spot
A-A3, A4 p38α  T180/Y182
A-A5, A6 ERK1/2 T202/Y204, T185/Y187
A-A7, A8 JNK 1/2/3 T183/Y185, T221/Y223
A-A9, A10 GSK-3α/β  S21/S9
B-A13, A14 p53 S392
B-A17, A18 Reference Spot
A-B3, B4 EGF R Y1086
A-B5, B6 MSK1/2 S376/S360
A- B7, B8 AMPKα1  T183
A-B9, B10 Akt 1/2/3 S473
B-B11, B12 Akt 1/2/3 T308
B-B13, B14 p53 S46
A-C1, C2 TOR S2448
A-C3, C4 CREB S133
A-C5, C6 HSP27 S78/S82
A-C7, C8 AMPKα2  T172
A-C9, C10 β-Catenin 
B-C11, C12 p70 S6 Kinase T389
B-C13, C14 p53 S15
B-C15, C16 c-Jun S63
A-D1, A2 Src Y419
A-D3, A4 Lyn Y397
A-D5, A6 Lck Y394
A-D7, A8 STAT2 Y689
A-D9, A10 STAT5a Y694
B-D11, D12 p70 S6 Kinase T421/S424
B-D13, D14 RSK1/2/3 S380/S386/S377
B-D15, D16 eNOS S1177
A-E1, A2 Fyn Y420
A-E3, A4 Yes Y426
A-E5, A6 Fgr Y412
A-E7, A8 STAT6 Y641
A-E9, A10 STAT5b Y699
B-E11, D12 STAT3 Y705
B-E13, D14 p27 T198
B-E15, D16 PLC-γ1  Y783
A-F1, A2 Hck Y411
A-F3, A4 Chk-2 T68
A-F5, A6 FAK Y397
A-F7, A8 PDGF Rβ  Y751
A-F9, A10 STAT5a/b Y694/Y699
B-F11, D12 STAT3 S727
B-F13, D14 WNK1 T60
B-F15, D16 PYK2 Y402
A-G1, G2 Reference Spot
A-G3, G4 PRAS40 T246
A-G9, G10 PBS (Negative Control)
B-G11, G12 HSP60
B-G17, G18 PBS (Negative Control)
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5.2.2 Acetate treatment regulated ERK1/2 and CREB activation on
differentiated IM-BAT cells
To further determine the time-course of ERK1/2 phosphorylation and CREB
activation in IM-BAT cells after acetate stimulation, IM-BAT cells were
treated with 10 mM of acetate from 5 to 60 min before cells were lysated with
RIPA lysis buffer. The cells without acetate treatment were used as control.
The ERK1/2 and CREB phosphorylation were analysed by Western blots
and normalized to ERK1/2 and CREB expression, respectively.
In agreement with results from phosphor-kinase array, ERK1/2
phosphorylation increased within 5 min after acetate treatment and sustained
at high levels for 30 min (figure 5-2 (A)). Furthermore, we also observed that
CREB phosphorylation increased starting from 5 min and kept at peaking
level at 10 min post stimulation (figure 5-2 (B)).
It has been well-established that activation of CREB enhances PGC-1α 
expression in a CREB-dependent manner (Wu et al., 2002). Therefore, these
data consistently suggest that ERK1/2 and CREB were activated by acetate
and that their activation may contribute to the increase in PGC-1α activity. 
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Figure 5-2 The time-course of ERK1/2 and CREB activation following
treatment with acetate in IM-BAT cells. (A) Time-course of ERK1/2 activation
following treatment with acetate in IM-BAT cells. Differentiated IM-BAT cells
were either left untreated or treated with acetate for 5, 10, 15, 30 and 60 minutes. (B)
Time-course of CREB activation following treatment with acetate in IM-BAT
cells. Differentiated IM-BAT adipocytes were either left untreated or treated with
acetate for 5, 10, 15, 30 and 60 minutes. Data are presented as mean ± S.E.M.. **P
<0.01, ***P<0.001, ****P<0.0001 compared to control by one-way ANOVA followed
by Post-Hoc tests.
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5.2.3 4-CMTB stimulation evoked ERK1/2 and CREB activationin in
differentiated IM-BAT cells
Similarly, we also treated differentiated IM-BAT cells with 4-CMTB (1 µM), a
selective agonist for GPR43, and measured the phosphorylation of ERK1/2
and activation of CREB upon stimulation.
As shown in figure 5-3 (A), 4-CMTB treatment also elicited the
phosphorylation of ERK1/2 in differentiated brown adipocytes from 5 min
post-stimulation, which was similar to the effects of acetate treatment on
ERK1/2 activation in IM-BAT cells.
Likewise, 4-CMTB induced phosphorylation of CREB at Ser133 was also
observed from 5 min, with a peak at 10 min post-stimulation, in differentiated
IM-BAT cells (figure 5-3 (B)).
Since 4-CMTB is specific for GPR43 over GPR40 and GPR41, these results
also consistently support the hypothesis that GPR43, not GPR41, is mainly
involved in acetate-mediated effects in IM-BAT cells.
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Figure 5-3 The time-course of ERK1/2 and CREB activation following
treatment with 4-CMTB in IM-BAT cells. (A) Time-course of ERK1/2 activation
following treatment with 4-CMTB in IM-BAT cells. Differentiated IM-BAT cells
were either left untreated or treated with 4-CMTB for 5, 10, 15, 30 and 60 minutes.
(B) Time-course of CREB activation following treatment with 4-CMTB in IM-
BAT cells. Differentiated IM-BAT adipocytes were either left untreated or treated
with 4-CMTB for 5, 10, 15, 30 and 60 minutes. Data are presented as mean ±
S.E.M.. **P <0.01, ***P<0.001 compared to control by student’s t-test.
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5.2.4 Knock-down of GPR43 impaired acetate induced activation of
ERK1/2 and CREB in brown adipocytes
To further assess the roles of GPR43 in acetate-mediated downstream
signalling pathways in brown adipocytes, we also examined the effects of
impaired GPR43 expression on acetate induced ERK1/2 and CREB
activation.
IM-BAT cells expressing GPR43 shRNA were differentiated as described
above and treated with acetate (10 mM) for 5 – 60 min. While the stimulatory
effects of acetate on ERK1/2 and CREB activation have been observed in
brown adipocytes, these effects were impaired in cells transfected with
shRNA for GPR43 (figure 5-4 (A)).
Similarly, although 4-CMTB has been shown to enhance ERK1/2 and CREB
phosphorylation in IM-BAT cells, there was no such stimulation in IM-BAT
cells in which the GPR43 gene had been knocked-down by shRNA (figure 5-
4 (B)).
These results also consistently support the hypothesis that GPR43, and not
GPR41, is mainly involved in acetated mediated ERK1/2 and CREB
activation in IM-BAT cells.
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Figure 5-4 The time-course of ERK1/2 and CREB activation following
treatment with acetate in IM-BAT cells stable transfected with GPR43 shRNA.
(A) Time-course of ERK1/2 activation following treatment with acetate in IM-
BAT cells stable transfected with GPR43 shRNA. Differentiated IM-BAT cells
were either left untreated or treated with acetate for 5, 10, 15, 30 and 60 minutes. (B)
Time-course of CREB activation following treatment with acetate in IM-BAT
cells stable transfected with GPR43 shRNA. Differentiated IM-BAT adipocytes
were either left untreated or treated with acetate for 5, 10, 15, 30 and 60 minutes.
Data are presented as mean ± S.E.M..
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5.2.5 ERK1/2 activation is required for short-chain fatty acids -induced
CREB phosphorylation
Several studies have demonstrated that ERK1/2 is located upstream of
CREB (Xing et al., 1996; Impey et al., 1998a). Having defined both ERK1/2
and CREB phosphorylation as consequence of acetate treatment, we sought
next to elucidate whether ERK1/2 activation is required for short-chain fatty
acid acetate evoked CREB phosphorylation.
For this purpose, U0126, a highly selective inhibitor of both MEK1 and MEK2,
was used to block the phosphorylation of ERK1/2. As shown in figure 5-5,
although treatment of brown adipocyte with acetate caused the expected
increase in both ERK1/2 and CREB phosphorylation, acetate treatment was
unable to induce CREB phosphorylation in cells pre-treated with U0126,
while the ERK1/2 phosphorylation was almost completely abolished (figure
5-5). These results indicated that ERK1/2 may be an indispensable mediator
of short-chain fatty acid acetate induced CREB phosphorylation.
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Figure 5-5 The effects of MEK inhibitor (U0126) on acetated induced ERK1/2
and CREB activation in brown adipocytes. Differentiated IM-BAT cells were
either left untreated or pre-treated with U0126 followed by treatment with acetate for
15 minutes. Data are presented as mean ± S.E.M.. *P <0.05, **P<0.01,
****P<0.0001 compared to control by one-way ANOVA followed by Post-Hoc tests.
5.2.6 Phosphorylatin of ERK1/2 and CREB is dependent of
G(i/o)βγ/PLC/PKC/MEK signalling pathway 
Previous research has demonstrated that GPR43 couples to both Gαq and
Gαi proteins, which interact with several downstream molecules (including
adenylate cyclase, phospholipase C, etc.) (Brown et al., 2003, Stoddart et al.,
2008). As shown in figure 5-6, pre-treatment with pertussis toxin (PTX), a
Gα(i/o)-type G protein inactivator, significantly attenuated both ERK1/2 and
CREB phosphorylation induced by acetate. It has been reported that Gα(i/o)
mediates the PLC-PKC-ERK1/2 pathway via its βγ subunits (Zhou et al., 
2012, Kimura et al., 2013). Therefore, we also examined the effects of pre-
treatment with Gallein (G(i/o)βγ inhibitor), U73122 (PLC inhibitor) on acetate-
induced ERK1/2 and CREB activation. Our results showed that acetate-
induced CREB activation was effectively blocked by these inhibitors (figure
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5-6 (B) & (C)). Taken together, these results suggested G(i/o)βγ/PLC/PKC 
pathway plays a crucial role in acetate induced ERK1/2 and CREB activation
in brown adipocytes.
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Figure 5-6 The effects of Gαi inhibitor (PTX), Gβγ inhibitor (Gallein), and PLC 
inhibitor (U73122) on acetated induced ERK1/2 and CREB activation in brown
adipocytes. Differentiated IM-BAT cells were either left untreated or pre-treated
with PTX (A), or Gallein (B), or U73122 (C) followed by treatment with acetate for
15 minutes. Data are presented as mean ± S.E.M.. * P<0.05, ***P<0.001,
****P<0.0001 compared to control by one-way ANOVA followed by Post-Hoc tests.
5.2.7 Acute acetate treatment showed no significant effects on β-
adrenergic receptors agonist induced CREB activation
To measure the effects of acute acetate treatment on the brown adipocytes
response to thermogenic activator (such as β-adrenergic receptors agonist), 
especially the effects of acute acetate treatment on β-adrenergic receptors 
agonist induced the downstream signalling such as CREB, differentiated IM-
BAT cells were treated with CL-316,243 with or without acetate for 10 min.
The results showed no significant difference in CREB activation was
observed (figure 5-7 (A)). We also measured the CL-316,243 induced CREB
in GPR43 knocking down cells, the results demonstrated the significant
CREB activation was still observed, suggesting β-adrenergic receptor 
agonist induced cAMP-PKA-CREB activation was not impaired (figure 5-7
(B)).
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Figure 5-7 The effects of acetate treatment on β-adrenergic receptors agonist 
induced CREB activation. (A) Differentiated IM-BAT cells were either left
untreated or treated with CL-316,234, or acetate, or CL-316,243 together with
acetate for 10 minutes. Phospho-CREB and total-CREB were measured by Western
blots. (B) Differentiated IM-BAT cells transfected with shGPR43 were either left
untreated or treated with CL-316,243 or acetate for 10 minutes. Phospho-CREB and
total-CREB were measured by Western blots.
5.2.8 Acetate or 4-CMTB stimulation decreased Akt activation in
differentiated IM-BAT cells
It has also been demonstrated by phospho-kinase array that acetate
treatment decreased Akt phosphorylation at Ser347. Since Akt signalling
pathway is also a key mediator during the adipogenesis in brown adipocytes,
therefore, we further confirmed the effects of acetate treatment on Akt
activation by Western blots. IM-BAT cells were differentiated and treated with
acetate for 15 min. In agreement with results from phosphor-kinase array,
acetate treatment significantly decreased Akt phosphorylation (figure 5-8 (A)).
Similarly, GPR43 agonist 4-CMTB treatment also elicited a reduction of Akt
activation in differentiated IM-BAT cells (figure 5-8(B)).
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Figure 5-8 The effects of acetate and 4-CMTB treatment on Akt activation in
brown adipocytes. (A) Differentiated IM-BAT cells were either left untreated or
treated with acetate for 15 minutes. (B) Differentiated IM-BAT cells were either left
untreated or treated with 4-CMTB for 15 minutes. Phospho-Akt and total-Akt were
measured by Western blots. Data are presented as mean ± S.E.M.. *P<0.05,
**P<0.01 compared to control by Student’s t-tests.
5.2.9 Acetate treatment increased PTEN phosphorylation in
differentiated IM-BAT cells
PTEN, a lipid phosphatase that catalyses the dephosphorisation of PIP3, is a
major negative regulator of Akt signalling. It has been shown that PTEN
activation positively regulates brown adipogenesis via decreasing Akt activity
(Ortega-Molina et al., 2012). Interestingly, GPR43 activation was also found
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to activate PTEN and inhibit Akt signalling in white adipocytes (Kimura et al.,
2013). Therefore, to test the hypothesis that acetate decreases Akt
phosphorylation at Ser347 via up-regulating PTEN activity, IM-BAT cells
were differentiated and treated with acetate for 15 min. The results showed
an increase in phosphorylation of PTEN (Ser380/Thr382 /Thr383) after
acetate treatment (figure 5-9). In agreement with acetate treatment, 4-CMTB
treatment also activated PTEN phosphorylation in IM-BAT cells (figure 5-9),
suggesting it is highly possible that GPR43 activation decreases Akt
phosphorylation via activation of PTEN in brown adipocytes. However, this
hypothesis still needs more evidence to support.
Figure 5-9 The effects of acetate and 4-CMTB treatment on PTEN activation in
brown adipocytes. Differentiated IM-BAT cells were either left untreated or treated
with acetate for 15 minutes. Phospho-PTEN and total-PTEN were measured by
Western blots.
5.3 Discussion
It has been demonstrated by [35S]GTPγS binding assay that GPR43 couples 
to both Gαq and Gαi G-proteins and affects second messenger molecules
such as cyclic AMP and calcium via adenylate cyclase and phospholipase C,
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respectively (Brown et al., 2003, Stoddart et al., 2008). Besides, it has also
been revealed that GPR43 activation leads to downstream signalling
pathways, such as PTEN activation, via Gβγ subunits, suggesting Gβγ 
subunits also play important roles in GPR43 functions (Kimura et al., 2013).
Based on the results obtained from phospho-kinase array assay, we found
that acetate treatment leads to an increase in ERK1/2 and CREB activation,
as well as decreased Akt phosphorylation at Ser473 in brown adipocytes.
Furthermore, we also identified that CREB phosphorylation seems to be a
consequence of ERK1/2 activation after acetate treatment in differentiated
IM-BAT cells, suggesting that MEK1/2 - ERK1/2 is a major mediator of
acetate induced CREB phosphorylation in brown adipocytes. This result is in
aggreement with previous studies, which demonstrated that ERK1/2
activation is located at upstream of CREB (Xing et al., 1996, Impey et al.,
1998).
Since GPR43 couples to both PTX-insensitive Gαq and PTX-sensitive Gαi,
therefore, using PTX pre-treatment we also explored the involvement of Gαi
in the GPR43-regulated downstream signals in brown adipocytes. Here our
results demonstrated Gαi is indispensable for ERK and CREB activation
induced by acetate treatment via GPR43 in brown adipocytes. Previous
studies have demonstrated that G(i/o)βγ mediates the PLC-PKC-ERK 
signalling pathway (Zhou et al., 2012, Kimura et al., 2013). Our findings also
indicated that the G(i/o)βγ mediated PLC-PKC-ERK signalling pathway is 
necessary for acetate induced CREB phosphorylation.
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Notably, although Gαq is also a classic activator for PLC-PKC signalling
pathways, up to date, all GPR43 functions were found to be mediated by
Gα(i/o) in adipose tissue; only in L cells GPR43 promotes GLP-1 secretion is
via Gαq (Kimura et al., 2013). Hence, GPR43 might mainly interact with Gα(i/o)
to exert its functions in adipocytes. Here, due to the limitation of commercial
Gαq inhibitor, we did not explore the possibility that Gαq also mediates
GPR43 induced PLC-PKC activation. However, based on these evidence, it
seems Gα(i/o) plays crucial roles for GPR43 mediated ERK-CREB activation.
Besides, it has been well-studied that brown adipocyte differentiation
requires activation of CREB-associated pathways (Reusch et al., 2000).
Therefore, it is reasonable to infer that ERK/CREB signalling pathways may
be the underlying mechanism by which GPR43 receptor exerts its pro-
adipogenic effects in brown adipocytes.
Furthermore, it has also been well-documented that activation of CREB
leads to increased PGC-1α expression in a CREB-dependent manner 
(Fernandez-Marcos and Auwerx, 2011). Therefore, our data consistently
suggested that ERK1/2 and CREB activation may be the underlying
mechanism of the increase in PGC-1α induced by acetate treatment in brown 
adipocytes.
Interestingly, short-chain fatty acid butyrate was also found to induce
phosphorylation of CREB via increased the activity of PKA, and elevated the
levels of cAMP in Caco-2 cells (Wang et al., 2012). Another study also
reported that short-chain fatty acids inhibit growth hormone and prolactin
gene transcription via cAMP/PKA/CREB signalling pathway in dairy cow
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anterior pituitary cells, indicating short-chain fatty acids induced activation of
CREB exists in a wide range of cell types (Wang et al., 2013b).
In addition, our results further identified Akt signalling pathway was
decreased after acetate treatment. Recently, it has been revealed that
PTEN-Akt signalling pathway plays as an important mediator for UCP1
expression in brown adipocytes (Ortega-Molina et al., 2012). Here our results
also suggested acetate treatment induced PTEN activation, which might
contribute to the increased expression of UCP1 in brown adipocytes.
Figure 5-10 Proposed mechanisms of UCP1 transcription regulation in brown
adipocytes. The main switch of UCP1 expression is cold induced norepinephrine
(NE), which increases protein kinase A (PKA) activity and activates CREB/CEBPβ 
to elevate the levels of Ucp1 expression. The modulator of UCP1 expression is
positively regulated by PTEN, which inhibits PI3K/AKT activity and activate UCP1
positive modulator FOXO1/PGC1α complex. PI3K inhibitors also positively regulate 
the transcription of UCP1 in this mechanism (Ortega-Molina and Serrano, 2013).
Collectively, using phospho-kinase array, we have successfully identified that
several key signalling pathways (including ERK1/2, CREB, Akt) involved in
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brown adipogenesis were mediated by acetate treatment. These results may
provide useful information to understand underlying mechanism by which
acetate exerts it pro-adipogenic effects in brown adipocytes. However, due to
the limitation of antibodies spotted on the array, acetate might also elicit
activation of other protein kinases. Besides, protein kinases-independent
signalling may also mediate the pro-adipogenic effects of short-chain fatty
acids. For example, it has been reported that short-chain fatty acids promote
adipocyte differentiation via inhibiting histone deacetylases (Li et al., 2014).
Therefore, more evidence may be needed to elucidate all the responses of
brown adipocytes to the short-chain fatty acids treatment.
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Chapter 6: The effects of acetate treatment on fatty
acids metabolism in brown adipocytes
215
6.1 Preamble
As another type of adipocytes besides white adipocytes, lipid metabolism is
also crucial for brown adipocytes. Free fatty acids released from triglycerides
via lipolysis can be directly utilized as energy source by β-oxidation in brown 
adipocytes (Mottillo et al., 2012). Studies have shown that lipolysis-derived
fatty acids are the preferred substrates oxidized in brown adipocytes,
providing most of the energy to dissipate in the form of heat by UCP1-
mediated mitochondrial uncoupling (Wu et al., 2006). Indeed, intracellular
lipolysis of triacylglyceride into fatty acids and glycerol is indispensable for
thermogenesis in brown adipocytes (Cannon and Nedergaard, 2004).
In respond to cold challenge, sympathetic nervous activity to interscapular
brown adipose tissue increases (Kawate et al., 1993). Acute adrenergic
stimulation up-regulates fatty acids oxidation in brown adipocytes by
increasing lipolysis and enhancing fatty acids into the mitochondria. β-
adrenergic receptors activation leads to increased adenylyl cyclase activity
and intracellular cAMP level, which further activates PKA and phosphorylates
PKA-dependent perilipin as well as hormone-sensitive lipase (HSL) (Kraemer
and Shen, 2002). The increased transport of fatty acids into mitochondria
after adrenergic stimulation is mainly mediated via carnitine
palmitoyltransferase (CPT) 1 (Nedergaard and Lindberg, 1979, Kuusela et al.,
1986, Zhao et al., 1994, Esser et al., 1996). Notably, up-regulation of fatty
acid levels in mitochondria alone would not necessarily increase energy
expenditure (Geisler, 2011). Therefore, other mechanisms must also be
involved in the effects of adrenergic stimulation on energy expenditure in
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brown adipocytes. Adrenergic signalling regulated UCP1 expression and
mitochondrial biogenesis are also required for the increasing in
thermogenesis (Golozoubova et al., 2006, Mattsson et al., 2011).
Opposite to the lipolysis, lipogenesis and triglyceride synthesis (fatty acids
esterification) mediate triglyceride storage in adipocytes. Although brown
adipocytes have ability to synthesize triacylglyceride from de novo
lipogenesis using glucose, however, circulating chylomicron- and very-low-
density lipoprotein (VLDL)-bound triacylglyceride are the major source of
fatty acids incorporated into brown adipocytes. Since triglycerides can not
cross cell membranes, triglycerides in the circulation must be break down
into free fatty acids and glycerol before entering into adipocytes. Lipoprotein
lipase (LPL) breaks down triglycerides carried by chylomicron and VLDL and
provides fatty acids for brown adipose tissue. Cold stimulation dramatically
increase LPL activity via downregulation angiopoietin-like 4 (ANGPTL4) and
provides more plasma triglyceride-derived fatty acids for non-shivering
thermogenesis in brown adipose tissue (Dijk et al., 2015). Fatty acid
transport protein 1 (FATP1), an integral transmembrane fatty acid transporter,
is also crucial for fatty acids uptake and thermogenesis in brown adipose
tissue. Cold stimulation or adrenergic stimulation also upregulates FATP1
expression, thus increasing cellular uptake of free fatty acids for non-
shivering thermogenesis. Since brown adipose tissue has great ability to
uptake circulating triglyceride, therefore, brown adipose tissue activity is a
major factor to mediate plasma triglyceride clearance in rodents (Bartelt et al.,
2011).
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In brown adipose tissue, glucose uptake is also closely linked to lipid
metabolism. Glucose in brown adipocytes can be changed into glycerol-3-
phosphate as well as fatty acid (palmitate) for triacylglyceride synthesis via
de novo lipogenesis. De novo lipogenesis is a tightly controlled process in
adipose tissue. The abnormal of de novo lipogenesis is often liked with a
range of metabolic disorders, such as obesity, non-alcoholic fatty liver
disease, etc.. Besides, glucose uptake is also crucial for non-shivering
thermogenesis in brown adipocytes. Large amounts of glycogen storage are
found in brown adipose tissue, which can be utilized during non-shivering
thermogenesis to provide necessary energy for sustaining mitochondrial
uncoupling (Farkas et al., 1999, Jakus et al., 2008).
Here, we investigated the effects of acute acetate treatment on lipid
metabolism in immortalized brown adipocytes, which could provide more
useful information to understand the roles of acetate in brown adipocytes
metabolism.
6.2 Results
6.2.1 The effects of acute acetate or 4-CMTB treatment on lipolysis in
differentiated IM-BAT cells
As shown in figure 6-1, differentiated IM-BAT cells treated with acetate for 3
h showed no significant change on lipolysis compared to cells without
treatment. We also test the effects of acetate treatment on white adipocytes
3T3-L1. Similar to previous reports, a significant decrease of lipolysis was
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observed after 3 h treatment, indicating acetate may demonstrate different
effects on lipolysis in two types of adipocytes.
Figure 6-1 The effects of acetate and 4-CMTB treatment on lipolysis in
differentiated IM-BAT cells and 3T3-L1 cells. IM-BAT cells and 3T3-L1 cells were
differentiated for 7 days and seeded into 96 wells plates at 5 × 104 / well. The cells
were treated with test compounds for 3 h and the glycerol released was measured
by lipolysis assay kit (fluorometric). The protein of adipocytes was measured and
used for normalization. Data are presented as mean ± S.E.M. * P <0.05 compared
to control by one-way ANOVA followed by Post-Hoc tests.
6.2.2 The effects of acetate or 4-CMTB treatment on fatty acids uptake
in differentiated IM-BAT cells
As shown in figure 6-2, the effects of acute acetate or 4-CMTB stimulation on
fatty acids (C12:0) uptake were measured by free fatty acid uptake assay kit
(ab176768, Abcam). The results demonstrated that differentiated IM-BAT
cells treated with acetate or 4-CMTB had significant lower FFA uptake
compared to the control adipocytes without treatment in first 20 mins after
loading with TF2-C12 fatty acid solution (figure 6-2).
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The FFA uptake approached normal level in later phase of experiment in
cells treated with acetate. Meanwhile, the significant reduction in FFA uptake
remained till 1 h post TF2-C12 fatty acid solution stimulation in 4-CMTB
treated cells (figure 6-2).
Figure 6-2 The effects of acetate and 4-CMTB treatment on FFA (TF2-C12)
uptake in differentiated IM-BAT cells. IM-BAT cells were differentiated for 7 days
and seeded into 96 wells plates at 5 × 104 / well. The cells were treated with test
compounds for 30 min and the FFA uptake was measured by free fatty acid uptake
assay kit (fluorometric). Data are presented as mean ± S.E.M.. * P <0.05 compared
to control by two-way ANOVA followed by Post-Hoc tests.
6.2.3 The effects of acetate or 4-CMTB treatment on glucose uptake in
differentiated IM-BAT cells
As shown in figure 6-3, differentiated IM-BAT cells treated with acetate or 4-
CMTB showed no significant changes of fluorescent glucose analog (2-
NBDG) uptake compared to the control group after 30 min of treatment,
suggesting acute treatment of acetate or 4-CMTB has little effects on
glucose uptake in vitro (figure 6-3).
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Figure 6-3 The effects of acetate and 4-CMTB treatment on glucose uptake in
differentiated IM-BAT cells. IM-BAT cells were differentiated for 7 days and
seeded into 96 wells plates at 5 × 104 / well. The cells were treated with test
compounds for 30 mins and the glucose uptake was measured by glucose uptake
assay kit (fluorometric). Data are presented as mean ± S.E.M..
6.3 Discussion
It has been demonstrated that GPR43 activation by short-chain fatty acids
leads to a decrease in lipolysis in white adipocytes as well as in white
adipose tissue without causing side effects (Ge et al., 2008). Here, as
positive control, we also observed this effect in differentiated 3T3-L1 cells.
However, in contrast to this anti-lipolytic effect in white adipocytes, no
significant effects on lipolysis were observed in differentiated IM-BAT cells.
Since the activation of thermogenesis requires increased lipolysis to provide
fatty acids as substrates and no thermogenesis can be evoked without
activation of lipolysis in brown adipocytes, therefore, our findings suggested
acetate treatment might not be an obstacle for brown adipocytes to exert its
non-shivering thermogenesis functions.
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Also our results showed that differentiated white adipocytes 3T3-L1 have
much higher lipolysis-released glycerol than differentiated brown adipocytes.
A similar phenomenon was also reported by Klaus et al. that differentiated
adipocytes isolated from white adipose tissue from Siberian dwarf hamster
released 4 times as much glycerol into the medium as corresponding
differentiated adipocytes isolated from brown adipose tissue (Klaus et al.,
1995).
Previous studies have suggested that fatty acids with different length are
absorbed by distinct routes (Dubikovskaya et al., 2014). Uptake of long-chain
fatty acids is regulated by several membrane proteins including fatty acid
translocase (FAT)/CD36 (Ehehalt et al., 2008), long-chain fatty acyl-CoA
synthetase (LACS) (Schaffer and Lodish, 1994) and fatty acid transport
proteins (FATPs) (Schroeder et al., 1998), while short-chain fatty acids (2-4
carbons) and medium-chain fatty acids (6-14 carbons) are absorbed by
direct passive diffusion and active transport through a number of transporters
including monocarboxylate transporters and sodium-dependent
monocarboxylate transporter 1 (den Besten et al., 2013).
Here our results indicated short-chain fatty acids acetate may also influence
the medium-chain fatty acids uptake. More interestingly, GPR43 agonist, 4-
CMTB, provide a more sustained effects to decrease FFA uptake. The
mechanism of this difference is still unclear, which might stem from the
different efficacy of 4-CMTB and acetate, or GPR43-independent effects of
acetate.
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Furthermore, fatty acid sensing GPCRs GPR41/43 and GPR120 have been
found to enhance glucose uptake via GLUT4 in skeletal muscle and white
adipose adipocytes, respectively (Canfora et al., 2015, Oh et al., 2010).
These studies hinted the potential crosstalk between fatty acids and glucose
uptake (Townsend and Tseng, 2014). Although no significant changes were
observed in brown adipocytes after acute acetate treatment, it is interesting
to investigate the effects of long-term acetate treatment on GLUT4
expression or translocation. Besides, it is notably that acetate treatment may
behave distinctively in cell models and in vivo. The effect of rosiglitazone on
glucose uptake in brown adipose tissue is a good example of this
phenomenon. Although rosiglitazone treatment leads to modest increase in
glucose uptake in brown adipocytes (Hernandez et al., 2003), however,
rosiglitazone reduces glucose uptake in brown adipose, the detailed
mechanism is still unknown. Therefore, it is also interesting to investigate the
effects of acetate on glucose tissue in vivo in future.
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Chapter 7: Conclusion
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It has been widely accepted that fatty acids serve not only as energy sources
or as constituent of membrane lipids, also as important regulators of cellular
signalling and metabolism. Current evidence about the roles of short-chain
fatty acids in metabolic regulation has suggested their potential benefits for
energy homeostasis, especially upon metabolic challenges such as high fat
diet. This thesis aims to investigate the roles of acetate treatment and
consequent short-chain fatty acid sensing GPCR(s) activation in the
regulation of brown adipocyte differentiation and energy metabolism.
Brown adipose tissue, regarded as an important endocrine organ, has
received a lot of attention recently as a potential target to combat obesity.
Brown adipose tissue is a metabolically active tissue that contributes to
energy expenditure by combustion of fatty acids into heat, a process called
thermogenesis. Mitochondria are known to be key functional organelles in
brown adipocytes, which mediate the heat dissipation via the unique
uncoupling protein UCP1 (Golozoubova et al., 2006). Fatty acids not only
provide the energy source for this process, but also mediate various aspects
of thermogenesis. Since brown adipose tissue has emerged as a novel
regulator for energy homeostasis, better understanding the mediating role of
fatty acids may provide clues to alleviate metabolic diseases.
Induction of mitochondria biogenesis and UCP1 expression during the
maturation of brown adipocytes is important for the normal thermogenic
capacity in brown fat. In this research, the effects of acetate on adipogenesis
in immortalized brown adipocytes derived from mice interscapular brown
adipose tissue were mainly investigated. Several novel outcomes provide
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mechanistic insight into the regulation of short-chain fatty acid acetate in the
differentiation of immortalized brown adipocytes. Considering the pro-
adipogenic property of short-chain fatty acids has also been studied in
several white adipocyte models (Hong et al., 2005), our results suggested
that short-chain fatty acids might exert their pro-adipogenic effects in both
white and brown adipocytes.
To investigate the mechanisms governing the pro-adipogenic effects of
acetate in brown adipocytes, the phosphor-kinase activities were screened.
Consistence to acetate induced UCP1 expression, ERK-CREB activities
were elevated while Akt activity was decreased after acetate treatment.
Since it has been suggested that CREB and Akt signalling pathways serve
as the main switch and modulator of UCP1 transcription, respectively
(Ortega-Molina and Serrano, 2013), these findings strongly suggested that
alternation of CREB and Akt activities might be the molecular mechanism
underlying pro-adipogenic property of acetate.
Notably, our results also showed a great similarity between the CI curve of
IM-BAT cells and the CI curve of 3T3-L1 cells during differentiation,
supporting the idea that CI curve could be used as a novel tool to monitor the
adipogenesis in real-time, which would provide great benefit for the
adipocyte research.
GPR43 has been identified as one of short-chain fatty acids sensing GPCRs.
In this study, the expression of GPR43 was analysed in immortalized brown
adipocyte cells and interscapular brown adipose tissues of mice. The results
confirmed the existence of GPR43 expression in both brown adipocytes and
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brown adipose tissue. Moreover, our results also indicated that GPR43
expression levels seems to be rightly linked with the differentiation status of
brown adipocytes, suggesting GPR43 might be a novel adipogenic marker in
brown adipocytes. Several studies have also demonstrated GPR43
expression was influenced by diet composition and body weight. Diet-
induced obesity up-regulated GPR43 expression in multiple tissues including
white adipose tissue, liver, and skeletal muscles (Cornall et al., 2011, Dewulf
et al., 2011). In contrast, administration of inulin-type fructans in diet lowered
the body weight and counteracted HFD-fed induced GPR43 overexpression
in white adipose tissue (Dewulf et al., 2011), suggesting GPR43 expression
levels might reflect metabolic status in body.
Current evidence about the functions of short-chain fatty acids, especially
acetate, in metabolic regulation has suggested GPR43 is an important
mediator for short-chain fatty acids exerting their roles in adipose tissue.
Previous studies have suggested that GPR43 is dependent for the pro-
adipogenic and anti-lipolytic properties of short-chain fatty acids in white
adipocytes (Hong et al., 2005). In vivo studies also suggested acetate
treatment suppressed plasma free fatty acids without inducing the flushing
side effect via GPR43 (Ge et al., 2008). Furthermore, GPR43 knock-out mice
were demonstrated to exhibit obesity, reduced short-chain fatty acids-
triggered GLP-1 secretion, impaired systemic insulin sensitivity and a parallel
impairment of glucose tolerance while adipose-specific GPR43 transgenic
mice were lean and showed enhanced systemic insulin sensitivity (Kimura et
al., 2013, Tolhurst et al., 2012). Here, our results also suggested that GPR43
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involved in pro-adipogenic effects of short-chain fatty acids. It is noteworthy
that GPR43 independent mechanism (inhibiting histone deacetylases) has
also been shown to mediate promotive effects of acetate on adipogenesis in
white adipocytes (Li et al., 2014). Therefore, GPR43 independent
mechanisms may also be mediating short-chain fatty acid-induced effects in
brown adipose tissue.
GPR43 reportedly couples to either Gα(i/o) or Gαq signalling pathways (Brown
et al., 2003). Up to date, nearly all of GPR43 roles identified in adipose tissue
were found to be mediated by Gα(i/o). Our findings also indicated that G(i/o)βγ-
PLC-PKC-ERK signalling pathway was necessary for acetate induced
downstream effects, which supported the importance of Gα(i/o) signalling
pathway in acetate induced GPR43 activation in brown adipocytes.
Interestingly, using radioactivity-labelled acetate, it was not only
demonstrated the existence of brown adipose tissue in human, but also
revealed cold stimulation significantly increased the uptake of acetate in
brown adipose tissue (Ouellet et al., 2012). After intravenous injection of 11C-
labeled acetate, radioactivity in brown adipose tissue, but not subcutaneous
adipose tissue was increased throughout exposure to cold (Ouellet et al.,
2012). This evidence also highlighted the possible roles of short-chain fatty
acids in human brown adipose tissue upon cold stimulation. However, more
evidence is needed to elucidate the links between acetate and brown
adipose tissue in human.
Recently, it has also been identified that long-chain fatty acids are required
for UCP1 to transport H+ across mitochondrial inner membrane (Fedorenko
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et al., 2012). This evidence together indicated that fatty acids are vital and
necessary for normal physical functions of brown adipocytes and brown
adipose tissue, especially their highly specific non-shivering thermogenesis.
Lastly, evidence also suggested dietary fibre leads to increased short-chain
fatty acids, especially acetate, in circulation. Based on previous studies and
results from this research, dietary supplementation of fibre might provide
health benefits to keep energy homeostasis via increased brown
adipogenesis and increased insulin sensitivities in muscle and liver, as well
as reduced appetite.
Collectively, our finds provided useful evidence to deepen the understanding
toward the functions of short-chain fatty acids on brown adipose tissue.
Since brown adipose tissue has emerged as a novel regulator for energy
homeostasis, better understanding the mediating role of fatty acids may
provide clues to alleviate metabolic diseases as well as keep energy
homeostasis. In order to examine the findings from this study in further, in
vivo investigations as well as clinical trials are especially required.
It has been demonstrated that the amount and type of diety fiber consumed
dramatic affect the composition of the intestinal microbiota and consequently
on the amount of short-chain fatty acids produced in gut (den Besten et al.,
2013). Analysis of the microbiota from the feces of mice fed diets revealed
that fiber-rich diet increased the proportion of phyla Bacteroidaceae and
Bifidobacteriaceae, which have acetate and propionate as the primary
metabolic end products (Trompette et al., 2014). Further analysis also
confirmed dietary fiber content alters the both local and systemic levels of
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short-chain fatty acids (Trompette et al., 2014). Therefore, dietary fibre
supplementary may serve as a therapeutic application to improve metabolic
health and hold significant clinical potential via activating brown adipose
tissue in human.
Of note, the majority work done in this study was to investigate the direct
effects of acetate on immortalized brown adipocytes using in vitro cell
models, however, the development and metabolism of brown adipose tissues
were controlled by a complex network of development and metabolism of
brown adipose tissues were controlled by a complex network of interorgan
connections. It has been demonstrated that short-chain fatty acids also exert
their functions in multiple organs. Therefore, in vivo assays are needed to
predict the overall effects of short-chain fatty acid on development of brown
adipose tissue as well as energy expenditure. Meanwhile, to test the direct
effects of short-chain fatty acids on brown adipose tissue in vivo, novel
delivery approaches are required to disassociate the central effects from
peripheral actions of short-chain fatty acids in mice model since short-chain
fatty acids can be transported through blood–brain barrier into brain (Frost et
al., 2014). Recently, a novel delivery method using Liposome encapsulated
Acetate (LITA) nanoparticle has been reported to partially overcome this
obstacle since LITA nanoparticles can only reach peripheral tissues but do
not cross blood–brain barrier (Sahuri-Arisoylu et al., 2016). Besides,
although the circulation level of short-chain fatty acids has been measured
by mass spectrometry (Opie and Walfish, 1963, Tollinger et al., 1979), the
local concentration of short-chain fatty acids in brown adipose tissue is still
not clear. The lack of quantitative data on actual fluxes of short-chain fatty
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acids around brown adipose tissue also impaired the understanding towards
the effects of short-chain fatty acids on brown adipose tissue in vivo.
Therefore, these limitations within our study require further research to
elucidate.
In conclusion, in this study we unveil short-chain fatty acids sensing
machinery triggers a GPR43-dependent signalling to promote the
differentiation and mitochondrial biogenesis in brown adipocytes. In addition,
evidence given in this study also suggests that short-chain fatty acids
treatment may affects lipid metabolism in brown adipocytes. Taken together,
our findings highlight the potential to manipulate short-fatty acid sensing
machinery in brown adipose tissue to regulate energy expenditure and keep
energy homeostasis.
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